Prostaglandins and Phosphodiesterases in the urinary bladder wall by Rahnama'i, M.S.
  
 
Prostaglandins and Phosphodiesterases in the urinary
bladder wall
Citation for published version (APA):
Rahnama'i, M. S. (2013). Prostaglandins and Phosphodiesterases in the urinary bladder wall. Maastricht:
Maastricht University.
Document status and date:
Published: 01/01/2013
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall
Mohammad Sajjad Rahnama’i
Thesis M.S. Rahnama’i.indd   1 10-10-13   13:36
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall – Mohammad Sajjad Rahnama’i (sajjad_r@yahoo.com) 
© 2013 Mohammad Sajjad Rahnama’i
ISBN 978-90-820560-0-6
Design, Printing & Binding: 5nul8 Grafische Producties, Valkenburg a/d Geul, The Netherlands –  info@5nul8.nl
Sponsors: Stichting Wetenschappelijke Activiteiten Maastrichtse Urologie (WAMU); Astellas Pharma; Zambon 
Nederland; GlaxoSmithKline; Ipsen Farmaceutica; Goodlife Pharma; AbbVie; Pohl-Boskamp; Eurocept Pharmaceuticals; 
Takeda; Lilly; Rochester Medical; Allergan; Mundi Pharma; A.N.W. Nederland; M.M.S. en ChipSoft bv.
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval center of any nature, or transmitted, in 
anyform or by any means, electronic, mechanical, photocoping, recording or otherwise, without the permission of the 
author.  
Thesis M.S. Rahnama’i.indd   2 10-10-13   13:36
Prostaglandins and Phosphodiesterases 
in the Urinary Bladder Wall
PROEFSCHRIFT
ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector Magnificus, Prof. Dr. L.L.G. Soete,
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen
op vrijdag 22 november 2013 om 14:00
door
Mohammad Sajjad Rahnama’i
Thesis M.S. Rahnama’i.indd   3 10-10-13   13:36
Promotores
Prof. Dr. Ph.E.V. Van Kerrebroeck
Prof. Dr. S.G.G. de Wachter (universiteit van Antwerpen)
Co-promotor
Dr. G.A. van Koeveringe
Beoordelingscommissie
Prof. Dr. H. Steinbusch (voorzitter)
Prof. Dr. M. Drake (Urological Research Institute Bristol, United Kingdom)
Prof. Dr. J. Schalken (Radboud Universiteit Nijmegen)
Prof. Dr. Y. Temel
Prof. Dr. A. zur Hausen
Dit proefschrift is tot stand gekomen middels een persoonlijke onderzoeksprijs (mozaïek-prijs) 
aan de promovendus Drs. M.S. Rahnama’i, verleend door 
de Nederlandse Organisatie voor Wetenschappelijke Onderzoek (NWO)
Thesis M.S. Rahnama’i.indd   4 10-10-13   13:36
Contents
Chapter 1: Introduction 9
Chapter 2: The Role of Prostanoids in Urinary Bladder Physiology 33
(Nature Reviews Urology, 2012)
Chapter 3: Prostaglandin Receptor EP1 and EP2 Site in Guinea Pig Bladder Urothelium 
and Lamina Propria 53
(The Journal of Urology, 2010)
Chapter 4:  The Relationship Between Prostaglandin E Receptor 1 and Cyclooxygenase I
Expression in Guinea Pig Bladder Interstitial Cells 
Proposition of a Signal Propagation System 71
(The Journal of Urology, 2011)
Chapter 5: The Distribution of the Prostaglandin E Receptor Type 2 (EP2) in the 
Detrusor of the Guinea Pig 89
(Prostaglandins and Other Lipid Mediators, 2012)
Chapter 6: The Effect of Indomethacin on the Muscarinic Induced Contractions 
in the Isolated Normal Guinea Pig Urinary Bladder 109
(BioMed Central Urology, 2013)
Chapter 7: The Role of Phosphodiesterases in Bladder Pathophysiology 125
(Nature Reviews Urology, 2013)
Chapter 8: The Distribution of Phosphodiesterase Type 5 Enzyme (PDE5) 
in The Lateral Wall of The Guinea Pig Urinary Bladder 151
(British Journal of Urology International, 2013)
Chapter 9: General Discussion 169
Summary  183
Samenvatting 189
Acknowledgements / Dankwoord 193
Thesis M.S. Rahnama’i.indd   5 10-10-13   13:36
Abbreviations 197 
List of Publications 199
Abstracts and Presentations 201
Curriculum Vitae 205
Thesis M.S. Rahnama’i.indd   6 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   7 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   8 10-10-13   13:36
9Chapter 1
General Introduction
The clinical problem 
The overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as 
urinary urgency which is accompanied by urinary frequency and nocturia, with or without urgency 
urinary incontinence1,2. OAB has a greater impact on people’s quality of life than diabetes3-6 and 
an economic burden and cost comparable to rheumatoid arthritis and asthma7. Therefore, OAB 
deserves more research resources and research efforts. Those affected by the symptoms of OAB 
tend to curtail their participation in social activities and isolate themselves and are predisposed 
to depression8. Furthermore, many patients are often too embarrassed to seek medical treatment 
which contributes to an underestimation of the prevalence and difficulties in understanding 
the social burden of the disease3,9. It is estimated that about 60% of all patients seeking help, 
experience some symptoms of bladder dysfunction10. The symptoms encompassing OAB still 
present a therapeutic challenge. An unmet medical need clearly exists for an effective and well 
tolerated pharmacological therapy. The current treatment mainly consists of anticholinergic drugs, 
which have a slightly better effect than placebo, but poor patient compliance, due to the side effects 
and the lack of sufficient efficacy11.
Hence, OAB is a major problem affecting a large number of individuals. The underlying causes 
are not known and the precise mode of action of pharmacological treatments, remains unclear. 
Therefore, new insights into the problem and new therapeutic modalities are urgently needed.
Relevance of the problem for society 
OAB affects nearly 100 million people in the Western world (33 million in the US and 66 million in 
the European Union)12,13 and has severe effects on quality of life and ability to work. OAB is reported 
to have an incidence of, up to 17% in the Western population12 and an overall prevalence of 16.6 
% in Europe13. This number is significantly higher in the older population where up to 40% of the 
individuals over the age of 70 is reported to be affected13. A recent study has estimated the prevalence 
of OAB in the United States to range from 26 to 33% in men and from 27 to 46% in women14. 
The total economic cost of OAB is high. In 2002 the costs in the US were approximately $12.7 billion 
which increased to €22 billion/year in 2005. Approximately 25% of this expenditure, is spent on 
treatment (drug therapy, clinical consultation, surgery and incontinence pads). From those who 
suffer from OAB, only 28% sought help and only half of those currently receive treatment. Less than 
3% of the patients regain long lasting continence. Therefore, the above mentioned costs are likely 
to be an underestimation and most probably, the problem is much larger11-13,15. As the incidence of 
OAB increases with age, it will be an increasing problem in aging societies.
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The exact economic costs and prevalence of OAB in the Netherlands are unknown. However, it 
has been calculated that about €200 million are annually spent on protective material such as 
incontinence pads. In Germany, the direct annual costs have been estimated to be comparable to 
those of other chronic diseases such as dementia or, diabetes mellitus16.
A better management of the symptoms of OAB, will improve quality of life, decrease morbidity and 
disease related costs. 
Figure 1. The Prevalence of OAB in Different Age Groups in West-Europe.4
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Overactive bladder syndrome 
OAB occurs in both men and women. In some patients, it is accompanied by uncontrolled 
contractions of the detrusor muscle during bladder filling, called detrusor overactivity (DO). 
However, patients with OAB do not always present with DO. In fact, DO is detected in only about 
half of patients with OAB by conventional techniques. But, up to 50% of patients presenting with 
DO on urodynamics, do not complain of clinical symptoms17,18. The differences in the relationship 
between sensation and bladder activity, may be indicative of different clinical states. However, it is 
more likely that we don’t understand the true nature of the clinical condition yet.
The only currently available tool to link OAB and DO is urodynamics. Nevertheless, DO and OAB 
share therapeutic options and, partially, common pathophysiological mechanisms17,18.
The characteristic symptom of OAB is a sudden and strong sudden desire to void, that can not be 
postponed (urgency). In some patients, this can result in involuntary urine loss, which is called 
urgency incontinence. 
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The term frequency refers to an increased number of micturitions per day (more than 8 times a day) 
and can occur as a result of reduced functional bladder capacity. Frequency is at least partly caused 
by patients’ adaptation (‘coping mechanism’) to avoid leaking urine by maintaining a relatively 
low urinary volume in the bladder. Patients with OAB usually try to keep their bladder as empty 
as possible and therefore, pass urine more than 8 times during the day to maintain continence. 
Despite this adaptive coping mechanism, incontinence may still be a significant problem. 
Even a small increase in urgency and/or frequency can have a marked effect on the patient, 
depending upon when it occurs. Urgency incontinence is the most bothersome symptom of 
overactive bladder and is reported in around 20% of men and 40% of women with overactive 
bladder symptoms15,19,20. The diagnosis of OAB is made on the basis of symptoms alone. However, 
cystometry can be used to verify that uncontrolled contractions during bladder filling are 
responsible for the OAB symptoms. 
OAB symptoms can also be attributed to spinal cord injury or neuronal lesions within the spinal 
cord or the central nervous system (e.g. as a result of multiple sclerosis, Alzheimer’s disease, 
stroke or Parkinson’s disease). This condition is also known as neurogenic OAB and has a different 
aetiology as compared to the aforementioned group of patients with OAB, also called idiopathic 
OAB. While a number of theories have been proposed, the true pathophysiology of OAB remains 
uncertain and therefore the syndrome of OAB is described as idiopathic. 
Current therapies for OAB
Since OAB symptoms have been shown to be associated with detrusor overactivity, it was argued 
that drugs affecting contractility would alleviate symptoms21. Activity in the bladder smooth 
muscle is initiated by muscarinic receptor stimulation. Drugs designed to target these muscarinic 
receptors are proven to have some effect in decreasing urgency sensation and incontinence. 
Currently, antimuscarinic drugs are the first-line treatment for OAB. These drugs produce good 
initial response rates. However, adverse effects and decreasing efficacy cause poor long-term 
compliance22. Therefore, it is desirable that alternative treatment methods are developed and made 
available for patients. At the moment, a lot of research is focused on compounds with potential 
efficacy for the treatment of OAB some of which are undergoing preclinical and clinical testing. In 
OAB, there are many potential pathophysiological targets for intervention. This is reflected in the 
broad variety of mechanisms amongst the agents that are under development. In general, the new 
drugs for OAB are being designed to target mucosal (urothelial) signalling, myocyte signalling or, 
aim at modulating the central nervous system.
The focus of therapy has been shifted from the efferent side, trying to reduce muscle activity (e.g. by 
inhibiting muscarinic receptors in the neuromuscular junction) to the afferent side, trying to reduce 
the afferent outflow by interacting through different peripheral and central signalling molecules. 
This thesis focuses on the local signalling molecules and more specifically on two possible targets 
for therapy called prostaglandins and phosphodiesterases. 
Chapter 1 –  General Introduction
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Anatomy of the lower urinary tract 
The urethra, the bladder and in some opinions also the distal part of the ureters, are referred to 
as the lower urinary tract. These structures are located in the lower pelvis and are supported by 
muscles and ligaments. The urethra contains both smooth and striated muscles. The bladder 
can be divided into two main components: the bladder dome, which is located above the ureteral 
orifices, and the base, consisting of the trigone, ureterovesical junction, lateral wall of the detrusor 
along with the anterior bladder wall. The bladder is essentially a hollow organ composed of separate 
layers i.e. the urothelium, the suburothelial layer and the detrusor muscle (figure 2). The detrusor 
muscle consists of a complex network of smooth muscle fibers, connective and nervous tissue 
that is responsible for bladder contractility. The inner lining of the bladder is called the urothelium, 
which has a barrier function and is thought to act as a sensor which is also a site of production of 
many physiologically active molecules. The detrusor muscle is built up by smooth muscle cells and 
is structurally and functionally different from trigonal and urethral smooth muscle. 
In both men and women, continence is based upon the preservation of low pressure within the 
bladder during urine storage and a high tonic tension of the sphincter muscle of the bladder outlet. 
The latter comprises the smooth muscle of the bladder neck, proximal urethra, and the striated 
muscle fibers (also referred to as the rhabdosphincter, external urethral sphincter or the striated 
urethral sphincter) that wrap around the urethra. Furthermore, the pelvic floor muscles are important 
in the maintenance of urinary continence and in preventing the descent of the pelvic organs.
Kidney
Ureter
Bladder
Prostate
Urethra
Perivesical fat
Serosa
Detrusor muscle
Suburothelium
Urothelium
Bladder dome 
Lateral wall
Trigone
Bladder neck
Figure 2. A Schematic View of Bladder Anatomy. 
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Histology of the bladder wall
The bladder wall can be divided into three main layers: the urothelium, the suburothelial layer and 
the muscle layer (figure 3). The urothelial surface cells are covered by a glycosaminoglycan layer 
(GAG). The function of the GAG layer remains controversial. Suggested tasks of this layer include 
an osmotic barrier function and also an antibacterial coating of the urothelium (low adherence 
of the bacteria)23. 
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Figure 3. A Schematic View of the Cellular Structures in the Different Bladder Layers.
Urothelium
The uro-epithelium, better known as urothelium, is the interface between the lumen of the urinary 
tract and underlying tissues. The urothelium is composed of at least three layers: a basal cell layer 
attached to a basement membrane, an intermediate layer, and a superficial or apical layer composed 
of large hexagonal cells (25-250 μm diameter) known as ‘umbrella cells’24,25. The umbrella cells are 
interconnected by tight junctions (which are composed of multiple proteins such as the claudins) 
and are covered on their apical surface (nearly 70-80%) by crystalline proteins called uroplakins 
that assemble into hexagonal plaques26-28. The urothelium is more than a barrier that separates 
Chapter 1 –  General Introduction
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urine from extracellular fluid. It also has substantial sensory properties29. Moreover, the lamina 
propria has been shown to be extensively innervated30,31. Receptors for bradykinin, purines (P2X 
and P2Y) norepinephrine (α and β), acetylocholine (nitrotinic and muscarinic), and neurotrophions 
have been shown to be present in the urothelium29,32-36 as well as a number of transient receptor 
potential (TRP) channels (TRPV1, 2 and 4)37,38. Urothelium is shown to release several substances in 
response to physical and chemical stimulation. These substances include adenosine triphosphate 
(ATP), nitric oxide (NO), substance P, acetylcholine, prostaglandins (PGs) and cytokines39-43, which 
suggest the existence of reciprocal communication with neighbouring urothelial cells, nerves 
and interstitial cells. The urothelium is thought to serve as a mechano-sensor, which can control 
activity in afferent nerves through the production of NO, ATP, acetylcholine and other mediators44. 
Therefore, the urothelium is considered an important regulatory part of the bladder wall and a 
possible target for therapeutic agents.
Suburothelium 
The area between the urothelium and underlying smooth muscle layers is called the suburothelium. 
This layer is richly supplied by blood vessels, nerves and fibroblasts including myofibroblasts or 
interstitial cells (IC), which are embedded in a collagen matrix30,45. Suburothelial interstitial cells 
have been identified in human and animal bladders. 
At present, there is still debate on what precisely defines an interstitial cell in the bladder. Several 
terms have been used to describe cells in the bladder interstitium including; myofibroblasts, 
interstitial cells of Cajal, and interstitial cells. The initial description of physiologically active 
interstitial cells in the human and guinea pig bladder was based on their ability to show a rise in 
Guanosine 3’, 5’- cyclic monopohsphate (cGMP) in response to NO donors46,47. Interstitial cells 
have also been subdivided based on their location in the bladder wall. A rough subdivision is made 
between interstitial cells lying in the suburothelial layer and those in the muscle layer46. The muscle 
layer’s interstitial cells are further subdivided. Different cell markers, predominantly c-kit and 
vimentin, have been used to identify interstitial cells45,48-53. Both c-kit and vimentin positive cells, are 
found in the lamina propria and around the muscle bundles of the inner and outer muscle layers. 
Neither a c-kit, nor vimentin , nor cGMP labeling seem to be ideal for identification of interstitial 
cells. A large proportion of interstitial cells do not express c-kit45. Vimentin identifies several 
interstitial cell types. However, other cell types such as non-physiologically active fibroblasts can 
express vimentin45.
Furthermore, cGMP staining identifies, besides interstitial cells, other cells such as umbrella cells 
and some nerves47. True identification of cells, such as interstitial cells, requires investigations of their
ultrastructural properties using transmission electron microscopy. Ultrastructural features include: 
the presence of abundant intermediate filaments, numerous mitochondria, moderately developed 
Golgi apparatus, smooth endoplasmatic reticulum , contacts with nerves and the formation of 
gap junctions with each other and with smooth muscle cells54. The suburothelial interstitial cells 
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found in the bladder are located in close association with afferent nerves, and it has been suggested 
that these cells play a role in modulating the activity of the suburothelial sensory nerves50. For 
example, isolated c-kit positive cells from the suburothelial layer, can respond to stimuli such as 
caffeine, muscarinic and purinergic agonists with a rise in intracellular calcium concentration55,56. 
Furthermore, vanilloid receptors have been identified on interstitial cells57.
Muscle layer
In many species, such as the guinea pig, the bladder muscle is divided in an inner and an outer 
muscle layer which is surrounded by a thin layer of interstitial cells called the muscle coat. In the 
guinea pig, three types of muscle interstitial cells have been described based on their location: 
1. cells in the outer muscle coat (muscle coat interstitial cells) 2. cells on the surface of the muscle 
bundles (surface muscle interstitial cells) and 3. cells within the muscle bundles (intra muscle 
interstitial cells35,47,58). A subpopulation of cells may be identified based on their expression of 
choline acetyl transferase59. The muscle interstitial cells are similar to the interstitial cells of Cajal in 
the gut that mediate peristaltic contractions. Therefore, a pacing role has been suggested for these 
cells in the bladder wall60,61. Interstitial cells maintain close contact with intramural nerves, which 
might indicate that these cells may be under influence of nerves.
Bladder physiology 
As urine is produced in the kidneys, it enters the bladder via the ureters at a rate of 0.5–5 ml/min. 
The pressure within the bladder (intravesical pressure) remains relatively constant throughout the 
filling process. During this filling phase the pressure in the urethra must exceed that in the bladder 
to maintain continence. The ability to maintain a constant low pressure in the bladder during filling 
is possible as a result of the elastic and visco-elastic properties of the bladder wall, together with 
activation of neuronal mechanisms that inhibit the detrusor muscle from contracting62.
The desire to void usually starts when the bladder has reached about half its physiological capacity, 
after which the desire to void is suppressed by inhibitory input mainly from the cerebral cortex, 
until a suitable time and place for micturition has been chosen. When the micturition process is 
initiated, urethral pressure decreases (as a result of voluntary relaxation of the urethral sphincter), 
the pelvic floor muscles relax and the bladder neck forms a funnel. Next, increased parasympathetic 
stimulation leads to detrusor muscle contraction and an increase in intravesical pressure leads 
to the voluntary initiation of micturition. Detrusor muscle contraction is maintained throughout 
voiding. When urine flow is terminated, the pelvic floor contracts to elevate and close the bladder 
neck, urethral pressure increases and pressure within the bladder falls. Any urine within the 
proximal urethra is forced back into the bladder and bladder filling recommences.
The urinary bladder has two control mechanisms, a central and a peripheral mechanism, the later 
being the focus of this thesis.
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Central nervous system control 
As the bladder fills during the urine storage phase, the detrusor muscle remains relatively quiescent 
and the urethral outlet is kept in a contracted state. During the micturition phase, the detrusor 
muscle contracts and the urethral outlet relaxes. This involves a complex pattern of efferent (motor) 
and afferent (sensory) signalling in the autonomic and somatic nervous system. The nerves 
involved are part of a reflex pathway, with an incorporated conscious control component63. The 
cerebral cortex, brain stem and spinal cord (S2–S4 segments) are the main structures involved 
in the regulation of lower urinary tract function. The micturition cycle is thought to be initiated in 
the brain stem, specifically in a region known as the pontine micturition center. This area is in turn 
controlled by impulses from the cerebral cortex, which has an inhibitory effect on the detrusor 
muscle during bladder filling.
Both the autonomic (parasympathetic and sympathetic) and somatic nervous systems innervate 
the lower urinary tract (figure 4). Autonomic innervation includes parasympathetic (pelvic) neurons 
derived from the S2–S4 segments of the spinal cord and sympathetic (hypogastric) neurons 
from the T10–L2 segments. The parasympathetic nervous system mediates contraction of the 
detrusor muscle (micturition) while the sympathetic nervous system contributes to urine storage 
via relaxation of the detrusor muscle and contraction of the bladder neck and to a lesser extent 
the urethra64. The postganglionic neurotransmitter in parasympathetic neurons is acetylcholine, 
while in postganglionic sympathetic neurons the transmitter is noradrenaline (norepinephrine). 
Somatic nerves originate from the S2–S4 segments of the spinal cord and are thought to be solely 
responsible for direct innervation of the striated muscle of the urethral sphincter and pelvic floor 
using acetylcholine as the neurotransmitter.
Peripheral control
The bladder appears to have a peripheral control mechanism located in the bladder wall. This 
control mechanism is formed by the co-operative interaction of numerous regulatory cell types, of 
which the interstitial cells and the peripheral neurons are particularly important65. 
In the past decade, there have been a number of advances in our understanding of the detailed 
structure of the bladder and its more complex functions. One key step forward, was the 
appreciation that the urothelium released a range of substances when stretched21. This led to the 
concept that these chemical agents modify afferent nerve activity and sensation. The urothelium 
is an integral part of a ‘chemical’ sensory system’ and plays a role in generating and modulating 
bladder sensation. If the urothelium or sensory nerves become defective, as in for example the 
OAB syndrome, this would result in increased sensation of urgency. Urothelial cells express various 
receptors or ion channels that are responsive to external agents or mechanical or thermal changes, 
such as receptors to bradykinin,15 trkA, and p7516; purines (P2X and P2Y)29; noradrenaline 33; 
acetylcholine (nicotinic and muscarinic)66; protease activated receptors67 ; epithelial Na+ channels 
(ENaC)68, the Deg/ENaC family69 and a number of transient receptor potential (TRP) channels 
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Figure 4. A Schematic View of Bladder Neuronal Control.
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(TRPV1, TRPV2, TRPV4, TRPM8, TRPA1)70-72. Stimulation of these urothelial sensor molecules in 
turn can control the release of chemicals, such as ATP, PGs , acetylcholine, and NO43, which have 
excitatory and inhibitory actions on afferent nerves located close to or in the urothelium72,73. 
A second development was the concept that phasic activity during the filling phase is likely to be 
necessary for an adequate bladder sensation.
Although this idea was originally put forward over 100 years ago74, its significance as part of a motor-
sensory system contributing to the generation of bladder sensation, has only recently been put 
into a physiological and pathophysiological context74,75. The theory proposed, is that altered motor 
activity, will alter afferent firing and therefore sensation. This idea is embodied into the autonomous 
bladder hypothesis or theory76. 
As a consequence of this, it is generally accepted that the structure and functions of the bladder are 
more complex than previously thought. Many laboratories are describing and characterising new 
cell types, among them, the interstitial cells47,48,77 and neural networks78. The interstitial cells all play 
a role in the complex physiological and pathological events. An integral component, generating the 
Chapter 1 – General Introduction
Thesis M.S. Rahnama’i.indd   17 10-10-13   13:36
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall
18
non-voiding contractions in the bladder, is the concept that there is a specialised system operating 
within the bladder wall itself75. This system does not involve the post-ganglionic parasympathetic 
innervation of the detrusor, rather, it is thought to be generated and propagated within a network of 
specialised cells, the interstitial cells. 
The role of Prostaglandins in bladder physiology
Arachidonic metabolites, more specifically PGs, are released from the bladder into the general 
circulation in response to distension79-81. It was found that PGs in the bladder wall originate 
from both the urothelial and muscle layers79,80. The exact role of this endogenous PG is not 
known, but it is well documented that exogenous PG alters bladder motor activity in vitro and 
in vivo and that it can also influence the micturition reflex in humans82-84, rats85, guinea pigs86, 
rabbits87 and monkeys88. The main PGs synthesized in the bladder are PGE
2
79-81 and PGI
2 
89. PGs 
are locally synthesized in the bladder muscle and mucosa. This synthesis is initiated by stretch 
of the detrusor muscle, bladder nerve stimulation, bladder mucosa damage and inflammation 
mediators. The effects of PGs in the bladder have been studied in numerous studies. These 
studies have shown, that bladder infusion with PGE
2
 enhances the micturition reflex and that 
urine levels of PGE
2
 are increased in patients with OAB90,91. Moreover, PG
2
 has been suggested 
to facilitate afferent nerve activity via EP1 receptors during urinary bladder inflammation in 
rats92. The level of PGE
2
, released by bladder strips taken from rats with spinal cord injury, was 
greater than that observed in normal bladders79. This finding was confirmed in bladders from 
patients with neurogenic overactive bladder or detrusor overactivity due to spinal cord injury 
compared to healthy controls79. Furthermore, the increased number and amplitude of non-
voiding bladder contractions resulting from spinal cord injury in rats could be counteracted by 
the administration of an EP1 recep tor antagonist. This antagonist also increased micturition 
volume79. More data supporting the involvement of PGE
2
 in detrusor activity came from a study 
showing that intravesical instillation with PGE
2 
increased fre quency of micturition and increased 
basal intravesical pressure in normal, conscious rats93.
Although the role of EP1 receptors on bladder function has been subject of different studies92,93, 
the cellular localization and the expression of EP receptors in the bladder wall remain unknown. 
This information would provide useful data that would help to increase our understanding of how 
these receptors are involved in the regulation of the micturition reflex. Regarding the actions of 
PG on the smooth muscle, it was thought, that PG might be co-released with acetylcholine at 
efferent nerve endings and so, directly contribute to muscle excitation88. Alternatively, PG might 
act indirectly on pre-synaptic motor terminals to affect the release of excitatory transmitters85. It 
has also been postulated that PG might also inhibit acetylcholine esterase84 or enhance myogenic 
bladder activity94. With regard to PG related changes in the micturition reflex, it was envisaged 
that they might act directly on the afferent nerves to modulate firing and so, trigger micturition 
at lower bladder volumes95. Such an action could arise anywhere in the bladder wall where PG are 
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synthesised and where there are afferent nerves. One specific location where this could occur is the 
urothelium and suburothelial layer. It is conceivable that they could act upon suburothelial nerve 
fibres. This would represent a situation similar to the one proposed for urothelial derived ATP and 
its subsequent activation of afferent nerves52. The idea that PG might affect afferent firing directly 
has yet to be demonstrated. In the guinea pig, it has recently been shown that the enzymes cyclo 
oxygenase type 1 (COX1) and cyclo oxygenase type 2 (COX2) are located within specific cell types 
within the lamina propria. COX1 is found in the basal layers of the urothelium and associated with 
the distributed network of lamina propria interstitial cells96. In contrast, COX2 is associated with 
the nuclei of a population of umbrella cells and the nuclei of the suburothelial interstitial cells. Thus, 
PG signalling in this region of the bladder wall may be complex with multiple sites of production 
and sites of action.
Figure 5. A Schematic View of the Prostaglandin System in the Bladder.
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Prostaglandins in the treatment of OAB 
Prostaglandin is known to be increased in the urine of patients with pathological bladder conditions, 
including OAB97. These findings have generated interest in PG as a possible therapeutic target for 
OAB. There is also interest in the use of enzyme of the COX enzyme which is an essential enzyme 
in the conversion of arachidonic acid to PGs. The use of non-selective COX enzyme improved 
neurogenic detrusor overactivity in cerebrally infarcted rats98. In this regard, modulation of PG 
receptors would be another interesting target possibly through the peripheral afferent systems in 
the bladder wall. The efficacy of COX inhibi tors and PG receptor antagonists in decreasing muscular 
tone and spontaneous contractile activity of the bladder has been confirmed repeatedly in various 
animal model studies99-101. Intravesical aspirin instillations in partially obstructed rabbit bladders 
attenuated, albeit not significantly, the contractile response to cholinergic stimulation102. The 
effects of dexketoprofen (a nonselective COX inhibitor) and NS-398 (a selective COX2 inhibitor) 
have been studied in normal and inflamed bladders99. The results suggest that modulation of the 
PG production via COX1, might modulate the threshold for the activation of the micturition reflex 
in normal rats and that inhibiting COX2 could prevent the urodynamic changes associated with 
bladder inflammation99.
The role of NO-cGMP in bladder physiology 
Research in Maastricht has shown that interstitial cells responded to exogenous NO with a rise in 
cGMP46. Later, these findings were extended, demonstrating that the network of interstitial cells 
consists of several cell types: cells in the suburothelium (suburothelial interstitial cells; SU-ICs), 
cells which lie on the surface of the smooth muscle bundles (superficial muscle interstitial cells; 
SM-ICs) and cells which lie within the muscle bundles (intra-muscular interstitial cells IM-ICs). 
Examples of these cells are shown in several studies31,47,51-53,59,103-106. Most direct evidence that these 
interstitial cells are responsible for this phasic activity comes from work in the mouse. In the mouse 
bladder, the only NO responsive cells appear to be the interstitial cells, associated with the outer 
muscle layer107. Phasic activity can be generated in these preparations, using muscarinic agonists. 
Application of NO completely inhibits this muscarinic induced phasic activity. 
From this, it can be concluded that the muscle interstitial cells are involved in the generation of this 
phasic activity and that a rise in cGMP inhibits this phasic activity. Interstitial cells in the bladder can 
respond to NO and influence contraction. They are thought to have the characteristics of a network, 
with pacemaker and conducting elements108. Furthermore, it is known that the bladder urothelium 
and suburothelial cells (mucosa) from several different species, including human, releases a number 
of substances that have an inhibitory effect on smooth muscle contractility and include NO, PGs, 
and adenine nucleotides. However, there is no clear understanding of the role that these substances 
play in physiological or pathophysiological control of bladder contractility. In muscle bath studies 
of several different animal species, surgical removal of the mucosal layer increases the contractile 
response to several different agonists73. This indicates that the mucosa releases agents that depress 
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muscle contractility and metabolizes or otherwise inactivates these agonists. Furthermore, the 
mucosa acts as a barrier for diffusion and penetration of agents into the muscle or responds to the 
agonists through the release of substances that modulate the contraction of the underlying muscle.
During the voiding phase, the NO-cGMP signalling pathway is activated in men, allowing efficient 
voiding through the relaxation of the urethra and prostate109. Systemic NO augmentation lowers 
functional bladder outlet resistance very rapidly in men and the NO-cGMP pathway may be a future 
target in the treatment of lower urinary tract symptoms109. 
Phosphodiesterase inhibitors in the treatment of OAB
Phosphodiesterase (PDE) inhibitors prevent the degradation of cyclic guanosine monophosphate 
(cGMP) and cyclic adenosine monophosphate (cAMP), which are important mediators in 
maintaining smooth muscle tone. PDE inhibitors were originally designed to treat increased 
coronary artery tone in cardiovascular disease and were later used for the treatment of erectile 
dysfunction. Recently, they have been shown to be of potential therapeutic use in the treatment 
of OAB and male LUTS. There are 11 members in the family of PDE-inhibitors characterized and 
three more are suggested to exist110-112. Initial evidence regarding the utilisation of PDE inhibitors 
originates from a study of 19 patients with refractory urgency incontinence113. Patients were treated 
with a PDE1 inhibitor, vinpocetine, and 58% of these patients demonstrated an improvement 
in either clinical or urodynamic parameters. In vitro and in vivo studies are on-going since PDE 
inhibitors are a logic treatment for OAB. Another recent development has been the finding that 
PDE type 5 inhibitors (sildenafil, tadalafil and vardenafil) improve urinary symptoms in men 
with erectile dysfunction and OAB, and this finding has been confirmed in several well-designed 
randomized controlled trials114-117. Despite the potential benefits of PDE5-inhibitors in OAB, the 
mechanism of action on the bladder is not known yet. It was demonstrated in the anaesthetised 
rat, that the PDE5-inhibitor vardenafil, has an inhibitory effect on the non-voiding contractions 
during the filling phase, suggesting an action on the smooth muscle118,119. Furthermore, it has 
been demonstrated, that PDE5-inhibitors can reduce the force generated in strips of the detrusor 
muscle119. In this paper, it was also reported that the PDE5-enzyme was located within the muscle 
fibers. Using these data, it was argued that the observed muscle relaxation due to PDE5 inhibition, 
was the result of a raised cGMP, resulting in inhibition of detrusor contraction. 
However, there are several published reports, which demonstrate that, after stimulation of the 
production of cGMP by NO, the muscle cells of human, mice and guinea pig bladders do not 
respond with a rise in cGMP46,47,107. Nonetheless, a rise in cGMP does occur in cells of a different 
type, lying in between the muscle cells, the so called, interstitial cells. Based on these observations, 
it can be argued, that NO doesn’t have a direct relaxing effect on the detrusor muscle, through a 
rise in cGMP. Instead, it is hypothesized that the aforementioned NO excitable interstitial cells play 
a role in the regulation of the bladder contractions and that these might be the site of PDE inhibitor 
action in the bladder.
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Research question of this thesis 
This thesis has focused on two control mechanisms in bladder physiology and pathophysiology; 
first, the role and working mechanisms of PGs and second, the NO/cGMP/PDE system in the 
bladder physiology.
As PG pathways have been suggested to be a possible promising pharmacological target in the 
treatment of OAB, the first part of the thesis focuses on the PG receptors of the predominant 
prostanoid type shown in the bladder, which is PGE
2
. The choice of EP1 and EP2 is based 
on two reasons. First, EP1 and EP2 receptors in the bladder have not yet been studied with 
immunohistochemistry, whereas EP4 and EP3 immunohistochemical characterization in the 
bladder had been addressed before120,121. Second, at the time of our research there was a large 
phase I trial with a PGE
2
 receptor subtype EP1 antagonist, which was thought to be a promising new 
drug in the treatment of OAB122. Experiments, using visualisation techniques have been used to 
pinpoint the target and production site of PGs in order to answer our first research question on the 
localization and the role of EP1 and EP2 receptors in the bladder and on the possible use of these 
receptors as a target in the treatment of voiding disorders. 
The second part of the thesis concentrates on the PDE inhibitors. Recently, some studies have 
been conducted with PDE5 inhibitors as a possible treatment target in order to improve urinary 
symptoms 114,123. These studies have shown the positive effect of PDE5 inhibitors on men with 
mild to moderate lower urinary tract symptoms (LUTS). It is presumed, although unproven, that 
the working mechanism of this medication is through bladder neck/prostatic smooth muscle 
relaxation. It has also been shown that there are many cell types in the bladder wall, that respond 
to NO with a rise in intracellular cGMP47,107. It was generally assumed that if the PDE5-inhibitors 
are acting on the bladder, it should be upon one of these cell types. Our research was focused on 
identification of the cells which specifically expressed the PDE5 enzyme. Immuno-histochemical 
techniques were used in order to identify the location of PDE5. The tissue was exposed to the PDE5 
inhibitor in combination with nitric oxide that stimulates the guanylyl cyclase enzyme resulting in a 
rise in cGMP. An increase in cGMP, was visualised using highly selective antibodies against cGMP. 
PDE5 was chosen as PDE5 inhibitors are the most widely known and clinically applied of all available 
PDE inhibitors. Our second research question was the location and the physiological role of the 
PDE5 enzyme in the bladder, in order to form a basis for the study of the effect and possible use of 
PDE5 inhibitors in voiding dysfunctions.
Thesis outline 
This thesis is composed of two main sections. The first four chapters focus on the distribution 
and the role of PGs in the guinea pig bladder. The general introduction presented in Chapter 1 
introduces the problem of OAB, and gives a brief overview of bladder anatomy and physiology. The 
current literature on what is known on PGs and their role in the bladder are displayed in Chapter 2. In 
Chapter 3, the distribution of the PGE
2
 receptors EP1 and EP2 in the urothelium and suburothelium 
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of the guinea pig urinary bladder are presented. Chapter 4 and 5 deal with the EP1 and EP2 receptor 
distribution in the detrusor muscle layers. In Chapter 6, a study of the physiological role of PG is 
presented, with the results of an ex vivo study of the effects of inhibition of the enzyme responsible 
for PG production by a COX inhibitor (indomethacin) on the guinea pig bladder. 
The second part of the thesis focuses on the distribution of PDE5 in the guinea pig urinary bladder. 
In Chapter 7, a review of the literature is presented summarizing the current knowledge of the role 
of phosphodiesterases in bladder pathophysiology. The distribution and the site of action of PDE5 
in the guinea bladder are discussed in Chapter 8, based on an indirect visualization technique. A 
general discussion of all the studies presented in the thesis is given in Chapter 9. 
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Abstract
Five primary prostanoids are synthesized by the cyclooxygenase enzymes, COX1 and COX2: the 
prostaglandins PGE
2
, PGF
2α
, PGI
2
, PGD
2
 and thromboxane A
2
. High levels of these signaling 
molecules have been implicated—in both animal models and human studies—in decreased 
functional bladder capacity and micturition volume and increased voiding contraction amplitude. 
Thus, inhibition of prostanoid production or the use of prostanoid receptor antagonists, might 
be a rational way to treat patients with detrusor muscle overactivity. Similarly, prostanoid 
receptor agonists, or agents that stimulate their production, might have a function in treating 
bladder underactivity. Although some promising results have been reported, the adverse effects 
of nonselective cyclooxygenase inhibitors are a major concern that restricts their use in the 
treatment of functional bladder disorders. Further preclinical and clinical studies are needed before 
cyclooxygenase inhibitors, prostanoid receptor agonists and antagonists become worthwhile 
therapeutic tools in this setting.
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Introduction
The prostanoids are a subclass of signaling molecules consisting of the prostaglandins, thromboxanes 
and prostacyclins. Two cyclooxygenase enzyme isoforms—COX1 and COX2—catalyze the rate-
limiting step of prostanoid synthesis, which uses the fatty acid arachidonic acid as the substrate. Both 
cyclooxygenase isoforms produce labile cyclic endoperoxide, also known as PGH
2
, which is involved 
in two pathways of prostanoid synthesis. First, PGH
2
 is the substrate for the enzymes that produce the 
other prostaglandins and thrombox ane A
2
 (figure 1). Secondly, PGH
2
 rapidly undergoes spontaneous 
rearrangement in aqueous solution to PGE
2
, PGD
2
 and, via ring cleavage, to the seco-prostagladins, 
which are not discussed further in this article1. Although the exact rates of reaction of each pathway are 
not known, the seco-prostagladins constitute approximately 20% of PGH
2
 products2.
The involvement of the prostanoids in bladder physiology first became apparent in the early 1970s, 
after studies showed that prostaglandins were released upon distension of the bladder3 and as a 
result of mechanical damage to or inflamma tion of the bladder mucosa4. Research over the past 
several decades has confirmed that prostanoids have a role in control ling mammalian urinary 
bladder motil ity5,6.For example, vesical distension and pelvic nerve stimulation cause the release of 
prostaglandins PGE
2
 and PGF
2α
into the pelvic venous blood in anesthetized dogs3,7. Additionally, 
intra-arterial administration of PGE
2
 and PGF
2α
 in dogs decreases the threshold micturition volume 
considerably8, which, by contrast, can be increased by the inhibition of prostaglandin production 
using indomethacin8.
In the rabbit bladder, an enhancing role for PGE
2
 and PGF
2α
 has been demonstrated on cholinergic 
and purinergic contractions generated by electrical field stimulation9,10. In the human bladder, ex vivo 
studies have shown that the detrusor muscle relaxes in response to indomethacin administration 
and that this muscle produces PGE
2
 and PGF
2α
-like substances11. These data suggest a role for 
endogenous prostaglandins in the maintenance of baseline muscle tone in the normal human 
detrusor. Indeed, the high levels of prostanoids expressed in the bladder and their expansive 
distribution implies organ-specific roles for these sig naling molecules in bladder function and, by 
extension, dysfunction.
A role for prostanoids as biomarkers of disease has also been suggested. For example, urinary 
levels of PGE
2
 and PGF
2α
 are significantly increased in patients with overactive bladder syndrome 
compared with control patients12. Moreover, an inverse relationship was found between urinary 
PGE
2
 levels and both the bladder volume at first desire to void and the maximum cystometric capac-
ity12. However, urinary levels of PGE
2
 in a group of patients with detrusor overactivity, increased 
bladder sensation and interstitial cystitis were not significantly different from those in healthy 
controls13. These conflict ing findings illustrate that the role of pros tanoid levels in the diagnosis of 
functional bladder disorders remains controversial and merits further investigation.
In this chapter, we describe the role of prostanoids in bladder physiol ogy, summarize the findings 
from animal model and human studies and discuss the clinical use of prostanoids in the treatment 
of functional bladder disorders.
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Prostanoid expression in the bladder
The five primary prostanoids (PGE
2
, PGF
2α
, PGI
2
, PGD
2
 and thromboxane A
2
) are all synthesized 
and released in the bladders of various species during detrusor contraction14–16 and under basal 
physiological con ditions17,18. For example, in the rabbit, PGE
2
 is the major prostanoid produced, 
followed by PGI
2
, PGF
2α
 and thromboxane A
2
19. By contrast, PGI
2
 is the principle prostaglandin in the 
rat bladder; PGE
2 
and thromboxane A
2
 are produced to a lesser extent20 In the human bladder, the 
major prostanoid is PGI
2
, followed by PGE
2
, PGF
2α
 and throm boxane A
2
20. As well as these species-
specific prostanoid expression profiles in the mammalian urinary bladder21, marked local differences 
in prostanoid production are apparent within the bladder wall. For example, the rabbit bladder dome 
(body) produces considerably higher levels of all the prostanoids than the base19. In normal rats, the 
levels of thromboxane A
2
 and PGI
2
 were much greater in urine collected from the bladder than in that 
collected from the ureters22, which suggests that the bladder contributes considerably to the amount 
of prostanoids present in the urine.
Both COX1 and COX2 are expressed in the bladder23–25. Constitutive expression of COX1 is 
associated with cell somata of the urothelium and with the network of cells running over the 
smooth muscle bundles of the detrusor24. COX2 expres sion is induced by various stimuli, includ-
ing proinflammatory cytokines and growth factors26,27. The differences in expression of the two 
cyclooxygenase isoforms have led to the widely held belief that COX1 produces prostanoids 
required for the maintenance of homeostasis, whereas those produced by COX2 fulfil a primarily 
pathophysiologi cal role27. Interestingly, increased COX2 expression is apparent immediately after 
experimentally induced bladder outlet obstruction25, which suggests that selective COX2 inhibitors 
might alleviate symp toms in patients with overactive bladder. Indeed, in patients with bladder 
inflam mation, inhibiting COX2 could prevent urodynamic changes28.
The urothelium
The bladder urothelium secretes several molecules, such as nitrous oxide, ATP and various 
prostaglandins, which have cell signaling functionality23,24,29. The inter stitial cells of the urothelium 
and suburothelium also express several receptors for these signaling molecules29, including 
prostaglandin receptors30.
The expression of COX1 by the basal layer of the urothelium (and, to a lesser extent, the cells of 
the intermediate urothelial layer) indicates that prostanoids are active at these sites23,30. Indeed, 
stretching the urothelium can trigger the release of a number of different substances, including 
prostaglan dins24. Removal, damage or stimulation (by stretching or administration of muscarinic 
receptor agonists) of the urothelium and suburothelial layers can change the contrac tile activity of 
the underlying tissues, includ ing the smooth muscle31,32, which suggests that the prostaglandins 
are integral to the complex signaling system operating within the urothelium and between the 
urothelium, suburothelial cells of the lamina propria24,30 and the muscle layers31,32. Indeed, cells 
Thesis M.S. Rahnama’i.indd   36 10-10-13   13:36
37
Chapter 2 – The Role of Prostanoids in Urinary Bladder Physiology
Prostaglandin subtypes
Receptor subtypes
O
HO
PGE2 PGD2 PGI2 Thromboxane A2PGF2α
OH
COO–
O
HO
COO–
HO
OH HO
O
O
O
O
X
O
PHO
O
O
OH
COO–
OH
O
O
COO–
COO–
O
–OOC
HO OH
Glycerophospholipid
Arachidonic acid
COX-1
COX-2
Prostaglandin synthases
Prostaglandin H2
Cell 
membrane
Cell membrane
PLA2
OH
O
O
O
O–
EP1, EP2, EP3, EP4 DP1, DP2 FP2 IP TP
Figure 1. An overview of prostanoid synthesis and prostaglandin receptor affinity. The COX1 and COX2 enzymes catalyze
key steps in the biosynthesis of the labile cyclic endoperoxide prostaglandin PGH
2
, which is subsequently converted into
five structurally related primary prostanoids: the prostaglandins, PGE
2
, PGD
2
, PGF
2α
, PGI
2
, and thromboxane A
2
. These
prostanoids each have their own receptors—EP1–4, DP1–2, FP
2
, IP and TP, respectively—which comprise a distinct family 
of G-protein-coupled receptors. Abbreviations: COX, cyclooxygenase; PLA
2
, phospholipase A
2
. Permission obtained from
Nature Publishing Group. Gupta, R. A. & DuBois, R. N. Nature Reviews Cancer 1, 11–21 (2001).
within these bladder layers express COX1 (at least in the guinea pig bladder) and, hence, are capable
of prostaglandin produc tion23,30. COX1 expression predominates within the basal and intermediate 
layers of the urothelium and within a population of small cells closely associated with a network
of vimentin-positive interstitial cells23. These interstitial cells form a network throughout the
suburothelial space of the lamina propria that extends over the surface of the muscle bundles
and invades the inner layers of the bladder wall. Prostanoids are, therefore, pro duced by cells
throughout the bladder wall and its muscle layers23,24,30.
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The detrusor muscle
The cells of the bladder muscle layer express both COX1 and COX2 and, therefore, might also 
synthesize prostaglandins23–25. Indeed, rabbit detrusor muscle strips (free of urothelium) produce 
PGE
2
33. Furthermore, detrusor muscle contraction in response to acetylcholine and ATP activation 
is increased by prostanoid production in various animal models5,34–36, which might point to more 
complex prostanoid involve ment in the bladder than was previously thought. Further implicating 
the prostanoids in detrusor function was the observation that administering indomethacin or other 
NSAIDs, which inhibit prostanoid syn thesis, caused a reduction in tone and loss of spontaneous 
contractile activity of the isolated bladder; this phenomenon can be reversed by administering 
prostanoids14. In fact, application of exogenous prostaglan dins (PGF
2α
, PGE
1
 and PGE
2
) causes 
contraction of both human and animal isolated detrusor muscle7,37–44. Moreover, prostaglandins 
also affect the mammalian urethra7: PGF
2α
 causes it to contract37–40, whereas PGE
1
 and PGE
2
cause relaxation37,42. On the basis of these findings, one can envisage a role for agents that act on 
prostanoid pathways in treating incontinence disorders.
Prostanoid receptors
Each prostanoid interacts with a specific member of a family of G-protein-coupled receptors 
(Figure 1). Overall, with the exception of the prostaglandin DP and FP
2
 receptors, specific 
for PGD
2
 and PGF
2α
, respectively, all the prostanoid receptors have been shown (directly or 
indirectly) to be expressed in the bladders of various species (figure 2). Whether these recep-
tors have a function in bladder physiol ogy remains to be determined. One study showed that 
the prostaglandin DP
1
 receptor (for PGD
2
) mediates relaxation in human cavernosal tissue and 
stimulates erectile responses in rats and rabbits45. However, no other evidence supports the 
presence of prostaglandin DP
1
 and DP
2
 receptors else where in the urogenital tract. Similarly, no 
published data support the expression or the role of the prostaglandin FP
2
 receptor (for PGF
2α
) 
in the bladder. The expression and distribution of PGI
2
 (prostacyclin) receptors in the urinary 
bladder is also unknown. However, PGI
2
 is synthesized locally in the bladder in response to bladder 
distention, injury and inflammation10,46, which suggests that its receptor might also be present. 
This notion is supported by evidence that the PGI
2
 receptor antagonist RO3244019 was effective 
in the treatment of neurogenic detrusor overactivity rats with spinal cord injuries47. Similarly, no 
data have been published on thromboxane A
2
 recep tor expression or distribution in the bladder. 
However, thromboxane A
2
 induces con traction of isolated human urinary bladder smooth 
muscle48. Moreover, two thrombox ane A
2
 receptor antagonists inhibit sponta neous, rhythmic 
contractions of the rabbit bladder, which was free of urothelium, indi cating the presence of these 
receptors in the bladder muscle layer49.
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Figure 2. Schematic overview of the distribution of prostanoid receptors in the mammalian bladder.
Prostaglandin DP and FP receptors have not yet been identified in the bladder and their role in bladder 
physiology remains unclear. Expression of IP (the PGI
2
receptor) has been indirectly confirmed using an 
IP-selective antagonist, which reduced detrusor muscle overactivity in a rat model47. The PGE
2
receptors 
EP1 and EP2 are present in the guinea pig urothelium and suburothelial interstitial cells. The EP1 receptor 
is also expressed in muscle interstitial cells and smooth muscle cells63. The EP3 and EP4 receptors (not 
shown) have been implicated in rat bladder contraction but their distribution in the bladder has not yet 
been shown63,65,66. Abbreviation: TXA
2
, thromboxane A
2
.
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If the prostanoids do contribute to urinary bladder overactivity, PGE
2
 has been put forward as 
the most likely candi date. The evidence supporting this hypoth esis includes studies in which 
intravesical instillation of PGE
2
 resulted in diminished bladder capacity41,50–52. In addition, local 
PGE
2
 production is elevated in the blad ders of animals with overactive detrusor muscles53,54, as 
well as human patients with overactive bladders12,55. The physiological effects of PGE
2
 are mediated 
by the four prostaglandin EP receptors56, EP1–EP4, each of which responds to PGE
2
 in a differ ent 
manner57. In general, stimulation of EP1 and EP3 are thought to cause contraction of the bladder 
smooth muscle, whereas EP2 and EP4 stimulation induces muscle relax ation58,59. The molecular 
characterization of these receptors has led to renewed interest in the development of compounds 
with activ ity against specific human prostaglandin receptors, including EP160.
Initially, the effects of PGE
2
 on bladder function were thought to be mediated predominantly through 
EP1 receptors61, because these effects could be inhibited by antagonists of this receptor subtype62. 
In the guinea pig, the EP1 receptor is present in the urothelium, suburothelial interstitial cells, 
muscle interstitial cells and, to a lesser extent, smooth muscle cells30,63. The EP1 receptor is also 
involved in initiation of the micturition reflex in both normal rats and in animals with bladder outlet 
obstruction62. The EP1 receptor, therefore, is thought to contribute to the initiation of detrusor 
overactivity after bladder outlet obstruction62.
Little information is available on the exact role of the EP2 receptor in the bladder. However, the normal 
guinea pig bladder expresses EP2 receptors30, and the dual EP1 and EP2 receptor antagonist AH 6809 
decreases the amplitude of detrusor contraction in the human bladder, as observed in isolated bladder 
experiments48. In rats, pharmacological activation of the EP3 receptor with the agonist GR63799X was 
associated with reduced functional bladder capacity, whereas inhibition of this recep tor resulted in an 
enhancement of func tional bladder capacity64. A diminished response to intravesical instillation of 
PGE
2
 was observed in EP3-receptor-knockout mice; these animals also had increased bladder capacity 
under basal conditions51. Furthermore, cystometric studies have pro vided evidence in support of a role 
for EP3 receptor activity in urinary bladder activity and regulation of urinary flow64. Although its exact 
role remains to be determined, the EP3 receptor is (at least in this rat model study) a modulator of 
urinary bladder activ ity that might regulate urine flow. Despite these findings, the type and localization 
of cells expressing EP3 receptors in the bladder of any species has not yet been studied.
Expression of the EP4 receptor has been demonstrated in the rat bladder, albeit indi rectly via 
Western blot. EP4 expression can be inhibited by intravesical or intraspinal administration of 
botulinum toxin A in rats with cyclophosphamide-induced cystitis65. A study of rats with bladder 
outlet obstruc tion showed that activation of EP4 recep tors using the agonist ONO-AE1-329 might 
suppress detrusor muscle contraction and afferent nerve activity66. By contrast, upreg ulation via 
increased expression of EP4 receptors exacerbated cyclophosphamide-induced overactive bladder 
in rats; in this study, treatment with an EP4 receptor antagonist attenuated bladder activity67. 
Blockade of the EP4 receptor mechanism has, therefore, been proposed as a poten tial treatment 
for patients with overactive bladder. However, more studies are needed to truly understand the 
mechanisms underlying EP4 receptor signaling and the implications of its blockade.
Thesis M.S. Rahnama’i.indd   40 10-10-13   13:36
41
Pharmacological intervention
Numerous studies in animal models have examined the effects of targeting pros tanoids 
pharmacologically to treat bladder disorders. For example, the level of PGE
2
 released by bladder 
strips taken from rats with spinal cord injury was greater than that observed in normal bladders.68 
This finding was confirmed in bladders from human patients with neurogenic overactive bladder or 
detrusor overactivity owing to spinal cord injury and healthy controls68. Moreover, administration 
of an EP1 recep tor antagonist counteracted the increased number and amplitude of nonvoiding 
bladder contractions resulting from spinal cord injury in rats. This treatment also led to increased 
micturition volume68. In further support of the involvement of PGE
2
 and EP1 receptors in detrusor 
activity, normal, conscious rats that received intra vesically instilled PGE
2
 had increased fre quency 
of micturition and increased basal intravesical pressure52.
The efficacy of cyclooxygenase inhibi tors and prostanoid receptor antagonists for decreasing 
muscular tone and spon taneous contractile activity of the bladder has been confirmed repeatedly 
in various animal model studies14,28,69,70. For example, intravesical aspirin instillations in partially 
obstructed rabbit bladders attenuated, albeit not significantly, the contractile response to 
cholinergic stimulation71. The effects of dexketoprofen (a nonselective cyclooxygenase inhibitor) 
and NS-398 (a selec tive COX2 inhibitor) have been studied in normal and inflamed bladders28; the 
results suggest that COX1 might be involved in raising the threshold for activation of the micturition 
reflex in normal rats and that inhibiting COX2 could prevent the uro dynamic changes associated 
with bladder inflammation28. A subsequent study showed that selective COX2 and nonselective 
cyclooxygenase inhibitors were both effective in suppressing the micturition reflex in rats with 
bladder overactivity caused by bladder irritation72. Similar results were presented by a Japanese 
research group with regard to the urodynamic effects of the nonselective cyclooxygenase inhibitor 
indomethacin in rats with xylene-induced cystitis and healthy controls70. By contrast, NS-398 
(a selective COX2 inhibitor) was a much less potent inhibitor of the micturition reflex than the 
unselective cyclooxygenase inhibitor dexketoprofen in normal rats28. These results suggest that 
COX1 might be involved in raising the threshold for activating the micturition reflex in normal 
rats, whereas COX2 might prevent or reverse the uro dynamic changes associated with bladder 
inflammation induced either by surgery, endotoxins or cyclophosphamide treatment. Few clinical 
studies have examined pharmacological agents that target prostanoid signaling, despite the 
increasing evidence from animal models that cyclooxygenase inhibitors might be effective in 
the treatment of detrusor muscle overactivity. Treatment with the nonselective cyclooxygenase 
inhib itors flurbiprofen and indomethacin was associated with urodynamic and clinical benefits 
in a controlled study of 62 patients with urinary symptoms caused by detrusor instability73,74. 
Unfortunately, these two agents produced many adverse effects, including nausea, vomiting, 
headache and gastrointestinal symptoms73,74. The most promis ing results were reported in a 
double-blind, placebo-controlled study of the nonselective cyclooxygenase inhibitor ketoprofen 
(given intravesically for 4 weeks) in 30 women with urodynamically proven detrusor overactiv ity. Of 
these patients, 18 were symptom-free after this treatment, and no adverse effects were observed75.
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Cyclooxygenase inhibitors are also com monly used to treat postoperative pain76; reducing PGE
2
levels might, therefore, have a detrimental effect on postoperative voiding function. Unfortunately, 
no studies have been published on this potentially important relationship. By contrast, PGE
2
 has 
been assessed as a treatment for bladder hypocontractility or underactive detrusor syndromes, 
although little clinical benefit was observed77,78. Even in combination with the cholinergic agonist 
bethanechol chloride, intravesical instillation of PGE
2
 had only limited therapeutic benefit com-
pared to placebo79. However, intravesical instillation of PGE
2
 reduces the time to restoration of 
detrusor function after gynecological surgery80–82.
Future perspectives
The available clearly show that prostanoids are involved in the signaling cascade within the 
bladder wall. However, their exact role in the bladder is still not fully understood. One hypothesis 
presented in the litera ture is that prostanoids, specifically the prostaglandins, act as mediators of the 
noncholinergic, nonadrenergic control of contraction of the mammalian detrusor83,84. Prostaglandins 
are also thought to induce increased excitability of afferent nerve fibres in several disease states4, 
such as neuro genic bladder, outflow obstruction, idio pathic detrusor instability and interstitial 
cystitis, as well as in the ageing bladder, which in turn is thought to affect both effer ent and afferent 
neurotransmission. Several different prostaglandin receptors could potentially be involved in this 
mechanism4,6. This hypothesis is further supported by data showing that prostaglandin synthesis is 
stimulated during the contractile response of the detrusor smooth muscle to release of acetylcholine 
and ATP34,36. Indeed, ATP and PGE
2
 release from the bladder urothelium in rats with overactive 
detrusor muscles (induced by cerebral infarction) can be suppressed by the antimuscarinic agents 
imidafenacin and dariferacin.85 Additional support for the regulatory effect of pros taglandins 
in the bladder has come from observations that cyclooxygenase inhibi tors such as indomethacin 
exert a mild inhibitory effect on electrically evoked, nerve-mediated contractions of the mam malian 
detrusor36. By contrast, addition of exogenous prostaglandins enhanced the electrically evoked nerve-
mediated con tractions of isolated rabbit bladder smooth muscle as well as those evoked by the ATP 
analogue β,γ-methylene86. Spontaneous, rhythmic contractions of the rabbit and mouse detrusor are 
also thought to be mediated by PGE
2
6,33. Both ATP and PGE
2
 induce acetylcholine release from the 
guinea pig bladder urothelium5. In addition, some findings indicate that cyclooxygenase inhibitors 
might suppress ATP release from bladder epithelium by inhibiting produc tion of PGE
2
; EP1 and EP3 
receptors are thought to be involved in mediating this effect87. These observations suggest a strong 
interplay between the prostaglandins, their receptors and ATP in the control of bladder contractility 
that might provide a number of potential targets for therapy in bladder con tractility disorders. Indeed, 
some evidence points to an overall modulating influence of PGE
2
 on nerve excitability, and perhaps 
on intramural reflexes. However, little evi dence exists of any direct effect along the efferent arm of 
the micturition reflex4,5,35,38. Thus, from a therapeutic perspective, drugs that enhance prostaglandin 
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production or bladder sensitivity to these signaling mol ecules might be suitable for patients with 
hypocontractile bladder disorders. Emerging evidence indicates that PGE
2
 causes smooth muscle 
depolarization, induces intracellular smooth muscle Ca2+ waves and increases the frequency of action 
potential firing in smooth muscle cells in a manner resistant to neurotransmitter block ade with 
cyclopentolate6. Furthermore, another study revealed that guinea pig bladder smooth muscle cells 
express the EP1 receptor and the prostaglandin signal is propagated throughout the bladder wall via 
the interstitial cell network63. The implication of this finding is that the motor effect by prostaglandins 
is not necessarily mediated through nerve fibres but rather through the interstitial cell network.
Cumulatively, these hypotheses can be used to formulate a comprehensive view of the role of 
the prostanoids in the bladder. Although the urothelium has been historically viewed primarily 
as a barrier, it is increasingly being recognized as a responsive structure capable of detect ing 
physiological and chemical stimuli, and of releasing a number of signaling molecules23,24,29,30,87. 
Data indicate that bladder urothelial cells display a number of receptors similar to those of 
sensory neurons, such as nociceptors and mechanoreceptors, and that these cells use diverse 
signal-transduction mechanisms such as prostaglandins to detect and respond to physiological 
stimuli88. Several substances, including prostanoids, are released from urothelial cells following 
physical and chemical stimuli24,30. Thus, because pros taglandins are produced by the urothelium 
and lamina propria18,24,30, they are likely to have an effect on the bladder smooth muscle cells and the 
interstitial cell network24,30 and might also have a modulating effect on the nerves38,88.This hypothesis 
provides three possible, coexisting mechanisms of action for prostaglandins on bladder function: 
a neuromodulatory effect, effects mediated through the interstitial cell network and direct effects on 
smooth muscle cells.
More research is needed to elucidate the exact role of prostanoids in the bladder. Despite agreement 
in the literature that prostanoids have an important role in bladder physiology, approaches that target 
these factors (by modulating prostanoid receptors, inducing prostanoid synthesis or administering 
exogenous prostanoids) have failed to gain a place in the standard therapeutic arsenal for functional 
bladder disorders. This failure is partly attribut able to the high incidence of adverse effects associated 
with the medications used and, in some cases, to their poor clinical effi cacy73–75,77–79,81,82. Despite 
these setbacks, efforts to find effective prostanoid-based strategies to treat bladder disorders are 
ongoing. For example, long-acting prosta glandin agonists or cyclooxygenase activa tors could 
be beneficial in the treatment of patients with bladder underactivity(figure 3)89. ONO 85-39, an 
EP1 recep tor antagonist has entered phase I clinical trials in patients with overactive bladder90. 
Bladder-specific prostaglandin receptor antagonists or nonselective prostanoid receptor antagonists 
might also provide an avenue for treating bladder overactivity. In this regard, the EP receptors for PGE
2
seem to be the most promising targets. Importantly, the various prostaglandin receptors operate 
through different mecha nisms, and their nonselective activation or inhibition might inadvertently 
result in opposing effects. Thus, combination therapy with specific selective prostaglan din receptor 
agonist and antagonists of the other receptors is a potentially interesting area worthy of exploration.
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Inflammation
Detrusor sphincter
dyssynergia
External sphincter
Bladder neck
Bladder
Spinal cord injury
Idiopathic etiology
Detrusor overactivity
• Urgency
• Frequency
• Nocturia
• Urge incontinence
• High pressure
Hypocontractile detrusor
• Hesitancy
• Poor or interrupted stream
• Insensate bladder
• Low pressure
Possible treatment
• Intravesical instillation 
with prostanoids
• EP1 or EP3 agonists
• EP2 or EP4 receptor blockade
Incomplete bladder emptying
• High postvoid residual volumes
• Stasis of urine
• Bacterial growth
• Stones
Possible treatment
• Cyclooxygenase inhibitors
• EP1 and EP3 receptor 
blockade
• EP2 and EP4 agonists
Figure 3. Common pathological states of the urinary bladder. 
Prostanoid-related pharmacotherapy might be useful for treating detrusor overactivity or hypocontractility.
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Conclusions
Prostanoids are produced in the bladder and their receptors are located within the bladder wall. In 
animal experiments, the administration of prostanoids, specifically the prostaglandins, decreases 
functional bladder capacity and micturition volume and increases voiding contraction amplitude. 
This effect has also been demonstrated in a small number of human studies with limited numbers 
of patients. Inhibition of prostanoid production, or the use of prostanoid receptor antagonists, 
seems to be a rational method of treating patients with detrusor overactivity. By contrast, prostanoid 
receptor agonists or agents that stimulate production of prostanoids might have a role in treating 
bladder underactivity. Although some prom ising results have been reported, the adverse effects 
associated with nonselective cyclooxygenase inhibitors present a major obsta cle to the general use 
of prostaglandin-based pharmacotherapy in patients with functional bladder disorders. Further 
preclinical and clinical studies are needed before pros tanoid signaling pathways can become viable 
targets for pharmacotherapy in functional bladder disorders.
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Abstract 
Purpose
Urothelium has 2 main functions. It is a barrier to urine and has a sensory role. In response to 
stretch urothelium releases various substances that modulate afferent nerve activity. Recent data 
on the localization of cyclooxygenase type 1, the enzyme responsible for prostaglandin production, 
suggests that prostaglandin may have complex local action.
Materials and Methods
The bladders of 7 guinea pigs were stained for prostaglandin receptors type 1 and 2, and costained 
for vimentin and cyclooxygenase 1.
Results
Prostaglandin E
2
 receptor type 1 staining was seen in urothelial cells and in the suburothelium. 
Urothelial staining, which was often punctuate and weak, was detected in all urothelial cell layers, 
including suburothelial cells. In contrast, strong prostaglandin E
2
 receptor type 2 staining was seen 
in the urothelium and in suburothelial cells. Cyclooxygenase 1 was absent in interstitial cells and 
umbrella cells with the highest concentration in the basal cell layer.
Conclusions
Interstitial cells express prostaglandin receptor types 1 and 2, indicating that they can respond to 
prostaglandin. Umbrella cells do not express cyclooxygenase 1. Cyclooxygenase 1 was present in 
basal urothelial cells, making them a possible site of prostaglandin synthesis. Thus, prostaglandin 
produced by urothelium may target prostaglandin receptor types 1 and 2 in the urothelium and 
suburothelium. Therefore, prostaglandin is hypothesized to have a role in signal regulation in the 
bladder wall.
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Introduction
Arachidonic metabolites, principally PG, are released from the bladder into the general circulation 
in response to distention1 - 3. Bladder PG originates from urothelial and muscle layers1,2. The exact 
role of this endogenous PG is not known but it is well documented that exogenous PG alters bladder 
motor activity in vitro and in vivo, and can influence the micturition reflex in humans4-6, rats7, guinea 
pigs8, rabbits9 and monkeys10. The main PGs synthesized in the bladder are PGE
2
1-3 and PGI
2
11. PGs 
are locally synthesized in bladder muscle and mucosa. Synthesis is initiated by detrusor muscle 
stretch, bladder nerve stimulation, bladder mucosa damage and inflammation mediators. PGs 
are involved in the micturition reflex by decreasing thresholds of the stimuli necessary to trigger 
bladder contraction by activation of the capsaicin sensitive afferent nerves 2-4. The role of the PG 
signaling pathway on bladder function and more particularly the role of EP1 on bladder function 
is the subject of different studies12 , 13. However, to our knowledge prostaglandin receptor cellular 
localization and expression in the bladder wall remain unknown. This information would help us 
understand how these receptors are involved in micturition reflex regulation.
Regarding PG actions on smooth muscle, PG may be coreleased with acetylcholine at efferent nerve 
endings and so directly contribute to muscle excitation10. Alternatively, PG may act indirectly on 
presynaptic motor terminals to affect excitatory transmitter release7. It may also inhibit acetylcholine 
esterase6 or enhance myogenic bladder activity14.
PG related changes in the micturition reflex may act directly on afferent nerves to modulate firing 
and so trigger micturition at lower bladder volume15. Such action could arise anywhere in the bladder 
wall where PG is synthesized and there are afferent nerves. A specific site is the urothelial and 
suburothelial layers. PG is released from this region, as mentioned, and could act on suburothelial 
nerve fibers. This would represent a situation similar to that proposed for urothelial derived ATP 
and its subsequent afferent nerve activation16. To our knowledge whether PG directly affects afferent 
firing remains to be determined.
In the guinea pig the enzymes COX1 and 2 are located in specific cell types in the lamina propria. 
COX1 is found in the basal layers of the urothelium and is associated with the distributed network 
of lamina propria interstitial cells17. COX2 is associated with the nuclei of a population of umbrella 
cells and SU-IC nuclei18. Thus, PG signaling in this bladder wall region may be complex with multiple 
sites of production and action.
We used antibodies to EP1 and EP2 to explore this complexity by localizing potential cellular 
targets of PG in the lamina propria. We discuss our observations in terms of possible physiological 
mechanisms that may occur in this bladder wall region.
Materials and Methods
Seven male guinea pigs weighing 270 to 300 g were sacrificed by cervical dislocation. All procedures 
were done in agreement with Maastricht University ethical committee guidelines.
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The bladder, including the proximal urethra, was removed from each animal and placed in ice-
cold Krebs solution composed of 121.1 mM NaCl, 1.87 mM KCl, 1.2 mM CaCl
2
, 1.15 mM MgSO
4
, 25 
mM NaHCO
3
, 1.17 mM KH
2
PO
4
 and 11.0 mM glucose bubbled with 5% CO
2
 and 95% O
2
 (pH 7.4). 
Each bladder was divided into a ventral piece and a dorsal piece, and maintained in Krebs solution 
containing 1 mM of the nonspecific phosphodiesterase inhibitor isobutyl-methyl-xanthine (Sigma-
Aldrich) at 36 °C for 30 minutes. Incubation was terminated by immersing bladder pieces in ice-cold 
fixative solution of 4% freshly prepared depolymerized paraformaldehyde for 120 minutes at 4 °C. 
Tissues were fixed in 3 steps of 2 overnight and 1 daytime incubation at 4 °C in 0.1 M phosphate buffer 
with 10%, 20% and 30% sucrose, respectively. On day 3 the tissues were placed in Tissue-Tek OCT™ 
compound to form a single block, snap frozen in isopentane and cooled in liquid nitrogen. Cryostat 
sections (10 μm) were cut such that each section was perpendicular to the urothelial surface. 
Sections were thawed on chrome alum-gelatin coated slides and processed for imunocytochemistry.
Immunohistochemistry
Sections were dried for 20 minutes at room temperature, followed by 3 washes with TBS (pH 7.6), 
and incubated overnight with primary antibodies at 4°C. To visualize EP1 and EP2 we used polyclonal 
antibodies rabbit anti-EP2 and rabbit anti-EP1 (Cayman Chemical, Ann Arbor, Michigan). Mouse 
antibody against vimentin (Sigma-Aldrich) was diluted 1:5,000. Rabbit antibodies against EP1 and 
EP2 were diluted 1:100. Ater overnight incubation with primary antibodies diluted in TBS-T sections 
were washed in TBS, TBS-T and TBS. Each wash step was 15 minutes in duration. Rabbit primary 
antibody was visualized using Alexa Fluor 488 donkey anti-rabbit IgG (H + L) conjugate (Molecular 
Probes®) diluted 1:100 in TBS-T. Mouse primary antibodies were visualized with Alexa Fluor 488 
donkey anti-mouse IgG conjugate (Molecular Probes®) diluted 1:100. Goat primary antibodies 
were visualized with Alexa Fluor 594 donkey anti-goat IgG conjugate (Molecular Probes®). 
Sections were incubated with secondary antibodies for 60 minutes at room temperature in the dark. 
After washing with TBS-T and TBS sections were mounted with TBS-glycerol. All staining was done 
in duplicate and repeated on at least 2 separate days. Multiple sections were observed. Presented 
images are representative sections showing EP1 and EP2 distribution.
Sections were partly analysed and photographed using an AX70 microscope (Olympus, 
Center Valley, Pennsylvania) using 4x, 10x, 20x and 40x objectives. To detect Alexa 488 and 594 
fluorescence a narrow band pass MNIBA filter and a narrow excitation band U-M41007A filter were 
used, respectively (Chroma Technology, Rockingham, Vermont). Images were stored digitally as 
16-bit images using analySIS, version 3.0.
For confocal laser scanning microscopy fluorescent samples were imaged using an MRC600 
confocal microscope (Bio-Rad) equipped with an air cooled argon-krypton mixed gas laser and 
mounted on an Axiophote Microscope using an oil immersion objective (40 , NA¼ 3D1.3 or 63 , 
NA¼ 3D1.4). The laser scanning microscope was used in dual wavelength excitation at 488 and 568 
nm. Optical sections  were recorded in the Kalman filtering mode using 4 to 8 scans per picture.
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EP1 and EP2 Antibodies
To determine antibody specificity we performed a pre-absorption test and characterized the 
antibodies by Western blotting. Pre-absorption was done by overnight incubation of anti-EP1 and 
anti-EP2 antibodies (1:100) with or without 10 μg/ml of the peptide against which the antibody 
was raised. Antibody solution or antibody plus peptide solution was then applied to the sections.
Bladder homogenate of 2 guinea pig bladders were prepared for Western blotting. Bladders were 
cut into approximately 1 mm2 squares and homogenized with an Ultra-Turrax homogenizer at 4 °C 
in 1 × radio-immunoprecipitation assay buffer composed of 1% Triton-X-100, 137 mM NaCl, 20 mM 
tris-HCl, 2 mM ethylenediaminetetraacetic acid, 10% glycerol, 1 mM sodium orthovanadate, 10 mM 
NaF, 1 × protease inhibitor cocktails and 1 mM phenylmethylsulfonyl fluoride. Homogenates were 
centrifuged at 13,000 × gravity for 20 minutes at 4 °C. The pellet was discarded and supernatant 
was stored at −80 °C. Protein was measured using bovine albumin serum dilutions with the Bio-Rad 
protein measurement system according to manufacturer instructions.
Blot analysis was done under reducing conditions according to standard procedures using the 
Odyssey Infrared Imaging System. Primary antibodies for Western blotting were rabbit anti-EP1 
and rabbit anti-EP2 antibody, diluted 1:100. Staining was also confirmed by blocking peptide on 
the Western blot using pre-absorption with anti-EP1 and anti-EP2 antibody, diluted 1:100. The 
secondary antibody was donkey anti-rabbit IRdye™ 800.
Results
Figure 1, A, C and E shows the characterization of EP1, and figure 1, B, D and F shows the 
characterization of EP2. Figure 1, A and B shows that guinea pig urothelial and suburothelial walls 
stained positive with EP1 and EP2 antibodies, respectively. An approach to confirm that this was 
specific staining is to pre-incubate the antibody with the peptide to which it was raised (blocking 
peptide) to eliminate the antibody specific reactive site. When this was done, all observed staining 
was removed (figures 1, C and D). The camera gain was the same (figures 1, A to D). Figure 1 insets 
shows an enhanced view of tissue morphology. Figure 1, E and F shows Western blots of bladder 
protein exposed by EP1 and EP2 antibodies, respectively. A single protein band was seen of the 
predicted molecular weight of EP1 and EP2 protein. This band was also removed by pre-absorbing 
the antibody with the blocking peptide. Thus, these antibodies for EP1 and EP2 may be used with 
a high degree of certainty that they will specifically detect EP1 and EP2 in the guinea pig bladder. 
Figure 2 shows a section stained with EP1 antibody as green areas and an antibody to vimentin as red 
areas. Staining was noted in urothelial cells and in the suburothelium. Urothelial staining appeared 
weak and was detected in all urothelial cell layers. This EP1 staining was often punctuate (figure 2, B). 
EP1 staining was also associated with SU-ICs. It was relatively weak and not present in all cells (figure. 
2, C). Thus, although EP1 was present in this bladder wall region, staining was not pronounced. In 
contrast, strong EP2 staining was seen in the urothelium and in SU-ICs (figures 3 to 5). 
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Figure 1. Characterization of EP1 and EP2 antibodies. A, C and E, EP1. B, D and F, EP2. A 
and B, low magnification of bladder wall shows staining in urothelium and suburothelium. 
Scale bars indicate 20 µm. C and D, images obtained at same camera gain reveal staining 
with same antibody concentration but with pre-incubation with blocking peptide to which 
antibody was raised. Scale bars indicate 10 µm. Insets, enhanced images show section 
morphology. E and F, Western blots show antibody characterization. MW, molecular 
weight calibration. C, native protein stained with EP 1 or EP2 antibody. +P, native protein 
exposed to antibody plus appropriate blocking peptide.
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Figure 2. EP1 in urothelium and lamina propria of guinea pig bladder lateral wall. A, section of 
urothelium (UR) and suburothelium stained with antibody for EP1 (green areas) and vimentin 
(red areas). L, bladder lumen. Calibration bars: 50 µm. B, higher magnification shows weak 
staining in urothelium with appearance of highly localized fluorescent foci. Calibration bars: 
20 µm. C, some SU-ICs colocalized with EP1 and vimentin (arrows). Others were vimentin 
positive but did not express EP1. Calibration bars: 20 µm.
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Figure 3. EP2 in urothelium and lamina propria of guinea pig bladder lateral wall. A, laser scan 
microscopy reveals overview of EP2 (green areas) and vimentin (red areas). UR, urothelium. 
SU, suburothelium. MU, muscle layer. Calibration bars: 20 µm. B, confocal enlargement of 
SU-IC shows vimentin and EP2 co-localization. Calibration bars: 10 µm. C, EP2 in urothelium 
of another part of lateral wall was most expressed in outer layer with most expression in 
intermediate urothelial layer. Calibration bars: 20 µm.
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Figure 3 shows 2 sections from 2 regions in the lateral guinea pig bladder wall. The term lateral wall 
indicates the part of the bladder between the bladder dome and the bladder base lateral and cranial to 
the ureteral orifices. Each section stained with EP2 (green areas) and vimentin (red areas) at the same 
concentration. There were clearly 2 distinct patterns of EP2 staining in the urothelial cell layers. Figure 
3, A shows a representative region where the most pronounced staining was located in intermediate 
urothelial cells, which stained stronger than umbrella cells. Figure 3, C shows a different region of 
the lateral wall where the most intense staining occurred in the outer layer of umbrella cells with 
staining absent in the intermediate urothelial cell layer. Figure 4 shows different EP2 expression in the 
urothelium.
Figure 4. EP2 (green areas) and vimentin (red areas) posi-
tive cells in guinea pig lamina propria. A, site of umbrella 
cell layer (u), intermediate cell layer (il), basal layer (bl), 
SU-ICs and major lamina propria space (lp). Calibration 
bars: 100 µm. B, similar section of different bladder shows 
dense intermediate layer staining (pound sign) (#) and 
weak staining in umbrella cells (plus sign) (+). Note strong 
vimentin but relatively weak EP2 staining in this region of 
SU-IC layer. Asterisk (*) indicates near absence of stain-
ing in basal layer. Calibration bars: 25 µm. C, laser scan 
microscopy reveals urothelium (UR), suburothelium (SU) 
and muscle layer (MU) with EP2 expression on vimentin 
positive SU-ICS clearly visible. Calibration bars: 25 µm.
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Figure 5. EP2 (green areas) and COX1 (red areas) antibody staining in different guinea pig 
bladder urothelial layers. A, urothelium and suburothelium show preponderance of COX1 
staining in basal and internal intermediate cell layers, and dense EP2 staining of outer 
intermediate cell layer. Note small distinct spots of EP2 staining in SU-ICs. u, umbrella cell 
layer. Il intermediate cell layers. bl, basal layer. lp, lamina propria. Calibration bars: 50 µm. 
B and C, further details of similar staining in sections of other bladders. B, clear COX1 im-
munoreactivity in basal layers (asterisk) (*), strongly reactive EP2 cells in intermediate layer 
(pound sign) (#) and low EP2 staining in umbrella cells (plus sign) (+). Calibration bars: 
30 µm. C, some cells in intermediate urothelial layers expressed EP2 and COX1. Asterisk 
indicates COX1 positive umbrella cells. Plus sign indicates COX1 positive basal urothelial 
cells. Calibration bars: 15 µm.
Urothelial EP2 staining was seen in all 7 guinea pigs examined (figures 3, A and C). Figure 3, C 
shows the pattern that was seen more often with the most intense staining in the outer layer of 
umbrella cells. Thus, guinea pig urothelium showed a different staining pattern for EP2 in different 
parts of its lateral wall. To our knowledge the meaning of this heterogeneity of EP2 expression in 
the urothelium remains to be understood. A remarkable observation was EP2 in vimentin positive 
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Figure 6. EP2 expression in SU-IC layer.A, lamina propria (lp) region with basal urothelium (uro) and SU-ICs. EP2 
positive cells (green areas) were clearly seen in urothelial layer (uro) and associated with SU-ICs. Section also 
stained for vimentin (red areas) with only SU-ICs vimentin positive. 
Calibration bars: 40 µm. B and C, individual SU-ICs separating EP2 and vimentin stains. C, EP2 and vimentin 
colocalization (arrow). Calibration bars: 20 (B) and 15 (C) µm.
SU-ICs (figure 6). COX1 expressing cells, located primarily in the basal layers, did not strongly 
express EP2 (figures 4 and 5). 
These results suggest that when COX1 is active, there appears to be a close signaling system in the 
urothelium with basal cells signaling to the intermediate and outer layers. The implied complexity of 
this system was further noted using a more quantitative approach. Figure 6 shows EP2 staining in 
SU-ICs. This section stained for EP2 as green areas and for vimentin as red areas. The suburothelial 
layer was marked and individual interstitial cells were identified. Figure 6, B and C shows examples 
of individual SU-ICs that clearly express EP2 and vimentin. 
Figure 7, A shows the cellular location of COX1, EP1 and EP2 in the lamina propria layer of the guinea 
pig bladder wall.
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Figure 7. Guinea pig lamina propria cells expressing EP2, and COX1 and 2. A, overview 
of lamina propria structures and receptors. Pound sign (#) indicates EP2 alternative 
distribution in urothelium in some parts of bladder lateral wall. cGMP, cyclic guanosine 
monophosphate. nNOS, neuronal nitric oxide synthase. lp-ics, lamina propria suburo-
thelial interstitial cells. M3, type 3 muscarinic receptor. B, possible interactions between 
substances produced by different cells.
Discussion
PG receptors (EP1 and EP2) are expressed in interstitial cells, indicating that they respond to 
PGE
2
. Umbrella cells do not express COX1. However, COX1 was detected in basal urothelial 
cells, making these cells a possible site of PG synthesis. When urothelium is stretched, it 
releases different substances, including PG19,20, ATP21, NO21 and acetylcholine22. However, to our 
knowledge it is not known which cells in the urothelium or lamina propria are responsible for 
producing and releasing these signals, and which physiological systems they involve. A great 
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deal of study has focused on the idea that the release of these substances is an integral part of 
a sensory system assessing bladder volume23,24. Upon stretch ATP, acetylcholine and NO are 
released from the urothelium and then act directly or indirectly on suburothelial afferent nerves. 
Direct evidence shows a direct modulation of afferent nerve activity by ATP25 and indirect NO 
action26. This sensory model involving urothelial signaling was recently described in detail24, 27.Many 
observations underpinning these ideas are derived from rat bladder studies. In that species the 
urothelium is relatively simple, comprising 2 or 3 cell layers. To our knowledge no study to date 
has examined the possibility of functional heterogeneity between the different layers.
In regard to the suburothelial space little is known about the cell types present other than to 
describe presumptive sensory nerves28. The suburothelial innervation is sparse with the highest 
density of urothelial innervation at the base24-27. Our study in the guinea pig model shows that lateral 
wall urothelium and lamina propria have a high degree of structural complexity and potential for 
signaling despite relatively low nerve density. These data on the guinea pig bladder suggest that 
possibly complex signaling systems operate in the urothelium, and between the urothelium and 
lamina propria SU-ICs.
The basal urothelial cell layer and to a lesser extent the intermediate layer express COX1. Thus, 
this layer is capable of generating PG. In the normal healthy guinea pig bladder COX2 expression 
is much less abundant than COX1 expression and, thus, we do not discuss it. However, the 
basic mechanistic features may apply to PGs generated by COX2. Our data suggest that local 
cellular targets for this PG are most probably the intermediate layers and the umbrella cells of 
the urothelium, and SU-ICs. We hypothesize that this close spatial arrangement of signaling and 
responding cells could reflect some functional specialization involving interaction between the 
basal and outer urothelial cell layers.
Recently it was reported that guinea pig SU-ICs express type 3 muscarinic receptor29. Since the 
urothelium may synthesize and release acetylcholine30, this raises the possibility that SU-ICs receive 
multiple inputs. Our observations show that these cells also express EP2, indicating that they 
respond to PG. In the intact animal a major source of PGs acting on these cells may be derived from 
the basal and intermediate urothelial layers. Thus, SU-ICs may be a site of integration of different 
signals. If some signals such as PG are also under complex regulation by other urothelial signals 
(ATP and NO), the physiology of this bladder wall region is particularly complex. Figure 7 shows 
this complexity, including the different cell types and layers of the urothelium and suburothelium 
along with the signals and receptors present, and the emerging picture of urothelial derived signals 
and their interactions.
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Conclusions
To unravel the role and the importance of this system we need more data, particularly to 
identify other signals and interactions. Our hypotheses must be explored by physiological 
and pharmacological in vivo and ex vivo experiments to integrate the micro-anatomical data 
presented with functional data. Thus, the hypothesis can be tested and better understanding of 
bladder physiology may be achieved.
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Abstract 
Purpose
We explored the structural relationship between enzymes producing prostaglandin (cyclooxygenase 1) 
and one of the receptor families that respond to prostaglandin (prostaglandin E receptor 1) in the 
bladder muscle.
Materials and Methods
Nine male guinea pigs were sacrificed by cervical dislocation. Bladders were removed and fixed in 
4% paraformaldehyde in phosphate buffered saline. Frozen sections (10 μm) were cut and stained 
with antibodies to prostaglandin E receptor type 1, cyclooxygenase 1 and vimentin.
Results
Prostaglandin E
2
 receptor type 1 was identified on smooth muscle cells, and vimentin positive 
surface muscle and intramuscular interstitial cells. Muscle staining was less intense than on 
interstitial cells and had a punctuate appearance. Prostaglandin E
2
 receptor type 1 expression on 
interstitial cells was highly localized. Discrete regions of intense staining were noted on interstitial 
cell processes. Cyclooxygenase 1 was also expressed in muscle interstitial cells. Cyclooxygenase 
1 positive interstitial cells were more prevalent in the muscle bundles of the inner muscle than in 
the outer muscle layers. Cyclooxygenase 1 staining was noted on discrete regions of the cell or cell 
processes. Double staining with prostaglandin E receptor 1 and cyclooxygenase 1 suggested that 
cell regions expressing the former are different from those expressing the latter.
Conclusions
The discovered arrangement of Prostaglandin E
2
 receptor type 1 and cyclooxygenase 1 may have 
the potential to facilitate the propagation of signals in the interstitial cell network. Such a signaling 
system may have a role in coordinating events, as in bladder pathology, facilitating the global 
coordinated changes associated with bladder wall remodelling.
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Introduction
Prostaglandin is generated in the bladder wall in the lamina propria and muscle layers1-3.Production 
is stimulated by stretch or receptor mediated processes1-3 and involves de novo synthesis via 1 of 2 
enzymes (COX1 or 2)4 ,5. The physiological role of prostaglandin (PG) in any region of the bladder 
wall remains controversial.
PG is released in the muscle layers6. Application of exogenous PG induces contractile activity in 
bladder smooth muscle in different species, including humans7 -9, rats10, guinea pigs11, rabbits12
and monkeys13. In vivo these actions may be brought about directly or indirectly. For example, 
direct actions of PG may occur if PGs were coreleased with acetylcholine at efferent nerve endings 
to directly affect smooth muscle13. Alternatively it may act presynaptically to affect the release of 
excitatory transmitters10 or inhibit acetylcholine esterase9. However, COX1 and 2 are rarely if ever 
associated with nerves. They are found in specific populations of muscle layer interstitial cells14. 
COX1 is found predominantly in interstitial cells on the surface of the muscle bundles of the inner 
layers but not on outer muscle bundles14,15. This led to the suggestion that PGs may be involved 
in the interplay between interstitial cells and smooth muscle, resulting in coordinated complex 
contractile activity14 , 15.
Exogenous PG can increase autonomous activity in the isolated bladder14 , 15. In animal studies 
intravesical PG increased voiding frequency, decreased bladder capacity and enhanced nonvoiding 
activity. When PG was placed in the human bladder lumen, it increased urge sensations and 
decreased bladder capacity7,16.This suggested that 1 action of PG in the bladder may be to enhance 
the motor component of a motor/sensory system and so increase bladder sensation14,15. In this way 
PGs may have a role in the pathological development of clinical sensory conditions such as urge.
Clearly PG production and PG signaling are an integral part of the physiology of different regions of 
the bladder wall. Despite this generalization we have little detailed insight into signaling processes. 
We explored the relationship between COX1 and PG receptors (EP1) in the muscle layers. Data 
showed that COX1 and EP1 are associated predominantly with muscle layer interstitial cells. 
Enzyme and receptor expression did not coincide in any interstitial cell, giving the appearance of 
regional distribution. To our knowledge the physiological significance of this arrangement is not 
known but it is consistent with a system that would facilitate the propagation of prostanoid signals 
in an interstitial cell network.
Materials and Methods
Nine male guinea pigs weighing 270 to 300 g were sacrificed by cervical dislocation. All procedures 
were done in agreement with Maastricht University ethical committee guidelines. Tissues were 
prepared as we previously described17.
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Immunohistochemistry
Sections were dried for 20 minutes at room temperature, followed by 3 washes with TBS (pH 
7.6), and incubated overnight with primary antibodies at 4 °C. To visualize EP1 we used polyclonal 
antibody rabbit anti-EP1 (No. 101740, Cayman Chemical, Ann Arbor, Michigan) (1:100). The enzyme 
COX1 was visualized using goat polyclonal antibody to COX1 (Santa Cruz Biotechnology, Santa 
Cruz, California) (1:2,000). Mouse antibody against vimentin (No. V 5355, Sigma-Aldrich) was also 
used (1:5,000). Rabbit primary antibody was visualized using Alexa Fluor 488 donkey anti-rabbit 
IgG (H+L) conjugate (1:100 in TBS-T). The mouse primary antibody was visualized with Alexa Fluor 
488 donkey anti-mouse IgG conjugate (Molecular Probes) (1:100). Goat primary antibody was 
visualized with Alexa Fluor 594 donkey anti-goat IgG conjugate (Molecular Probes). Sections were 
incubated with secondary antibodies for 60 minutes at room temperature in the dark. After 3 wash 
steps the sections were incubated at room temperature for 10 minutes with the nuclear marker 
Hoechst 33342 (Sigma-Aldrich) and mounted with TBS-glycerol.
All staining was done in all animals, and duplicated and repeated on at least 2 separate days. We 
accumulated observations from different slides and different bladders.
Microscopy
Most sections were analysed and photographed with an Olympus AX70 microscope using a ×4, 
×10, ×20 or ×40 objective. To detect Alexa 488 fluorescence we used a narrow band pass MNIBA 
filter and for Alexa 594 we used a narrow excitation band U-M41007A filter (Chroma Technology, 
Bellows Falls, Vermont).
We performed confocal laser scanning microscopy fluorescent imaging in the samples using a 
Bio-Rad MRC600 confocal microscope equipped with an air cooled argon-krypton mixed gas laser 
and mounted on an Axiophot microscope (Carl Zeiss), using oil immersion objectives. The laser 
scanning microscope was used in dual wavelength excitation at 488 and 568 nm. Optical sections 
were recorded in Kalman filtering mode using 4 to 8 scans per picture. We generated Z series 
by collecting a stack of optical sections using a step size of between 0.18 and 0.46 μm in the Z 
direction.
We also obtained confocal triple staining images with an Stereo Investigator Confocal Spinning Disk 
(SI-SD) system (MBF Bioscience, Williston, Vermont), consisting of a modified BX51 fluorescence 
microscope with UPlanSApo objectives and a customized DSU spinning disk unit (Olympus). We 
previously characterized the EP1 antibody used17.
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Results
Vimentin and EP1
Figure 1 shows key study observations. Sections of guinea pig bladder wall stained for EP1 revealed 
the receptor on detrusor smooth muscle cells and vimentin positive muscle interstitial cells. 
Figure 1. EP1 and vimentin in inner and outer muscle layers of guinea pig bladder lateral wall. A, inner muscle layer section 
stained with EP1 (green areas) and vimentin (red areas) antibodies. Calibration bars: 50 μm. Insets B & C, D & E are ROIs. B 
and D, higher magnification shows individual EP1 staining. Note cells (arrows) expressing vimentin as well as EP1. M, muscle. 
Asterisk (*) indicates vimentin staining structures. Pound sign (#) indicates EP1 staining structures. Calibration bars: 10 
μm. C and E, higher magnification shows individual vimentin staining. B to E, Calibration bars: 10 μm. F, section of outer 
muscle layers stained with EP1 and vimentin antibodies. Calibration bars: 50 μm. Insets G & H, and I & J are ROIs. G and I, 
higher magnification shows individual EP1 staining. H and J, higher magnification shows individual vimentin staining. G to J, 
Calibration bars: 10 μm.
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Muscle staining was less intense than interstitial cell staining and had a punctuate appearance, 
suggesting localized receptor expression regions (figure 2 and 3).
We found 2 types of vimentin positive interstitial cells in the inner and outer muscle, including 
sm-ics and intramuscular interstitial cells (figure 1). Many interstitial cells clearly expressed EP1 
receptors and some did not. EP1 expression was not uniform throughout the cell and appeared to 
be localized to discrete regions (figures 1, G to J).
Figure 2. Confocal images reveal EP1 and vimentin in outer muscle layer of guinea pig bladder lateral wall. A, Z projection 
stained with antibody for EP1 (green areas) and vimentin (red areas). Inset, ROIs (B to E). Calibration bars: 10 μm. B to E, 
individual ROIs at different confocal stack planes. Slices were separated by 1.5 μm. F to I, individual vimentin staining. J to 
M, individual EP1 staining. B to M, Calibration bars: 20 μm.
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Figure 3. EP1 and vimentin in interstitial cells of outer muscle layer of guinea pig 
bladder lateral wall. A, confocal image projections stained with antibody for EP1 
(green areas), vimentin (red areas) and Hoechst (blue areas). Interstitial cell shows 
intense vimentin and EP1 staining. Same cell expresses vimentin and EP1 but not at 
same site. Note single process with high EP1 density at 1 site. Asterisk (*) indicates 
vimentin staining structures. Pound sign (#) indicates EP1 staining structures. 
Scale bar indicates 10 μm. B, individual vimentin (vim) images. C, individual EP1 
staining. D, individual Hoechst (hoe) nuclei staining images. B to H, scale bar 
indicates 10 μm. E, confocal image projections stained with antibody for EP1, 
vimentin and Hoechst. Interstitial cell shows intense vimentin and EP1 staining. 
Same cell expresses vimentin and EP1 but not at same site. Note interstitial cell with 
EP1 expression in highly localized region of cell process. Calibration bars: 10 μm.
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Figure 4. EP1 and COX1 in guinea pig bladder lateral wall. A, full-thickness bladder wall section. Green areas indicate staining 
for EP1. Red areas indicate staining for COX1. LP, lamina propria. IM, inner muscle. OM, outer muscle. Calibration bars: 
200 μm. B, inner muscle layer region. Arrows indicate surface muscle interstitial cells (a and b) as COX1 and EP1 expression 
regions that did not colocalize. Calibration bars: 100 μm. C to E, higher magnification of surface muscle interstitial cell as 
expression region that did not colocalize (B, a). D and E, individual COX1 and EPI staining, respectively, of noncolocalized 
region (B, a). F to H, higher magnification of surface muscle interstitial cell as expression region that did not colocalize (B, 
b). G and H, individual COX1 and EPI staining, respectively, of noncolocalized region (B, b). C to H, Calibration bars: 20 μm.
Figure 2 shows this observation of regional EP1 expression using confocal microscopy. Figure 2, A
shows a projection of the confocal stack. Punctate EP1 expression on the muscle was clearly visible 
as green areas. In the identified region of interest a sm-ic was noted. Figure 2, B to M show separate 
images of this region from the confocal stack. The vimentin positive sm-ic is apparent running 
through the stack. Colour images showed vimentin as red areas. Some section planes showed hot 
spots of yellow, indicating EP1 expression and its colocalization with vimentin structures. They were 
also apparent in EP1 single images (figures 2, J to M). Thus, discrete regions in a single SM-IC
expressed EP1 receptors. 
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Figure 3 shows such regions at higher magnification. Remarkably we identified localized EP1 
expression on a single process of an interstitial cell in close proximity to an adjacent interstitial cell 
(figure 3, A). Figure 3, B shows another example of a single process of an interstitial cell with highly 
regionalized EP1 expression.
EP1 and COX1
Figure 4 shows a full-thickness section of the bladder wall stained for COX1 as red areas and EP1 
as green areas. COX1 expression was clear in the urothelial basal and intermediate layers. COX1 
was also apparent on lamina propria interstitial cells and on muscle interstitial cells on the inner 
muscle layers14, 17. COX1 positive interstitial cells were less prominent in the outer muscle layers14. 
Figure 4, B shows a region of the inner muscle layer at higher magnification. We identified 2 regions 
of interest that stained for COX1 and EP1 (figure 4, B to H). Some interstitial cells were noted to 
express COX1 as well as EP1 (figure 4, arrows). Hot spots shown as yellow areas indicated cell 
regions with EP1 and COX1 in close proximity. As with EP1 (figure 1-3), localized COX1 expression 
to processes of muscle interstitial cells was identified using vimentin to identify interstitial cell 
processes (figure 5). Figure 6 further reveals punctate EP1 and COX1 distribution. Regional COX1 
and EP1 expression was observed on the same interstitial cell.
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Figure 5. COX1 and vimentin in interstitial cells of inner muscle layer 
guinea pig bladder lateral wall.A, interstitial cell processes (arrows). One 
process (asterisk) (*) shows intense COX1 staining (red areas). Green 
areas (plus sign) (+) indicate vimentin staining. Blue areas indicate 
Hoechst staining. Calibration bars: 10 μm. B, ROI (A). C, individual 
vimentin (vim) staining (A). D, individual COX1 staining (A). B to D, 
Calibration bars: 10 μm. E, another example of regional COX1 expression 
in interstitial cell process. COX1 regions are adjacent to vimentin positive 
interstitial cells not expressing COX1. Calibration bars: 10 μm. F, ROI (E). 
G, ROI individual vimentin staining (E). H, ROI individual COX1 staining 
(E). F to H, Calibration bars: 10 μm.
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Figure 6. Regional COX1 and EP1 expression in single surface muscle 
interstitial cells. A, region where EP1 (green areas) and COX1 (red 
areas) are easily seen. a and b, individual interstitial cells expressing 
COX1 and EP1. c, cell with COX1 but no EP1 expression region and 
adjacent cell with EP1 but no COX1 expression. Calibration bars: 20 
μm. B, E and H, ROI (A, a). C, F and I, ROI (A, b). D, G and J, ROI (A, 
c). E to G, individual COX1 staining. H to J, individual EP1 staining. 
B to J, Calibration bars: 10 μm.
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Discussion
We focused on the expression of EP1, which is 1 of the 4 PG receptor subtypes. These receptors 
are found in many tissues in which intracellular signals are generated in response to PG, involving 
diacylglycerol and 1,4,5-triphosphate18. In such systems EP1 is involved in regulating intracellular Ca2+
and cell excitability. The presence of EP1 receptor on bladder interstitial cells suggests that they may 
also be excitable. This idea was put forward in relation to the coordination of localized contractions 
in the bladder wall (autonomous activity) as part of a motor/sensory system regulating bladder 
afferent activity19,20. Experimental evidence shows that bladder interstitial cells are excitable21 and 
activating these cells can initiate smooth muscle contraction, possibly via direct electrical coupling 
through gap junctions22. Also, in the isolated bladder exogenous PG produces coordinated phasic 
contractions in the bladder wall14. The idea is now put forward that bladder interstitial cells could 
form a communication network, similar to interstitial cells of Cajal in the gut. This network could be 
more effective than smooth muscle bundles, which are relatively uncoupled. Thus, signal transduction 
through these coupled interstitial cells would be more rapid than via the spread of electrical or Ca2+
signals. Hence, such coordinated contractions are more likely to be mediated via EP1 receptors on 
interstitial cells than on muscle since by local PG release random activation of the latter would result 
in random uncoordinated activity. Thus, the EP1 stimulation of muscle interstitial cells may be involved 
in the rapid generation of coordinated contractile responses.
EP1 receptors respond to PG. Therefore, a key question is where the PG used to activate these 
receptors comes from. PG is generated in the lamina propria and muscle layers6. However, to our 
knowledge the precise cell types responsible have not been investigated. Recently it was reported 
that in the guinea pig bladder the basal and intermediate layers of the urothelium strongly express 
1 of the PG synthesizing enzymes, COX114, suggesting that this is the site of PG synthesis in the 
lamina propria. EP1 and EP2 receptors were localized to urothelium and suburothelial interstitial 
cells, suggesting that these cells are the target of urothelial derived PG17.
The physiological role of this system is not fully understood. However, ideas are now being put 
forward that suggest involvement in regulating early physiological responses involved in bladder 
inflammation23.
Muscle interstitial cells were identified as a potential source of PG in the muscle layers14, which 
was confirmed in the current study. Our data reveal an unusual, interesting micro-anatomical 
arrangement in interstitial cells, that is localized expression of EP1 receptors and sites of PG 
production (COX1 expression). The PG production site in a cell is different from the site that 
expresses the receptors. Figure 7, A shows this micro-anatomical specialization. The arrangement 
of a cell that produces a signal and has receptors to that signal is a classic autocrine arrangement. 
This may also be the case in the bladder. However, the specialization of discrete signal producing 
regions and signal responsive regions suggests a further degree of complexity. Figure 7, B shows 
an idea. We propose that the system operates to facilitate signal propagation in the interstitial cell 
network. Cell activation would stimulate COX1 and local PG release, which would then activate an
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Figure 7. EP1 (green dots) and COX1 (red dots) distribution pattern on interstitial 
and smooth muscle cells of guinea pig detrusor, and proposed signal propagation 
system. A, COX1 and EP1 regional sites on surface muscle interstitial cells and 
colocalization of 2 markers in smooth muscle. COX1 muscle staining intensity was 
considerably lower than on interstitial cells. B, surface muscle interstitial cell network 
with COX1 and EP1 expression regions. Hypothesis is that this arrangement allows 
signal propagation along and throughout network. PG produced by COX1 exits cells 
and acts on adjacent cells expressing EP1. After activation these cells then release 
PG from their COX1 sites. Adjacent cells with EP1 receptors are then activated and so 
on. Net result is possible propagation of COX1/PG/EP1 signal throughout network.
adjacent cell via its EP1 receptor region. After it is activated this cell would release PG to activate 
neighbouring cells. In this way activation would spread throughout the network as an avalanche 
effect. The propagation of such a chemical signal may be somewhat slower than electrical activity 
moving from cell to cell via gap junctions.
The physiological consequence of this structural finding needs further exploration. It is known that 
signals propagate throughout the bladder wall. In the rat urothelial stimulation can trigger a Ca2+
signal that travels deep into the muscle layer24. To our knowledge how this signal is generated is not 
known but it may occur as described via the interstitial cell network. Based on micro-anatomical 
evidence it can be suggested that the network of suburothelial, lamina propria and muscle 
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interstitial cells may form a communicating network14. Recent data on an isolated lamina propria 
preparation revealed that signals released from urothelium are targeted at the suburothelial cell 
layer23. Thus, the activation of propagated signals in the suburothelial network may originate from 
the urothelium.
Also, the number of lamina propria and muscle interstitial cells is increased in the bladder of 
animals with experimentally induced partial bladder outflow obstruction25. Bladders from animals 
with partial bladder outlet obstruction have increased excitability (sensitivity to exogenous 
acetylcholine) and enhanced autonomous activity. Such changes are linked to changes in the 
interstitial cell network25. Our observations may provide further evidence for an explanation of 
this process. Activation of the interstitial cell network using the COX1/PG/EP1 system may trigger 
changes in cell excitability and, presumably in view of the latter finding, proliferation.
Conclusions
The localized presence of COX1 in interstitial cells suggest the localized production and release 
of PG. The proximity of EP1 receptors suggests that they may be a possible target of this PG. Such 
an arrangement in the muscle interstitial cell network has the potential to propagate signals 
throughout the entire bladder wall. Activation of this network could result in increased excitability 
and be associated with triggering cell proliferation. These findings suggest that the PG system 
may have a role in the structural pathological bladder changes, for example those after partial 
bladder outlet obstruction. As a consequence, these structural changes may be inhibited by 
pharmacological agents targeting the PG system. More functional experiments are needed to 
investigate these hypotheses.
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Abstract
Purpose 
To explore the distribution of prostaglandin E receptor type 2 (EP2) in the bladder muscle layers and 
its spatial relationship to cyclo oxygenase type 1 (COX1).
Materials and methods: 
Twelve male guinea pigs were killed by cervical dislocation, the bladders removed and fixed in 4% 
paraformaldehyde in PBS. Frozen sections of 10 μm were cut and stained with antibodies to EP2, 
COX1 and vimentin.
Results
EP2 receptor immunoreactivity is located on the smooth muscle cells as well as on vimentin positive 
surface muscle and intramuscular interstitial cells. EP2 expression on interstitial cells is highly 
localized. Discrete regions of intense staining were observed on the interstitial cell processes. 
COX1 is expressed in the muscle interstitial cells and was found to be located on discrete regions of 
the cell and cell processes. Double staining with EP2 and COX1 suggests that the regions of a cell 
expressing EP2 are different from those expressing COX1.
Conclusions
The presence of COX1, prostaglandin E receptor type 2 (EP2) immune-reactivity in the network 
of interstitial cells suggests a role of this network in the propagation of signals. Due to a cAMP 
coupling of the EP2 receptor in many other tissues and a lower dissociation constant of EP2, it 
is suggested that a rise in PG levels may gradually push the balance from a relaxant EP2 effect 
towards a contractile effect. Hence, PG could have a modulatory role on the non-voiding bladder 
contractions by changing the threshold level for excitability of the interstitial cell network.
Thesis M.S. Rahnama’i.indd   90 10-10-13   13:36
91
Chapter 5 – The Distribution of EP2 in the Detrusor of the Guinea Pig
Introduction
It is now generally accepted that prostaglandin (PG) plays a role in the control of mammalian 
urinary bladder motility1,2. In the bladder, both the lamina propria and the muscle layers can 
produce Prostaglandins3–6. Prostaglandin E2 (PGE
2
) is known to be the predominant PG in the 
urinary bladder of most mammals7 and the receptors for PGE
2 
are classified into four types: EP1, 
EP2, EP3 and EP48. PGE
2
 is an agonist at EP receptors,1–4 all G-protein coupled, which mediate 
its physiological effects9. PGE
2 
is the main PG suggested to be involved in the pathophysiology 
of detrusor overactivity (DO) and overactive bladder syndrome (OAB)9,10. This involvement is 
based on three observations. Firstly, the ability of PGE
2
 infused into the bladder to induce DO in 
humans and animals. Secondly, the increased PGE
2
 production in DO models and thirdly, the high 
concentrations of PGE
2
 that have been detected in the urine of patients with OAB9. It has also been 
shown that upon stretch, PGE
2
 is released by the urothelium11 and that this release is regulated 
by a complex interaction of signals through ATP and NO1. the literature contains substantial data 
that the wall of the mammalian urinary bladder contains several sub-populations of cells in the 
interstitial space, called interstitial cells (ICs) after the interstitial cells of Cajal in the gut12. These 
interstitial cells are located in the lamina propria and within the detrusor and have been suggested 
to form a network called the interstitial cell network3,13–15. The expression of prostaglandin E receptor 
type 1 (EP1) in the guinea pig muscle interstitial cell network has been studied recently3.
Moreover, it has been shown that the cyclo oxygenase 1 (COX1) enzymes are located within specific 
cell types within the lamina propria of the guinea pig bladder16. In addition, COX1 is found in the 
basal layers of the urothelium and associated with the distributed network of lamina propria 
interstitial cells16. It has also been suggested that the arrangement of EP1 and COX1 might have the 
potential to facilitate the propagation of signals in the interstitial cell network3. Such a signalling 
system is thought to have a role in coordinating events in the normal bladder17 and might be 
defective in bladder pathology13. It might also have a function in facilitating the global coordinated 
changes associated with bladder wall remodelling3,18. PG receptors EP1 and EP2 have been shown 
to be expressed in the ICs in the lamina propria indicating that this part of the bladder wall can 
respond to PGE
2
4. There is hardly any literature about the exact role of the EP2 receptor in the 
bladder. However, it is known that the normal guinea pig urothelium does express EP2 receptors4
and that the combined EP1/EP2 receptor antagonist AH 6809 decreases detrusor contraction in 
isolated human bladder experiments19. Unlike EP13, the cellular localization and the expression of 
EP2 receptor in the muscle layers of the bladder have not been studied before. In the present study, 
we have used antibodies to EP2 in order to study the distribution of this receptor in the muscle 
layers of the guinea pig urinary bladder. Our results are discussed in terms of possible physiological 
mechanisms, which might be occurring in this region of the bladder wall.
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Materials and methods
Guinea pigs (12 male, weight range 260–300 g) were killed by cervical dislocation. All procedures 
were carried out in agreement with the guidelines of the Maastricht University Ethical Committee.
The tissue workup of the lateral wall of the guinea pig bladders as well as freezing and the cutting of 
the sections are as described in our previous paper4. 
Tissue preparation
The bladder, including the proximal urethra, was removed from each animal and placed in ice-cold 
Krebs solution composed of 121.1 mM NaCl, 1.87 mM KCl, 1.2 mM CaCl
2
, 1.15 mM MgSO
4
, 25 mM 
NaHCO
3
, 1.17 mM KH
2
PO
4
 and 11.0 mM glucose bubbled with 5% CO
2
 and 95% O
2
 (pH 7.4). Each 
bladder was divided into a ventral piece and a dorsal piece, while maintained in Krebs solution. 
Then, the bladder pieces were immersed in ice-cold fixative solution of 4% freshly prepared 
depolymerized paraformaldehyde for 120 min at 4 °C. Tissues were fixed in 3 steps of 2 overnight 
and 1 daytime incubation at 4 °C in 0.1 M phosphate buffer with 10%, 20% and 30% sucrose, 
respectively. On day 3 the tissues were placed in Tissue-Tek OCTTM compound to form a single 
block, snap frozen in isopentane and cooled in liquid nitrogen. Cryostat sections (10 μm ) were cut 
such that each section was perpendicular to the urothelial surface. Sections were thawed on chrome 
alum-gelatin coated slides and processed for immunocytochemistry.
Characterization of the EP2 antibody
In order to gain insight in the specificity of our antibody, we conducted a pre-absorption test and 
characterized the antibodies by Western blotting as described in our previous paper4. In short, 
preabsorption was done by overnight incubation of the anti-EP2 antibody (1:100 by Cayman 
Chemical, Catalogue No. 301740) with or without 10 μg/ml of the peptide against which the 
antibody was raised. Thereafter the antibody solution or antibody plus peptide solution was 
applied to the sections. Bladder homogenate of guinea pig bladders (N = 2) was prepared for 
Western blotting. Bladders were cut into squares of approximately 1 mm2 and homogenized 
using an UltraTurrax homogenizer (Janke & Kunkel, Ika Labortechnik, Staufen, Germany) at 
4 °C in 1× radio-immunoprecipitation assay buffer (1% Triton-X-100, 137 mM NaCl, 20 mM 
Tris–HCl, 2 mM EDTA, 10% glycerol, 1 mM sodium orthovanadate, 10 mM NaF, 1× protease 
inhibitor cocktails, 1 mM phenylmethylsulphonyl fluoride). Subsequently the homogenates were 
centrifuged at 13,000 × g for 20 min at 4 °C . The pellet was discarded and the supernatant was 
stored at −80 °C. Protein measurements were done using bovine albumin serum dilutions with 
the Biorad protein measurement system (Bio-Rad Laboratories, Inc., Hertfordshire, CA, USA) 
according to the manufacturer’s instructions. The blot analysis was performed under reducing 
conditions following standard procedures and using the Odyssey infrared imaging system (Li-
cor Biosciences, USA). Primary antibody used for Western blotting was rabbit anti-EP2 antibody 
(Cayman Chemicals) used in a dilution of 1:100. The staining was also confirmed by a blocking 
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peptide on the Western blot using pre-absorption with anti-EP2 antibody in a dilution of 1:100 
(Cayman Catalogue Nos. 301750 and 301740). The secondary antibody used was donkey anti-
rabbit IRdye800 (Rockland, 611-732-127).
Immunohistochemistry
Sections were dried for 20 min at room temperature followed by three washes with Tris–buffered 
saline (TBS; pH 7.6), and thereafter incubated overnight with primary antibodies at 4 °C. To 
visualize the prostaglandin receptor EP2, we used a polyclonal antibody rabbit anti-EP2 (Cayman 
Chemical, Catalogue No. 101750) which was diluted 1:100. The COX1 enzyme was visualized using 
an optimized concentration of goat polyclonal antibody to COX1 (1:2000; Santa Cruz Biotech, 
Catalogue No. sc-1752). Furthermore, a mouse antibody against vimentin (Sigma–Aldrich, 
Catalogue No. V 5355) was used at a dilution of 1:5000. The rabbit primary antibody was visualized 
using Alexa Fluor 488 donkey anti-rabbit IgG (H + L) conjugate (Molecular Probes), diluted 1:100 
in TBS-T. The mouse primary antibody was visualized with Alexa Fluor 594 donkey antimouse 
IgG conjugate (Molecular Probes), diluted 1:100. The goat primary antibody was visualized with 
Alexa Fluor 594 donkey antigoat IgG conjugate (Molecular Probes). Sections were incubated with 
the secondary antibodies for 60 min at room temperature in the dark. After three wash steps the 
sections were incubated at room temperature for 10 min with a nuclei marker, HOECHST 33342 
(Sigma, Zwijndrecht, The Netherlands) and mounted with TBS-glycerol. All stainings were done in 
all the animals and duplicated and repeated on at least 2 separate days. All results were confirmed 
with negative control stainings, without application of the primary antibody. Observations were 
accumulated from the different slides and from the different bladder specimens of all 12 animals. A 
representative section of all animal bladders was studied.
Microscopy
The majority of the sections was analysed and photographed using an Olympus AX70 microscope 
using a 10×, 20× and 40× objective. For the detection of Alexa 488 fluorescence, a narrow band-
pass MNIBA-filter and for Alexa 594 a narrow excitation band U-M41007A filter was used (both 
from Chroma Technologies). Confocal laser scanning microscopy fluorescent imaging was done 
on the samples using a Bio-Rad MRC600 confocal microscope (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) equipped with an air-cooled Argon–Krypton mixed gas laser and mounted onto an 
Axiophotemicroscope (Zeiss), using oil-immersion objectives (40 , NA¼ 3D1.3 or 63 , NA¼ 3D1.4). 
The laser-scanning microscope was used in dual wavelength excitation at 488 and 568 nm.
Optical sections were recorded in the Kalman filtering mode using 4–8 scans for each picture. 
Z-series were generated by collecting a stack consisting of optical sections using a step size between 
0.18 and 0.46 mm in the z-direction.
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Results
Figure 1 shows the characterization of the EP2 antibody used in this study. This characterization was 
described in our previous paper4. There were two approaches chosen to confirm that this is specific 
staining. Firstly, the antibody was pre-incubated with the peptide to which it was raised (blocking 
peptide) and the antibod-ies specific reactive site was eliminated. Where this was done, all of the 
observed staining was removed (panel A). In order to see the tissue morphology, an enhanced 
(overexposed) image is shown in the inset. Panel B shows a Western blot of bladder protein exposed 
EP2 antibody (middle lane). A single protein band of the predicted molecular weight of the EP2 
protein was seen. This band was also removed by pre-absorbing the antibody with the blocking 
peptide. Thus, this antibody for EP2 can be used with a high degree of certainty that they will detect 
specifically the EP2 receptors in the guinea pig bladder. 
The EP2 receptor is present on both the detrusor smooth muscle cells as well as on vimentin positive 
muscle interstitial cells (figure 2). The vast majority of interstitial cells clearly express EP2 receptors. 
More detail about the EP2 expression is shown in figures 2,5 and 6 where it can be noted that the EP2 
expression is not equal throughout the cell and appears to be localized in discrete regions. 
Figure 1. Characterization of the EP2 antibody. Panel A illustrates the 
staining observed with the same concentration of antibody as used 
in all the stainings of other figures, but with pre-incubation with the 
blocking peptide to which the antibody was raised. (The inset shows 
an enhanced image showing the section morphology.) Panel B shows 
a characterization of the antibodies using Western blotting. Three 
lanes are shown: the molecular weight calibration bands, the native 
protein stained with the EP2 antibody and the native protein but 
exposed to antibody plus appropriate blocking peptide.
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Figure 2. The distribution of EP2 and vimentin in the inner- and outer-muscle layers of the lateral wall 
of the guinea pig bladder. Panels show an image of the guinea pig bladder stained with the antibody 
for EP2 (green) and vimentin (red). In panel A, a low magnification image of a full thickness guinea 
pig bladder section is shown. The bladder lumen, the urothelium (UR), suburothelial interstitial 
cells (SuIC’s), the lamina propria interstitial cells (LPICs), inner muscle (IM) and outer muscle layer 
(OM) are marked. In the right panels, regions of interest of the inner (1) and the outer muscle layer 
(2) are shown in a larger magnification. Interstitial cells co-expressing vimentin and EP2 receptor are 
marked with asterisk (*) and those vimentin positive interstitial cells not expressing EP2 are marked 
with pound sign (#). Calibration bars: 100 μm in A and 20 μm in the insets 1 and 2. 
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In figure 3, vimentin positive (red) processes of intramuscular interstitial cells (IM-ICs) are clearly 
visible. These fibres also express EP2 (green). The EP2 staining on the muscle cells is less intense 
and has a punctuate appearance. The EP2 expression in the outer muscle layer is shown in figure 
4. In the middle of the muscle bundles, IM-ICs can be seen in which the EP2 (green) and vimentin 
(red) co-localization is visible by the yellow colour. Thus, the vimentin positive interstitial cells seem 
to express the EP2 receptor. In this outer muscle region, the muscle is positive for EP2 with a less 
intense punctuate staining. On the upper edge of the panel, muscle coat interstitial cells are visible. 
Black and white panels on the right show clearly that only some of the muscle coat vimentin positive 
interstitial cells express EP2. Distinct groups of vimentin positive interstitial cells are seen between 
the muscle bundles.
Figure 3. The distribution of EP2 and vimentin in the inner muscle layer of the lateral wall of the guinea pig bladder. An image 
taken from a confocal stack of the inner muscle layer of the guinea pig bladder stained with the antibody for EP2 (green) and, 
vimentin (red) is shown. The nuclei of the IM-ICs are visualized by a HOECHST nuclei staining (blue). A region of interest is 
enlarged in inset 1. The black and white insets show the individual EP2 and vimentin staining. 
Calibration bars: 40 μm in A and 10 μm in 1. 
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Figure 4. The distribution of EP2 and vimentin in the outer muscle layer of the lateral wall of the guinea pig bladder.
An image taken from a confocal stack of the outer muscle layer of the guinea pig bladder stained with the antibody 
for EP2 (green) and vimentin (red) is shown. The nuclei of the IM-ICs are visualized by a HOECHST nuclei staining 
(blue). Two regions of interest from panel A are enlarged as panels 1 and 2. The black and white insets show the 
individual EP2 and vimentin staining. Calibration bars: 100 μm in A and 10 μm in 1 and 2. 
In figure 5, a number of ICs are shown in the vicinity of each other. The fibres of these cells are noted 
as red fibres (vimentin positive) running through and in between the muscle bundles. Many of 
these ICs co-express vimentin and EP2 causing the yellow co-staining. In figure 5, the expression 
of EP2 in an IM-IC in the lateral wall is shown. The processes of these cells are visible as vimentin 
positive fibres (red) running on the surface of the muscle bundles. Spots of EP2 expression (green) 
are also visible on these fibres. Moreover, the punctuate expression of EP2 on the muscle bundles 
can be seen in figure 6. 
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Figure 5. The expression of EP2 in a group of nearby intramuscular interstitial cells in the lateral wall of the guinea 
pig bladder. An image of the outer muscle layer of the guinea pig bladder stained with the antibody for EP2 (green) 
and vimentin (red) is shown. The nuclei of the cells are visualized by a HOECHST nuclei staining (blue). The black 
and white insets show the individual EP2 and vimentin staining. Calibration bar: 20 μm. 
Figure 6. The expression of EP2 in an intramuscular interstitial cell in the lateral wall of the guinea pig bladder. An 
image taken from a confocal stack of the outer muscle layer of the guinea pig bladder stained with the antibody for 
EP2 (green) and vimentin (red) is shown. The nuclei of the cells are visualized by a HOECHST nuclei staining (blue). 
The black and white insets show the individual EP2 and vimentin staining. Calibration bars: 20 μm. 
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The EP2 staining (green) is especially located on the membrane of muscle cells. The punctuate 
expression of EP2 on the muscle bundles (green) is further displayed in figure 7. It can be noted that 
some COX1 positive interstitial cells (red) are in close proximity of EP2 positive interstitial cells and 
EP2 receptors on the near by muscle bundles. Another remarkable observation was that some cells 
expressing EP2 co-express COX1. This phenomena was seen in about one third of all interstitial cells 
expressing COX1. A low power image of the guinea pig bladder stained for EP2 (green) and COX1 (red) 
is shown in fig.ure 8. It can be noted that beside the urothelium, many interstitial cells throughout the 
muscle layer express COX1. Both COX1 positive IM-ICs as well as SM-ICs can be noted.
The findings on EP2 expression within the muscle layers of the guinea pig urinary bladder are 
summarized in a cartoon shown in figure 9, which was adapted from our previously published 
cartoon4. In this cartoon it is demonstrated that COX1 and the EP2 receptor are expressed on 
the intramuscular interstitial cells as well as on the muscle bundles. Furthermore, the suggested 
propagation of the PG signal from the urothelium to the muscle layers is visualized.
Figure 7. The expression of EP2 and COX1 on the muscle bundles of the lateral wall of the 
guinea pig bladder. An image of the outer muscle layer of the guinea pig bladder stained with 
the antibody for EP2 (green) and COX1 (red) is shown. The black and white insets show the 
individual EP2 and COX1 staining. Calibration bar:  20 μm. 
Thesis M.S. Rahnama’i.indd   99 10-10-13   13:36
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall
100
Figure 8. The expression of EP2 and COX1 on the muscle bundles of the lateral wall of the 
guinea pig bladder. A low power image of the guinea pig bladder stained with the antibody for 
EP2 (green) and COX1 (red) is shown in panel A. A region of interest is indicated in panel A and 
enlarged in the inset 1. The black and white insets show the individual EP2 and COX1 staining. 
Calibration bars: 100 μm in A and 20 μm in 1. 
Discussion
Cyclo oxygenase inhibiting drugs, have been shown to alter normal voiding function in rats as well 
as bladder hyperactivityinduced by chemical irritation of the lower urinary tract20. Furthermore, 
it is known that intra-arterial administration of PGE
2
 to the urinary bladder enhances the 
micturition reflex21. Therefore, it has been suggested that PG might act at various sites to regulate 
or modulate voiding itself and non-voiding activity as well as voiding sensation. Very recently, it 
was demonstrated that both ATP and PGE
2
 can induce acetylcholine release from the bladder 
urothelium1. Therefore, the stretch-induced acetylcholine release, previously described in the 
bladder22, is suggested to be a part of the result of a more complex series of signalling interactions 
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within the urothelium. This complexity is increased because acetylcholine can also modulate PGE
2
release. This mechanism is suggested to provide a rapid amplification of urothelial signal output1. 
In the present study we have focused on EP2 expression in the muscle layers of the guinea pig 
bladder. EP2 receptor presence on umbrella cells and the suburothelial interstitial cells (SU-ICs) has 
previously been demonstrated4. The present study shows that EP2 receptors are further expressed 
on intramuscular interstitial cells (IM-ICs) and surface muscle interstitial cells (SM-ICs) of the inner- 
and the outer-muscle layer. Moreover, our stainings show a punctuate low intensity expression 
of EP2 in guinea pig detrusor muscle bundles. This punctuate appearance deserves more future 
attention as to whether this might be due to certain areas serving a specific function for example 
in cell to cell contacts. In the muscle, each of the EP receptors is known to act through different 
intracellular pathways that involve calcium transport and the stimulation or inhibition of adenylate 
cyclase to elicit muscle contraction or relaxation depending on the EP subtypes (figure 7)23. In general, 
EP1 and EP3 are thought to cause contraction of the smooth muscle, whereas EP2 and EP4 are 
thought to cause relaxation24,25. Each receptor uses a different G-protein coupled transduction 
system24,25. This difference in response of the muscle to each of the EP receptors has been shown 
for uterine smooth muscle where indeed, activation of EP1 and EP3 causes muscle contraction and 
stimulation of EP2 and EP4 leads to relaxation26. Earlier observations showed networks of ICs with 
short and long processes, running from the urothelium and suburothelium through the muscle 
layers and form connections with other ICs nodes (figure 8). There is a clear COX1 expression 
in the basal urothelial layer as also reported by earlier papers3,4, suggesting the possibility 
that a PG signal presumably mediated and enhanced by ATP release from the urothelium can 
be picked up by EP1 receptors and be spread further via the IC network3,4. Furthermore, these 
data showed that some COX1 positive interstitial cells are in very close proximity of EP1 positive 
interstitial cells and EP1 receptors on the nearby muscle bundles. It was described that, PG can 
be produced in close vicinity, or even within the same cell containing the EP1 receptor, which 
suggested the possibility for a PG signal to be further spread and maybe even augmented3,4. Our 
present data show similar global configurations for the EP2 as was previously shown for the EP1 
receptor4. For EP2, COX1 and EP2 immuno-reactivity was in close proximity or even co-expressed 
in the same cell. Further research is necessary in order to determine the physiological role of 
this EP2 receptor configuration. However, a spread and augmentation of a signal mediated by 
PG via EP2 is unlikely as in most smooth muscle preparations, other than the urinary bladder, 
EP2 has been shown to cause muscle relaxation.24 In several tissues, EP2 receptors have been 
shown to couple to a G-protein (G_s), resulting in increased formation of cAMP. In the smooth 
muscle of different organs, this rise in cAMP through EP2 leads then to muscle relaxation27. It is 
unknown whether this is the predominant effect of EP2 in the detrusor muscle. In several recent 
reports EP2 action has been shown to be coupled to immune responses or secretion of specific 
agents, which might also suggest an activation instead of an inhibition8,29. The cyclic nucleotide 
mono-phosphates, cAMP and cGMP, are now generally accepted to be important intracellular 
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regulators of several physiological processes, including smooth muscle function30. Rat bladder 
studies have suggested that beta-adrenoceptor-mediated relaxation is mainly attributed to cAMP-
dependent mechanism31,32. Moreover, the phosphodiesterase (PDE) type 1 inhibitor vinpocetine 
has been shown to have a relaxant effect on human detrusor. This relaxing effect was paralleled 
by an increase in tissue levels of cAMP and cGMP33. There is also some clinical support for the 
involvement of cAMP in human detrusor control. A randomized double-blind placebo-controlled 
study, showed that treatment with PDE1 inhibitors which lead to a rise in cAMP levels in patients 
with urgency and urge incontinence was superior to placebo with regard to the clinical outcome 
parameters micturition frequency, bladder volume at first sensation, bladder volume at voiding 
desire, maximum detrusor pressure, and voided volume34. Moreover, an influence on the above 
mentioned parameters also suggests a coupling to the bladder sensory system. It can be concluded 
from these findings that the cAMP-pathway might be of functional significance in the control of 
detrusor smooth muscle and indeed have a relaxant effect. The question to be answered now is the 
possible physiological meaning of the shown EP2 arrangement in relation to the previously shown 
EP1 distribution in the bladder muscle layers. It is known that PGE
2
, may have multiple and at times 
apparently opposing functional effects on a given target tissue such asvascular smooth muscle35,36. 
Although no functional experiment was included in this study, some possible hypothesis could be 
put forward. These hypotheses are not based on data and need to be confirmed in future functional 
studies. One possible explanation could be based on differences in affinity of EP2 and EP1 for PG. 
In fact, it has been shown that the rat EP2 receptor signal transduction pathway is approximately 
20-fold more sensitive for PGE
2
 than for EP1, as the concentration of PGE
2
 required to produce 
a half-maximal response was 37 nM for EP2 against 2.1 nM for EP137. Furthermore, in order to 
determine the affinity of PGE
2
 for EP1 and EP2, saturation analysis has been done showing KD values 
of PGE
2
 for EP1 and EP2 be around 24 and 5 nM, respectively37. Therefore, it can be hypothesized 
that under normal conditions, PGE
2
 levels in the detrusor might be such, that the inhibiting EP2 
effect predominates the activating EP1 effect, which might result in a stabilization of the muscle 
layer. Under certain circumstances, the PGE
2
 levels may increase above a certain threshold level in 
which case the contractile EP1 effect becomes more predominant. Small sub-threshold increases of 
PGE
2
 might, in such a case, be due to subtitle bladder wall irritation, inflammation or stretch. The 
exact role of the EP2 receptor in the bladder wall remains to be determined by future analysis of the 
activation, signal propagation and bladder sensory pathways by functional studies. The PGE
2
 signal 
is suggested to be spread out through suburothelial and intramuscular interstitial cells expressing 
EP1. The narrow balance between the contractile EP1 and the possible relaxant EP2 effect might be a 
system that modulates the autonomous, non-voiding contractions and relaxation which can become 
disrupted when PGE
2
 levels reach certain higher levels. This idea is supported by earlier studies 
showing that frequency and amplitude of the non-voiding activity is reduced by stimulation of an 
adrenergic/cAMP-linked mechanism38.
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Figure 9. Cartoon of the expression of EP2 and COX1 in the muscle bundles. A schematic 
overview of the lateral wall of the guinea pig bladder and the proposed PG signal transduction.
Conclusion
This morphological study indicates that the EP2 receptor is expressed on muscle interstitial cells 
and on muscle bundles. The proximity of the COX1 positive interstitial cells to EP2 positive cells 
suggests that PG targeting these EP2 receptors can be produced locally. It is hypothesized that the 
PGE
2
 concentration in the tissue might be responsible for the threshold level setting of interstitial 
cell excitability. However, functional experiments are needed in order to confirm this hypothesis and 
the physiological significance of the EP1 and EP2 receptors in the bladder.
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Abstract
Purpose
To investigate the effect of prostaglandin depletion by means of COX-inhibition on cholinergic 
enhanced spontaneous contractions. 
Methods
The urethra and bladder of 9 male guinea pigs (weight 270–300 g) were removed and placed in 
an organ bath with Krebs’ solution. A catheter was passed through the urethra through which the 
intravesical pressure was measured. The muscarinic agonist arecaidine, the non-selective COX 
inhibitor indomethacin, and PGE
2
 were subsequently added to the organ bath. The initial average 
frequency and amplitude of spontaneous contractions in the first 2 minutes after arecaidine 
application were labelled F
ini
 and P
ini
, respectively. The steady state frequency (F
steady
) and amplitude 
(P
steady
) were defined as the average frequency and amplitude during the 5 minutes before the next 
wash out. 
Results
Application of 1 μM PGE
2
 increased the amplitude of spontaneous contractions without affecting 
frequency. 10 μM of indomethacin reduced amplitude but not frequency. The addition of 
indomethacin did not alter F
ini
 after the first application (p = 0.7665). However, after the second 
wash, F
ini
 was decreased (p = 0.0005). F
steady
, P
steady
 and P
ini
 were not significantly different in any of 
the conditions. These effects of indomethacin were reversible by PGE
2
 addition. 
Conclusions
Blocking PG synthesis decreased the cholinergically stimulated autonomous contractions in the 
isolated bladder. This suggests that PG could modify normal cholinergically evoked response. A 
combination of drugs inhibiting muscarinic receptors and PG function or production can then 
become an interesting focus of research on a treatment for overactive bladder syndrome.
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Introduction
The overactive bladder syndrome (OAB) is defined as urinary urgency with or without urgency 
incontinence, urinary frequency and nocturia. These symptoms still present a therapeutic challenge. 
Currently, antimuscarinic drugs are first-line treatment for OAB. How their beneficial action is 
achieved is still a matter of discussion. Depending on the studied compound, antimuscarinic drugs 
often have only moderate response rates when compared to placebo1. However, adverse effects and 
decreasing efficacy cause long-term compliance problems2. Therefore, it is desirable that alternative 
treatment methods are developed and made available. The lower urinary tract has two basic 
functions: to store urine for most of the time at low pressure and expel it at a socially convenient 
time and place. Therefore, it is equipped with an extensive relay network to transmit information on 
bladder fullness to the brain3. One of the proposed mechano-transduction mechanisms is stretch 
dependent urothelial release of mediators such as acetylcholine, Nitric oxide, ATP and prostaglandin 
(PG)4. PGE
2
 appears o be the main PG involved in the regulation of the bladder5 and exert its effect 
through the endoprostanoid receptors, of which four subtypes (EP1, EP2, EP3, and EP4) have been 
described6,7. In the bladder, PG release depends on de novo synthesis rather than release from 
pre-formed stores8. Cyclooxygenase type 1 and 2 (COX1 and COX2) are the central enzymes in the 
production of PG9. COX1 is a constitutive form, whereas COX2 an inducible form in the bladder. 
Its expression is regulated by various stimuli, including pro-inflammatory cytokines and growth 
factors9. An increased expression of COX2 has been described immediately after experimentally 
induced bladder outlet obstruction10. There is an increasing amount of data available pointing to a 
role of PG in the regulation of non-voiding contractions and afferent activity10-13. The isolated whole 
bladder shows autonomous small contractions, which resemble non-voiding contractions that 
increase in amplitude and/or frequency by muscarinic agonists14,15 and PG10. Similarly, intravesical 
PG administration in vivo increases nonvoiding contractions during bladder filling and decreases 
the inter-micturition interval16, whereas EP1 and EP3 knockout mice show an increased micturition 
threshold. Moreover, in these animals, the PGE
2
 induced hyperactivity is decreased16. How PG 
exerts its effect is not well understood. However, involvement of capsaicin sensitive afferents and 
autonomous ganglia has been suggested.12 An interaction or crosslink between the cholinergic and 
prostanoid pathway has been suggested before17 and may be another mechanism of action. This 
idea is supported by the fact that muscarinic agonists can induce production of PGE
2
18. The current 
study aims to further investigate the crosslink between the cholinergic and prostanoid pathway in 
order to explore a possible new treatment modality through COX inhibition for OAB. Therefore, 
the non-specific COX inhibitor indomethacin was used to investigate the effect of prostaglandin 
depletion on cholinergic enhanced spontaneous contractions. 
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Material and Methods
Animals
A total of 9 male guinea pigs (weight 270–300 g) were killed by cervical dislocation, followed by 
exsanguination. Male guinea pigs were used because of the favourable urethral length, which made 
catheterization of the isolated bladder easier. All procedures were carried out with the approval 
of guidelines of the animal ethics committee of the University of Maastricht and were in line with 
European Community guidelines. 
Pressure recordings 
The urinary bladder and proximal urethra were excised immediately after cervical dislocation of the 
animal and placed in Krebs’ solution (mM: NaCl 121.1; KCl 1.87; CaCl
2
 1.2; MgSO
4
 1.15; NaHCO
3
25; KH
2
PO
4
 1.17; glucose 11.0), bubbled with 5% CO
2
 and 95% O
2
 (pH 7.4, 34°C). The urethra was 
cannulated with a flexible plastic cannula (2 mm diameter) secured using a fine ligature. The bladder 
was then transferred to a heated organ bath (40 mL, 33–36°C) containing constantly gassed Krebs’ 
solution, and the cannula was connected through a fluid filled tube containing three-way connector 
to a pressure transducer (DTX Plus, Becton Dickinson, Franklin Lakes, NJ, USA). The bladder was 
allowed to empty. Subsequently, the bladder was filled to 2 ml in approximately 30 seconds. The 
transducer output was amplified, digitized at 20 Hz and recorded using a data capture system 
(MP100 with AcqKnowledge 3.7.3 software, BIOPAC systems inc, California). The pressure range 
of this apparatus was 0.02–180 cmH
2
O. The transducer was calibrated before each experiment. 
Recordings started 30 minutes after the animal was sacrificed. The timeline of the experiments 
is given in figure 1. The pressure recordings started with cholinergic stimulation with 1 μM of the 
cholinergic agonist, arecaidine (t = 0). This was followed by empting the organ bath and washing 
the bladder twice with fresh Krebs’ solution, 15 minutes after arecaidine stimulation (t = 15). In 
order to investigate the effect of inhibition of PG production on the arecaidine response, the non-
selective COX inhibitor, indomethacin was applied to the bladder For this purpose, after another 15 
minutes, 10 μM of the nonspecific COX inhibitor indomethacin was added to the Krebs’ solution 
in the organ bath (t = 30), followed by a second stimulation with 1 μM arecaidine, given 15 minutes 
later (t = 45). After another 15 minutes, a wash step was conducted (t = 60). This was then followed 
by an arecaidine stimulation (t = 75), followed by a wash step, 15 minutes later (t = 90). At this point, 
in 4 experiments, 1 μM PGE
2
 was added to the organ bath after 10 minutes in order to check the 
reversibility of the indomethacin effect by PGE
2
. (t = 105). Again this was followed by arecaidine 
stimulation 30 minutes later (t = 135). At the end another wash step was conducted (t = 150). 
Drugs
Concentrated drug solutions were added directly to the bath to achieve the required final dilution. 
All drugs were added to the solution bathing the serosal surface. The non selective COX inhibitor,
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Figure 1. The timeline of the experiments. Pressure recordings started with stimulation of 
the guinea pig bladder by adding the cholinergic agonist arecaidine to the organ bath with 
Krebs’ solution in which the isolated guinea pig bladder was kept. After 15 minutes the Krebs’ 
solution is renewed (wash step). The COX inhibitor indomethacin was added 15 minutes 
after the first wash step. This was then followed by two sets of arecaidine stimulation and 
wash steps each separated by 15 minutes. In four experiments PGE
2
 was added to the 
organ 15 minutes after the third wash step which was then followed by a set of arecaidine 
stimulation and wash step, 30 minutes later.
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indomethacin (Sigma, St Louis, Missouri) was used in a concentration of 10 μM. As muscarinic 
agonist, a 1 μM concentration of arecaidine but-2-ynyl ester tosylate (Tocris, Avonmouth, UK) was 
used 14 . PGE
2
 (Sigma, St Louis, Missouri) was used in a concentration of 1 μM 19 . 
Definitions
In figure 2 the different defined phases of the bladder contraction amplitude and frequency are 
marked. The baseline activity (
base
) is defined as spontaneous baseline contractions before arecaidine 
stimulation. The initial phase (
ini
) is defined as the first 2 minutes after arecaidine application and 
is characterized by average frequency (F
ini
) and amplitude (P
ini
) of spontaneous contractions. The 
steady state (steady) is defined as the 5 minutes before the next wash out, and is characterized by 
frequency (F
steady
) and amplitude (P
steady
). Instantaneous frequency plot The raw pressure at the peak 
of every contraction was acquired from the measurement system along with the exact time of the 
contractions. The frequencies were then calculated and plotted as demonstrated in the figures.
Statistical analysis
The analysis of the data was done, by conducting a double sided, paired t-test using the SPSS 
software.
Results
The figures displayed represent raw experimental data conducted in different animals on different days. 
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Response to muscarinic stimulation 
The isolated bladder response to the non-selective muscarinic agonist, arecaidine, is shown in 
figure 2 (arrow). The initial phase was characterized by a rapid rise in basal pressure, followed by 
high-frequency bladder contractions. Frequency declined within 5 minutes after which contraction
Figure 2. Pressure changes and instantaneous frequency plot of an isolated guinea pig bladder induced by 
arecaidine. A. Pressure changes of an isolated guinea pig bladder induced by 1 μM arecaidine. The average 
frequency in the initial phase, defined as the first 2 minutes after arecaidine application, is labelled F
ini
. The 
steady state frequency (F
steady
) is defined as the average frequency over a 5 minutes period prior to the wash out. 
B. Instantaneous frequency plot of an isolated guinea pig bladder. The time of stimulation with 1 μM arecaidine 
is indicated with an arrow. The frequency of the autonomous contractions initially increases and then return 
back to a lower steady level after approximately 5 minutes.
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amplitude increased, eventually reaching a steady state. These findings are consistent with previous 
observations15,20. 
Effect of prostaglandin and COX inhibition on the baseline activity 
The effects of PGE
2
 and indomethacin on the baseline transients are shown in figure 3. P
base
increased about 2-fold in the presence of 1 μM PGE
2
 (control 8.0 ± 4.6 cmH
2
O vs. PGE
2
 17.1 ± 7.5 
cmH
2
O; p = 0.01; n = 5). F
base
 was not affected by PGE
2
 (control 0.026 ± 0.01 Hz vs. PGE
2
 0.039 ± 
0.02 Hz; p = 0.26; n = 5). Application of 10 μM of indomethacin decreased P
base
 (control 13.2 ± 6.2 
cmH
2
O vs. indomethacin 11.6 ± 5.9 cmH
2
O; p = 0.03; n = 6). F
base
 was not affected by indomethacin 
(control 0.028 ± 0.0066 Hz vs. indomethacin 0.030 ± 0.0051 Hz; p = 0.32; n = 6). 
10
 c
m
 H
2O
 
10
 c
m
 H
2O
 
1 µM PGE2
1 min
10 µM Indomethacin
1 min
A 
B 
Figure 3. Spontaneous activity of the isolated guinea pig bladder after administration of PGE
2
 and indomethacin. A. 
Spontaneous activity of the isolated guinea pig bladder. The arrow indicates when 1 μM of PGE
2
 is added. The amplitude of 
the contractions is significantly increased. B. Spontaneous activity of the isolated guinea pig bladder. The arrow indicates 
when 10 μM indomethacin is added. The amplitude of the contractions is slightly decreased by indomethacin. However, the 
frequency of contractions is not affected.
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Effect of indomethacin and PGE
2
 on the muscarinic response
The recordings of an experiment with COX inhibitor indomethacin are shown in figure 4. At t = 30
indomethacin was added to the bath. The bladder response on arecaidine stimulation in the
presence of indomethacin (t = 45) was not different from the response to arecaidine stimulation 
in the absence of indomethacin (t = 0), for any of the parameters P
ini
 (p = 0.081), F
ini 
(p = 0.77), 
P
steady
 (p = 0.19), F
steady
 (p = 0.32). However, after a wash step and a the second stimulation, with 
arecaidine (t = 75), F
ini
 was significantly decreased (p = 0.0005), whereas P
ini
 (p = 0.086), F
steady
(P = 0.32) and P
steady
 (p = 0.33) remained unchanged. To check the reversibility of the described 
indomethacin effect after the wash step, by prostaglandin, PGE
2
 was given exogenously at t = 105 in 
four animals. One of these recordings is shown in figure 5. After adding PGE
2
 a strong response, i.e. 
high amplitude contractions, were observed as shown in figure 5. In order to achieve a steady state 
before adding arecaidine, arecaidine was added 30 minutes later instead of 15 minutes. Data of all 
four experiments show that, compared to arecaidine stimulation after indomethacin exposure (t = 45 
and T = 75), F
ini
 was increased (p = 0.014), so the indomethacin effect on F
ini
 was reversed by PGE
2
. 
There were no changes noted in P
ini
 (0.38), neither F
steady 
(0.27) nor P
steady 
(0.19). F
ini
 at t = 135 was not 
significantly changed when compared to the initial arecaidine stimulation (t = 0) (p = 0.06).
Discussion
Presence of PG receptors in the bladder and involvement of PG in the bladder physiology has 
been demonstrated before6,13,21,22. The urothelium is shown to release acetylcholine, ATP, Nitric 
Oxide and prostaglandin4,6. The physiological role of these signals is poorly understood and a 
possible interaction between them has not widely been considered. The link between PG and 
cholinergic effects in the bladder has been suggested before. In a study in rat detrusor it was 
shown that indomethacin suppressed frequency of muscarinic-induced contractions but only 
in strips of certain orientation and with urothelium intact23. Furthermore, in another study in rat 
bladders studied in an organ bath model it was shown that PGE
2
 release could be antagonized by 
indomethacin and concluded that COX inhibitors suppress ATP release from bladder epithelium 
via decreasing PGE
2
. In addition, EP1 and/or EP3 receptors were suggested to participate in this 
effect24. In a study in rabbit detrusor strips it was shown that both indomethacin and ibuprofen 
suppress spontaneous contractions25. In addition, it has been suggested that endogenous PGs in 
isolated human detrusor facilitate the action of acetylcholine17.This effect was thought to be through 
an increase in the concentration of the cholinergic neurotransmitter probably via an inhibition of 
the acetylcholinesterase activity17. Moreover, PG has been suggested to have a modulatory role in 
the release of acetylcholine and ATP in the guinea pig bladder26. The aim of our study was to further 
investigate the link between the prostaglandin and the cholinergic system and explore the possibility 
of COX inhibition as a treatment modality for OAB. It has been demonstrated that that there is a 
basal acetylcholine release in human detrusor muscle in vitro27. This release was resistant to nerve
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Figure 4. Timeline, pressure changes and instantaneous frequency plot of an isolated guinea pig bladder pre-exposed to
indomethacin before stimulation with arecaidine. A. an outline of the experiment. After the first 1 μM arecaidine simulation 
(enlarged in panel B as 1), the organ bath is washed to remove the arecaidine. After 15 minutes, 10 μM indomethacin is added
followed by a second stimulation of arecaidine (enlarged in panel B as 2). After a wash step, a third arecaidine stimulation is 
performed (enlarged in panel B as 3). B. Parts of panel A in an expanded scale. C. Instantaneous frequency plot comparing 
the three conditions described in panel A.
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Figure 5. Timeline, pressure changes and instantaneous frequency plot of an isolated guinea pig bladder after stimulation 
with arecaidine showing the reversibility of the indomethacin effect by PGE
2
. A. an outline of another typical experiment. The 
same protocol as described in Figure 3 was followed. To check the reversibility, at the end of the experiment, 1 μM PGE
2
 is 
added in to the organ bath and a last arecaidine stimulation is conducted. The first arecaidine stimulation is marked as (1) 
followed by the stimulation with presence of indomethacin (2) followed by stimulation after a wash step (3). At the end an 
arecaidine stimulation is shown after adding PGE
2
 to the system (4). B. Each of the arecaidine responses shown in panel A in 
an enlarged scale, starting from the left, the first trace shows the basic arecaidine response (1), the second trace shows the 
previously shown effect of the inhibition of PG production (2). The third trace shows the effect of washing the organ bath with 
fresh Krebs’ before stimulation with arecaidine (3). The last trace from the right shows the effect of addition of exogenous 
PGE
2
 (4). C. Instantaneous frequency plot comparing the four conditions described in panel A.
Thesis M.S. Rahnama’i.indd   118 10-10-13   13:36
119
Chapter 6 – The Effect of Indomethacin on Contractions in the Guinea Pig Bladder
blocker tetrodotoxin, and considerably reduced when the urothelium was removed, suggesting 
that the released acetylcholine was of non-neuronal origin and, at least partly, generated by the 
urothelium. Stretch of the muscle increased the release. 
There are thus reasons to believe that acetylcholine can be generated by nonneuronal structures 
within the bladder, and it may be speculated that urothelially derived acetylcholine can excite 
suburothelial afferent nerves and that this contributes to OAB. During filling of the bladder, 
there is no activity in the parasympathetic nerves innervating the bladder, and direct evidence for 
spontaneous release of acetylcholine from nerves during the filling phase of the bladder has so 
far been lacking28. However, it has been shown that there is a spontaneous tetrodotoxinresistant 
release of acetylcholine from autonomic cholinergic nerves in guinea pig and rat bladders under 
both in vitro and in vivo conditions29. This release was shown to significantly affect bladder 
contractility (autonomous activity)29. These findings provide further support for the hypothesis 
that antimuscarinic drugs can act also by inhibiting a myogenic afferent pathway during the filling 
phase 28. Thus, during the storage phase, acetylcholine may be released from both neuronal and 
non-neuronal sources, and directly or indirectly excite afferent nerves suburothelially and within 
the detrusor. It is has been shown that an isolated bladder in an organ bath shows spontaneous 
rhythmical contractions14,15. The frequency of this baseline activity was shown to be unaffected 
by PGE
2
 and the COX-inhibitor indomethacin (figure 3). Although F
base
 was not significantly 
affected by PGE
2
 (control 0.026 ± 0.01 Hz vs. PGE
2
 0.039 ± 0.02 Hz; p = 0.26; n = 5) there was 
an increase of about 50%. Therefore, this might be due to a lack of power in our study and might 
become significant if more animals were tested. On the other hand, the amplitude of the baseline 
contractions was significantly raised by PGE
2
 and decreased by indomethacin, indicating that PG is 
needed for and has a stimulating effect on the amplitude of these baseline contractions. The non-
selective muscarinic agonist, arecaidine induces a rapid rise in basal pressure with high-frequency 
bladder contractions which declined within 5 minutes. After this, contraction amplitude increased, 
eventually reaching a steady state. These findings are consistent with previous observations15,20 and 
represent a typical response by the isolated bladder to arecaidine as shown in figure 2. Furthermore, 
data presented in this paper show that inhibition of PG production by indomethacin diminished 
the average frequency of the initial burst of transients of the isolated guinea pig bladder, in the first 
2 minutes after of the application of the muscarinic agonist, arecaidine (F
ini
). As explained in figure 
2B, indomethacin by itself, i.e. in the absence of arecaidine, did not change baseline contraction 
frequency but slightly reduced contraction baseline amplitude. However, arecaidine stimulation 
after COX inhibition by indomethacin application, lead to a significantly less outspoken response, 
after the second arecaidine stimulation. The explanation of this delayed effect of indomethacin 
on F
ini
 could simply be due to a longer incubation time needed for indomethacin to exert its effect. 
Indomethacin is still believed to be present in the organ bath since the recordings after the second 
wash step are not the same as control. This can be clearly seen in figures 4 and 5, especially at the 
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diagram at the bottom of the figures. The difference in 1 (control) and 3 (after second wash step) 
is only in the addition of indomethacin and since these two recordings are persistently different 
in all experiments we assume that indomethacin is still present in the system. Furthermore, the 
conducted control experiments (data not included) have ruled out that this effect is simply due to 
time or a repeated wash step. However, another plausible explanation may be that the second wash 
step, applied after the second arecaidine stimulation, could have caused a further washout of the 
previously produced PG. Since de novo production of the PG is inhibited by indomethacin, there is 
no new PG production in the isolated bladder. The delayed effect may therefore also be explained 
by the small amount of previously produced PG, which might still be present and active in the 
system during the first arecaidine stimulation. Therefore, the initial burst induced by arecaidine 
is not affected the first time. We hypothesize that after the addition of indomethacin followed by 
the second wash step, there is practically no PG left in the organ bath and the tissue. Therefore, 
there is a significantly less outspoken response to arecaidine. Thus, inhibition of PG production 
seems to reduce F
ini
 of the muscarinic response and it can be suggested that PG is necessary for 
the normal increase in autonomous activity following cholinergic stimulation, i.e. the arecaidine 
response. In line with this, an exogenous dose of PGE
2
 increases the initial burst frequency after 
arecaidine stimulation, to levels even higher than the control (figure 4). PG has been suggested to 
be linked to acetylcholine before. In a study conducted in another species and It has been shown 
that patients with the overactive bladder syndrome (OAB) have an increased urinary PG38,39 which 
is thought to affect bladder activity directly by effects on smooth muscle and/or indirectly via effects 
on neurotransmission40.
Conclusions
In summary, our data show that inhibition of PG production has an influence on the cholinergically 
induced bladder response in the isolated bladder. In order to evaluate the effect of PG on the 
autonomous activity in the presence of local reflex loops and control by the central nervous system, 
these experiments should be performed in vivo. By this, a combination of drugs inhibiting both 
muscarinic receptors and PG function or production can become an interesting focus of research 
in the quest for a better treatment for OAB. In order to gain a full understanding of the PG effect 
shown on the cholinergically induced bladder response, more studies need to be conducted using 
selective EP blockers in vitro and in vivo.
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Abstract
Nitric oxide and the cyclic nucleotide monophosphates cAMP and cGMP have a role in control of 
the micturition process and hence, are suggested to be involved in the pathophysiology of storage 
and voiding disorders. Phosphodiesterase enzymes (PDEs) hydrolyse cAMP and cGMP. Inhibition 
of PDEs increases cAMP and cGMP levels and relaxes urinary bladder smooth musculature. 
Although many preclinical studies have been conducted, to date, only PDE1 and PDE5 inhibitors 
have been tested clinically for the management of storage and voiding disorders. Treatment with 
PDE1 inhibitors might improve micturition frequency in patients with overactive bladder, whereas 
inhibition of PDE5 improves lower urinary tract symptoms in men, either with or without benign 
prostatic hyperplasia and erectile dysfunction. Furthermore, the combination of a PDE5 inhibitor 
and an α-adrenoceptor antagonist has superior efficacy to monotherapy with either agent. However, 
the role of PDE5 inhibitors in the treatment of women with detrusor overactivity remains unclear. 
The clinical application of agents that inhibit other PDEs, including PDE4, also certainly merits 
scientific attention. PDE inhibitors seem likely to become a valuable alternative treatment for 
patients with storage and voiding disorders in the future. Phosphodiesterases (PDEs) hydrolyse 
cAMP and cGMP, and are thought to have a crucial role in 
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Introduction
Many families of enzymes can break phosphodiester bonds, including phospholipases C and D, 
autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, 
among others. However, in most circumstances, the term phosphodiesterase (PDE) refers to the 
cyclic nucleotide PDEs, which break down the second-messenger molecules cAMP and cGMP that are 
important endogenous mediators of many cellular processes, including smooth muscle motility1–3. 
PDE inhibitors block breakdown of these molecules and consequently elevate intracellular levels of 
cAMP, cGMP, or both.
cAMP is synthesized by adenylyl cyclases either in the cytoplasm or associated with G-protein-coupled 
receptors in the plasma membrane, termed soluble and particulate adenylate cyclases, respectively. 
Although these enzymes have different subcellular localizations and respond differently to various 
regulators, they share a conserved catalytic domain architecture and function via a common catalytic 
mechanism4. Eight of the nine particulate adenylyl cyclase isoforms (the exception being adenylate 
cyclase type 9) are activated by GTP-bound G
s
α (stimulatory G protein subunit α) and forskolin5. 
Soluble adenylate cyclases, by contrast, are regulated by bicarbonate and calcium ions, and are 
insensitive to both forskolin and activated G
s
α4. cGMP is synthesized by guanylyl cyclases, again 
located either in the cytoplasm or plasma membrane. Particulate guanylyl cyclases are activated 
by extracellular natriuretic peptides, whereas soluble guanylyl cyclases are triggered by nitric oxide 
(figure 1)6.
In the lower urinary tract, nitric oxide is an important nonadrenergic, noncholinergic neurotransmitter 
that acts alongside the classical adrenergic and cholinergic systems to regulate micturition7,8. Nitric 
oxide is thought to inhibit efferent neurotransmission in the urethra and to modulate afferent 
neurotransmission in the bladder, as well as related reflex pathways in the spinal cord7–9. Nitric oxide 
released from nerve endings and endothelium diffuses into smooth muscle cells, where it stimulates 
cGMP synthesis, which subsequently leads to their relaxation10. cGMP is hydrolysed to inactive 5’ GMP 
by PDEs11. cAMP and cGMP are also generally accepted to be involved in the control of micturition, and 
hence to have a role in the pathophysiology of storage and voiding disorders9,11–16.
In vitro studies indicate that human detrusor smooth muscle is relatively inert to the nitric-oxide-
producing agent, sodium nitroprusside, and to activation or inhibition of targets acting via the 
cGMP system17. Animal studies, however, suggest that nitrinergic nerves innervate the bladder 
stroma and suburothelium, and that the urothelial layer both expresses nitric oxide synthase and 
can release nitric oxide8,18–20. In turn, nitric oxide may exert a cGMP-mediated inhibitory effect 
on bladder sensory afferent nerves21,22. Although little guanylyl cyclase activity can be detected 
in detrusor smooth muscle, and nitric oxide and PDE5 inhibitors have an insignificant effect on 
bladder relaxation (during filling) or contraction (during emptying), considerable amounts of 
guanylyl cyclase are present in bladder afferent nerves and interstitial cells. Excitation of bladder 
sensory nerves, caused by distention during bladder filling, inflammation or irritation, is a key trigger 
of the micturition reflex. Increased activity in these nerves can, therefore, contribute to bladder 
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overactivity. Inhibition of PDE5 increases cGMP or cGMP-binding protein kinase (PKG) activity in 
afferent nerves, and directly decreases neuropeptide release, thereby resulting in decreased afferent 
nerve signalling. In interstitial cells, increasing cGMP or PKG activity can decrease cytosolic Ca2+ via 
several mechanisms of action (figure 1)23.
Figure 1. Schematic diagram of the cyclic nucleotide signalling pathways. Stretch stimuli, or acetylcholine release increase 
internal Ca2+ levels in NOS-expressing urothelial cells. NOS produces nitric oxide, which signals to detrusor smooth muscle 
cells. NO is thought to have a modulatory role in the lower urinary tract, including the relaxation of urethral smooth muscle, 
modulation of neurotransmitter release from efferent nerves, regulation of urothelial permeability, and modulation of 
afferent nerve activity. Moreover, a pathophysiological role of NO has been suggested because injury or chronic inflammation 
can upregulate the expression of inducible NOS. Guanylyl cyclases located in the cytoplasm or plasma membrane 
synthesize cGMP in response to NO or CNP. cAMP is synthesized by adenylyl cyclases, either associated with G protein-
coupled receptors in the plasma membrane, or in the cytoplasm. Membrane-associated adenylyl cyclases are activated by 
GTP-bound G
s
α and forskolin, whereas cytoplasmic adenylyl cyclases are regulated by HCO
3
– and Ca2+, but insensitive to 
forskolin or activated G
s
α. cAMP and cGMP are hydrolysed to AMP and GMP, respectively, by phosphodiesterases (PDEs). 
Abbreviations: NOS, nitric oxide synthase; CNP, C-like natriuretic peptide; pGC, particulate (plasma membrane) guanylyl 
cyclase; sGC, soluble guanylyl cyclase; pAC, particulate (plasma membrane) adenyl cyclase; sAC, soluble (cytoplasmic) 
adenyl cyclase; PDE, phosphodiesterase.
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PDE isoenzymes are classified according to their preferences for either cAMP and/or cGMP, kinetic 
parameters of hydrolysis, sensitivity to inhibition by various compounds, allosteric regulation by 
other molecules and biochemical behaviour on anion exchange columns24. The PDE superfamily 
now includes more than 50 distinct isoforms, divided into 14 subtypes25. So far, 11 PDEs have 
been identified (figure 2), and three further isoenzymes are thought to exist, but have yet to be 
characterized26–28. The expression, distribution and function of the various PDE isoenzymes can 
vary in different tissues. Selective PDE inhibitors, therefore, have the potential to exert specific 
effects on a given target tissue25,29. Several selective PDE inhibitors have already been approved for 
clinical use and others are under investigation in ongoing clinical trials. To date, six PDEs (PDEs 1–5 
and 11) have been proven to be of pathophysiological importance in different clinical conditions30.
In this Review, we summarize current understanding of the distribution and physiological roles 
of PDEs in the urinary bladder. We also discuss the effects and clinical use of PDE inhibitors in 
the treatment of functional bladder disorders, including lower urinary tract symptoms (LUTS), 
overactive bladder (OAB) and detrusor overactivity (defined in Box 1).
Figure 2. A schematic overview of the different PDE isoenzymes and some of their characteristics, including affinity for cAMP 
and/or cGMP. PDEs 1-3, 10 and 11 hydrolyse both cAMP and cGMP. PDEs 5, 6 and 9 only hydrolyse cGMP. PDEs 4, 7 and 8 
only hydrolyse cAMP. Abbreviations: IBMX, 3-isobutyl-1-methylxanthine (a non-selective, competitive phosphodiesterase 
inhibitor); PDE, phosphodiesterase.
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Table 1. PDEs, their major substrates, inhibitors and their expression in the urinary bladder.11,16,34,36,37,90,101,102
Isoenzyme Major substrate(s) Inhibitor(s) [Ki] Expression in human bladder*
PDE1 cAMP & cGMP Vinpocetine, N (6-aminohexyl) Protein: IHC,33,34, activity90
 5-chloro 1-naphthalenesulphonamide, mRNA: RT PCR36
8-methoxy mixture 
PDE2 cAMP & cGMP Erythro 9-(2-hydroxy 3-nonyl)adenine Protein: activity90
mRNA: RT PCR36
PDE3 cAMP & cGMP Cilostamide, milrinone, zardaverine, Protein: activity90
olprinone, cilostazol, quazinone, mRNA: RT PCR37,101
siguazodan 
PDE4 cAMP Rolipram, Ro 20 1724, piclamilast, Protein: activity90
zardaverine, cilomilast, roflumilast mRNA: RT PCR36
PDE5 cGMP Zaprinast [130 nM], sildenafil, Protein: IHC,103,32 activity,90 WB104
vardenafil, tadalafil, E4021, mRNA: RT PCR,36,103,104 NB37
morpholinosulphonyl-prazolopyrimidine, 
dipyridamole 
PDE6 cGMP Zaprinast [400 nM], dipyridamole Not determined
[125 nM], sildenafil 
PDE7 cAMP MIX, dipyridamole [600 nM] mRNA: RT PCR36
PDE8 cAMP Dipyridamole [9 μM] mRNA: RT PCR36
PDE9 cGMP Zaprinast [35 μM] Protein: IHC35 
mRNA: RT PCR36
PDE10 cAMP & cGMP Dipyridamole [1 μM] Not determined 
PDE11 cAMP & cGMP Zaprinast [12 μM], dipyridamole Not determined
[400 nM], tadalafil
*mRNA was identified by either NB or RT PCR. Protein was identified by measuring enzyme activity 
(degradation of cyclic nucleotides), WB or IHC. ‡IBMX-insensitive. 
Abbreviations: IBMX, 3 isobutyl 1-methylxanthine (a non-selective competitive PDE inhibitor); IHC, 
immunohistochemistry; Ki, inhibitor binding activity (if known); NB, northern blot; PDE, phosphodiesterase; 
RT PCR, reverse transcription polymerase chain reaction; WB, western blot.
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Figure 3. Phosphodiesterases and innervation in the male lower urinary tract. Sympathetic fibres (blue) originate in T11–L2 and 
extend through the inferior mesenteric ganglia and hypogastric nerve or the paravertebral chain to enter the pelvic nerves at the 
base of the bladder and urethra. Parasympathetic preganglionic fibres (green) originating in S2–S4 extend through the pelvic 
nerves to ganglia in the pelvic plexus and bladder wall, where the postganglionic nerves that supply parasympathetic innervation 
to the bladder arise. Somatic motor nerves (yellow) supplying the striated muscle of the external urethral sphincter arise from 
S2–S4 motor neurons that extend through the pudendal nerve. Parasympathetic postganglionic axons in the pelvic nerve 
release acetylcholine, which produces bladder contractions by stimulating M3 muscarinic receptors in bladder smooth muscle. 
Sympathetic postganglionic neurons release noradrenaline, which activates β3 adrenergic receptors to relax bladder smooth 
muscle and activates α1 adrenergic receptors to contract urethral smooth muscle. Somatic axons in the pudendal nerve also release 
acetylcholine, which contracts the external sphincter striated muscle by activating nicotinic cholinergic receptors. Parasympathetic 
postganglionic nerves also release ATP, which excites bladder smooth muscle, and nitric oxide, which relaxes urethral smooth 
muscle (not shown). The distribution of PDE1 and PDE5 enzyme in the lower urinary tract is indicated. Abbreviations: IMP, inferior 
mesenteric plexus; L, lumbar root; S, sacral root; SHP, superior hypogastric plexus; SN, sciatic nerve; T, thoracic root. 
Permission obtained from Nature Publishing Group © C.J. Fowler et al. The neural control of micturition. Nat. Rev. 
Neurosci. 9, 453-466 (2008).
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PDE expression in the bladder
Various PDE subtypes have been identified in both animal and human bladders. PDE5 is 
expressed in the rat bladder, where its expression and activity are both thought to be regulated 
by testosterone.31 PDE5 is also present in guinea pig urothelium, suburothelial interstitial cells 
and bladder blood vessels, as demonstrated in studies that revealed these tissues (rather than 
bladder nerve fibres) to be the site of action of the PDE5 inhibitor, vardenafil32. In rabbits and 
humans, detrusor smooth muscle in the dome and lateral walls of the bladder express PDEs 
1–533–35. Furthermore, mRNAs encoding PDEs 7–9 and 15 are detectable by RT-PCR in the human 
bladder, and PDE1 and PDE9 are expressed in human urothelium. Finally, the presence and 
activity of PDEs 1–5 have also been demonstrated in the human bladder by biochemical assays 
and immunohistochemistry (table 1)34–37.
Urological effects of PDE inhibitors
The effects of several PDE inhibitors have been studied in many preclinical and clinical contexts, 
both in vitro and in vivo. However, to date, no published functional studies using isolated urinary 
bladder tissue have assessed inhibitors of PDE3 or PDEs 6–11.
Preclinical studies
PDE1 inhibition
The PDE1 inhibitor vinpocetine (the only such agent currently approved for clinical use) elicits 
relaxation of rabbit detrusor muscle, despite producing no detectable changes in cAMP or cGMP 
levels38. However, a subsequent study showed that PDE1 inhibition with 8-methoxymethyl-3-isobutyl-
1-methylxanthine relaxes guinea pig detrusor smooth muscle by raising cellular cAMP levels39. In vitro
studies using pig detrusor smooth muscle also suggest that PDE1 (which is stimulated by Ca2+ and 
calmodulin) has major functional importance in regulating hydrolysis of cAMP.40 Moreover, isolated 
human detrusor strips contracted by carbachol, an antagonist of muscarinic acetylcholine receptors, 
relax in the presence of either papaverine, a nonspecific PDE inhibitor, or vinpocetine. Relaxation was 
accompanied by an increase in tissue cAMP and cGMP levels41.
PDE2 inhibition
PDE2 inhibition has only been studied in the context of the bladder in amphibians. Blocking 
PDE2 activity using erythro-9-[2-hydroxy-3-nonyl]adenine had no effect on nitric-oxide-mediated 
inhibition of an arginine–vasotocin-induced increase in the osmotic water permeability of excised 
frog bladders, showing that PDE2 is present42.
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PDE4 inhibition
PDE4 is thought to be involved in the degradation of intracellular cAMP, which mediates phasic 
contractions in the bladder12. In rabbit detrusor muscles, cAMP levels rose significantly in response 
to PDE4 inhibition using rolipram, but this agent only elicited a moderate relaxation effect38. In human 
detrusor strips, however, PDE4 inhibition has a moderate relaxing effect on carbachol-induced 
contraction. This effect was increased in strips that were not devoid of urothelium, where nitric oxide 
is produced, suggesting that nitric oxide signalling potentiates this effect of PDE4 inhibition. An 
enhancement of this bladder-relaxing effect of rolipram was also seen in response to administration 
of the adenylyl cyclase activator, forskolin, which increases intracellular cAMP levels43.
In a rat urethral ligation model of bladder outlet obstruction (BOO), PDE4 inhibition with 
IC486051 decreased the frequency and amplitude of nonvoiding contractions and suppressed 
bladder overactivity44. urthermore, PDE4 inhibition with YM976 attenuated the development of 
cyclophosphamide-induced haemorrhagic cystitis45. Treatment with this agent also improved 
voiding behaviour and reduced histological damage in rats with cystitis (induced by instillation 
of hydrochloric acid)45. Additionally, inhibition of PDE4 with rolipram decreased the amplitude, 
frequency and strength (represented by the area under the time–contraction amplitude curve) 
of nonvoiding contractions in cyclophosphamide-treated rats, at doses that had no effect on 
carbachol-induced phasic bladder contractions and cystometric parameters46. In guinea pig 
studies, bladder strips contracted by electrical-field stimulation could be relaxed by treatment 
with rolipram, which also suppressed the contractile response to low concentrations of carbachol 
and potentiated the contractile response to high concentrations of this agent47. The mechanism 
underlying this potentiating effect of rolipram on bladder contractions induced by high-dose 
carbachol is not currently known. Furthermore, cAMP decreased mechanisms that influence 
the frequency of agonist-induced phasic activity in isolated guinea pig bladders47. Overall, these 
observations suggest that PDE4 inhibition has a moderate muscle-relaxing effect in the bladder.
PDE5 inhibition
The most widely studied PDE inhibitors in bladder pathophysiology are those that target cGMP-
specific PDE5. Vardenafil increases nitric oxide signalling, potentiates bladder relaxation and 
inhibits bladder smooth muscle proliferation, as well as decreasing nonvoiding contractions in 
rats with BOO31. Vardenafil also attenuated the contractions induced by carbachol as well as those 
induced by electrical-field stimulation in detrusor preparations with and without urothelium.48
Similar effects were seen in full-thickness bladder-wall preparations (which included urothelium) 
from rats with a partial urethral obstruction48.
Intra-arterial administration of udenafil to rats prolonged both bladder intercontraction intervals 
and the duration of urethral relaxation observed during high-frequency oscillations in urethral 
contractions49. n anaesthetized, decerebrated rats with neurogenic detrusor overactivity resulting 
from spinal cord injury, vardenafil attenuated the increase in bladder afferent nerve firing and also 
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reduced the frequency of nonvoiding contractions50. Once-daily vardenafil treatment reduces 
detrusor overactivity51 and significantly reduces the expression of hypoxia markers52 in the bladders 
of spontaneously hypersensitive rats (a model of OAB). These findings suggest that in addition 
to relaxation of bladder muscle, PDE5 inhibition can increase blood perfusion of the bladder52. 
By contrast, chronic vardenafil treatment increased the contractile force exerted in isolated strips 
of muscle from normal rat bladders53. In spontaneously hypertensive rats, the inhibitory effect of 
vardenafil on increased bladder contractility is thought to be partially mediated by cGMP-dependent 
inhibition of RhoA–Rho kinase signalling54.
Nitric oxide–cGMP signalling is presumed to predominantly activate sensory rather than motor 
components of the micturition reflex55. Indeed, systemic administration of the PDE5 inhibitor, 
tadalafil, reduced the activity of mechanosensitive afferent Aδ and C fibres elicited by mechanical 
distention of rat bladder in vivo. Another study demonstrated that tadalafil inhibits the increase 
in activities of both Aδ and C fibres induced by intravesical instillation of the irritant, acrolein56. 
In isolated guinea pig detrusor muscle tissue, sildenafil inhibited spontaneous contractions in 
multiple-bundle preparations, but not in single-bundle preparations. This observation suggests 
that the contraction-inhibiting effect of PDE5 inhibition is due to a decrease in synchronicity 
between functional units of muscle bundles rather than the direct inhibition of smooth muscle 
contractility57. In addition, the researchers showed that nitric oxide enhanced the spontaneous 
contractions observed in isolated guinea pig detrusor smooth muscle. The mechanism underlying 
enhancement of spontaneous contractions by nitric oxide is thought to be cGMP-independent, 
and possibly Ca2+-related (fgure 1)57. Chronic treatment with a high dose of vardenafil protected rat 
bladders from BOO-induced contractile dysfunction, as shown by attenuation of the stimulatory 
effect of carbachol58. In a rat model of benign prostatic hyperplasia (BPH), treatment with udenafil 
decreased urethral pressure59. Sildenafil decreases detrusor overactivity in a mouse model of 
BOO, and urodynamic as well as histological differences were seen between treated and untreated 
animals60. Furthermore, sildenafil treatment induced the relaxation of bladder neck smooth muscle 
in vitro, suggesting that this agent might be useful for improving LUTS associated with BPH61.
A different PDE5 inhibitor, zaprinast, had no effect on the contractile response of guinea-pig bladder 
strips to electrical-field stimulation, ATP or potassium chloride. However, zaprinast did suppress 
the contractile response to low concentrations of carbachol, and potentiated the response to a 
high concentration in bladder strips (as was also observed with the PDE4 inhibitor, rolipram, 
noted above)47. In strips of rabbit detrusor, sildenafil increased cGMP levels and had a relaxation 
effect on carbachol-contracted muscle38, similarly, treatment with udenafil reversed (in a dose-
dependent manner, such that the relaxation effect increased with increasing udenafil dose) the 
tonic contraction of isolated rabbit bladder and urethra strip preparations49.
In vitro data describing the effects of PDE5 inhibition on human bladder tissue are scarce. However, 
sildenafil relaxed carbachol-contracted detrusor strips obtained from patients without OAB who 
underwent cystatectomy for bladder cancer62. This effect was not altered by the presence of nitric 
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oxide donors, but was significantly attenuated by inhibition of either guanylyl or adenylyl cyclases62. 
In another study, exposure of isolated human detrusor smooth muscle to low concentrations of the 
nitric oxide donor, sodium nitroprusside, significantly increased the mean attenuation of muscle 
contraction induced by the PDE5 inhibitor MY 5,445, as well as that induced by the PDE1 inhibitor 
vinpocetine and the PDE4 inhibitor rolipram63. An enhancement in the potency of all three drugs 
was also registered in the presence of sodium nitroprusside63. Interestingly, however, sodium 
nitroprusside did not significantly affect the maximum attenuation of muscle contraction brought 
about by sildenafil in this study63. The researchers concluded from these findings that relaxation of 
human detrusor smooth muscle strips in response to PDE5 inhibition is mediated by both cGMP and 
cAMP signalling pathways62,63. However, the contribution of nitric oxide to this mechanism remains 
to be elucidated. Overall, we can conclude that PDE5 inhibition has a relaxing effect on the bladder.
Clinical data
Currently, PDE1 and PDE5 inhibitors are the only two families of agents used in the management of 
storage and voiding disorders in humans (table 2).
PDE1 inhibitors
Initial data from a randomized, double-blind, placebo-controlled trial of vinpocetine in patients 
with various forms of voiding dysfunction who had not responded to standard antimuscarinic 
therapy indicate a possible role for this agent in the treatment of urgency and urge incontinence 
(and, possibly, poor bladder compliance as well as interstitial cystitis) in both men and women64,65. 
Results from a large randomized, double-blind, placebo-controlled, multicentre trial of vinpocetine 
show a trend towards superiority of vinpocetine over placebo, although a statistically significant 
result has been documented only for one parameter, namely micturition frequency65. This lack of 
positive results might be due to the low dose of vinpocetine used (20 mg once daily) and limited 
number of participants (62 patients)65.
PDE5 inhibitors
No studies have been conducted on the use of PDE5 inhibitors in women with or without LUTS. 
However, a number of trials have assessed the effects of PDE5 inhibitors in men with erectile 
dysfunction accompanied by LUTS. PDE5 inhibitors are widely used in the treatment of erectile 
dysfunction, and have been suggested to be of potential utility in the preservation of penile smooth 
muscle and rehabilitation of erectile function after radical prostatectomy66,67. Moreover, PDE 
inhibitors might also counteract ejaculatory delay arising as an adverse effect of antidepressant 
therapy with a 5-hydroxytryptamine reuptake inhibitor17. In the search for new treatment options to 
improve symptoms related to storage and voiding disorders, including LUTS, OAB and detrusor 
overactivity, the clinical effects of PDE inhibition on urinary symptoms have gained increasing 
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interest68,69. Many studies have demonstrated a positive effect of PDE5 inhibitors on mild to 
moderate LUTS in men70–83. The pathophysiology of LUTS is complex and likely to be influenced by 
multiple factors; increasing the activity of the nitric oxide–cGMP pathway through PDE5 inhibition 
might, therefore, affect various pathological mechanisms (figure 3). The effects of PDE5 inhibition 
are presumed (although not yet proven) to be mediated through relaxation of smooth muscle in 
the bladder neck and/or prostate. In many studies, treatment with PDE5 inhibitors is associated 
with enhanced smooth muscle relaxation, proliferation of endothelial and smooth muscle cells, and 
increased nerve activity and tissue perfusion, and all these factors could have a beneficial effect on 
LUTS in men70. The use of individual agents is discussed in more detail below.
Sildenafil
Sildenafil monotherapy significantly improves international prostate symptom scores (IPSSs) 
and quality of life (QoL) scores in men with both erectile dysfunction and LUTS72. In total, IPSSs 
improved in 60% of patients, and 35% had an IPSS improvement of at least four points72. Another 
group reported that LUTS scores significantly improved in all 189 men with erectile dysfunction 
and moderate to severe LUTS due to BPH who were receiving sildenafil, and this improvement 
was independent of baseline BMI71. Moreover, the improvement in IPSS observed with sildenafil 
treatment was greater in men with severe LUTS than in men with moderate LUTS71. The same 
researchers also confirmed the positive effect of 12 weeks of treatment with sildenafil on both LUTS 
and erectile dysfunction74. Finally, in a further randomized study, men with previously untreated 
LUTS and erectile dysfunction received the α
1
receptor antagonist alfuzosin, sildenafil, or a 
combination of both compounds for 12 weeks. Patients in all three groups experienced a significant 
improvement in IPSS, but the effect was most pronounced in the combination-therapy group78.
Tadalafil
A single oral dose of tadalafil can exert significant positive effects on urodynamic parameters in 
patients with neurogenic bladder dysfunction associated with suprasacral spinal cord injury81. A 
placebo-controlled, double-blind trial of tadalafil in 281 men with erectile dysfunction and LUTS 
provided evidence that this agent is also effective in the treatment of LUTS secondary to BPH; 
however, the treated patients did not show significant changes in uroflowmetry findings73. In 
addition, a multicentre trial in 200 men with LUTS and BPH, both with and without BOO, compared 
tadalafil 20 mg once daily to placebo. After 12 weeks of treatment, no significant changes in bladder 
function (detrusor pressure at maximum urinary flow rate) or any other urodynamic parameter were 
seen. Interestingly, however, the men receiving tadalafil still had significant improvements in IPSS84.
A few trials have also compared the effectiveness of PDE5 inhibitors with that of α-blockers or 
antimuscarinic agents, or a combination of the two. In patients with erectile dysfunction and urinary 
storage symptoms after surgical treatment for LUTS due to BPH, a 5 mg dose of tadalafil given once 
daily for 12 weeks improved IPSSs, and this benefit was equivalent to that seen in men treated with the 
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antimuscarinic agent solifenacin (5 mg, given for the same period of time)77. A crossover study of 30 
men aged >50 years with LUTS secondary to BPH also demonstrated that tadalafil given in combination 
with the α-blocker tamsulosin was superior to tamsulosin treatment alone79. The long-term benefits of 
tadalafil treatment were also investigated in a 1-year open-label study in men with LUTS due to BPH, 
which showed that 5 mg of tadalafil once daily was well tolerated, and that the efficacy of this treatment 
was maintained85. Following these studies, once-daily 5 mg tadalafil was approved by the FDA for use 
in men with LUTS secondary to BPH (with or without erectile dysfunction).
Vardenafil
Vardenafil also improves LUTS in men. A study conducted in 39 patients with prostate cancer 
who had undergone bilateral nerve-sparing radical prostatectomy demonstrated that vardenafil 
treatment was associated with improved continence recovery compared with placebo86. Moreover, 
vardenafil significantly improved LUTS, erectile dysfunction and QoL in a cohort of 222 men 
with BPH and LUTS, and these improvements occurred as early as 8 weeks after initiation of this 
treatment75. The efficacy of a single dose of vardenafil was also assessed in a trial of 25 male patients 
with micturition disorders secondary to spinal cord injury, who were also taking the anticholinergic 
and antimuscarinic agent, oxybutynin. Vardenafil significantly decreased maximum detrusor 
pressure, improved maximum cystometric capacity, and increased bladder volume at first detection 
of detrusor overactivity77. As for tadalafil, the effect of a combination of vardenafil and the α-blocker 
tamsulosin was superior to that of tamsulosin alone80.
UK‑369,003
In 418 men with LUTS and BPH, 12 weeks of treatment with UK-369,003 resulted in a significant 
improvement in IPSS from baseline, compared to placebo. The researchers noted that increasing 
the drug dose from 100 mg to 400 mg increased the efficacy of this treatment82. The use of PDE5 
inhibitors to treat patients with OAB has only been studied in a single multicentre trial of UK-369,003 
in 310 consecutive male patients. This treatment improved the patients’ IPSSs, and improvements 
in the voiding and storage subscores of the IPSS were similar to those in overall IPSSs. However, no 
significant alterations were seen in voiding frequency, mean voided volume, urgency episode frequency 
or nocturia frequency in this study, at any dose of UK-369,003 (10 mg, 25 mg, 50 mg or 100 mg)83.
Interpretation of the clinical data
Increases in cAMP levels in the smooth muscles of the lower urinary tract are thought to have an 
important role in bladder relaxation. The results of studies of several agents that target the cAMP-
producing adenylyl cyclases show that relaxation of bladder smooth muscle correlated with an 
increase in intracellular cAMP levels15,87,88. cAMP is thought to have a similar role in the relaxation of 
human detrusor smooth muscle, which suggests that the cAMP signalling pathway might be of the 
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utmost importance in the regulation of detrusor muscle tone65. Specific regulation of intracellular 
signalling pathways that utilize cAMP and cGMP seems to offer a promising route to achieve 
selective modulation of urinary function, through modulation of either bladder afferent (sensory) 
signals or the contraction and relaxation of urinary bladder smooth musculature. Moreover, the use 
of selective inhibitors of the PDE isoenzymes present in the bladder might ensure a degree of organ 
selectivity, as both the distribution and function of PDE isoenzymes vary15,89.
The available data indicate that PDE1 and PDE5 represent interesting potential targets in lower urinary 
tract pathology. Firstly, PDE1 is expressed and functionally active in human urinary bladder tissue 
and, in vitro, the PDE1 inhibitor vinpocetine can reverse the contraction of bladder strips induced by 
muscarinic signalling. Relaxation was associated with an increase in tissue levels of both cAMP and 
cGMP in these studies33,34,36,41,90. Both preclinical and clinical studies show that PDE1 inhibition relaxes 
detrusor smooth muscle and benefits patients with OAB and poor bladder compliance64,65. However, 
to date, only one study of PDE1 inhibition has been conducted, in a limited number of male patients, 
although it did report positive findings, as discussed above65. The identification of appropriate, 
individualized treatment strategies for OAB in both men and women is, however, impeded by the 
apparent heterogeneity of its underlying pathophysiology. It is difficult, if not impossible, to subdivide 
the OAB population into categories of either disease or patient characteristics to determine which 
subgroups are most likely to derive benefit from any given treatment23.
Secondly, inhibition of the PDE5 isoenzyme induces relaxation of human detrusor smooth muscle62. 
Although functional studies in human bladders are limited, animal studies and clinical trials indicate 
that increasing cGMP levels by means of PDE5 inhibition might be beneficial in the treatment of 
patients with conditions such as LUTS, OAB and detrusor overactivity.15,92 Numerous clinical trials 
in male patients with LUTS secondary to BPH have investigated the safety and efficacy of the PDE5 
inhibitors sildenafil,71–74,78,92 tadalafil73,77,81 and vardenafil,75 both alone and in combination with the 
α-adrenoceptor antagonists tamsolusin and alfuzosin78. Overall, treatment with these three PDE5 
inhibitors resulted in a significant improvement in LUTS, expressed as increases in IPSS and QoL 
scores. Although some studies did not report any changes in urodynamic parameters associated 
with PDE5-inhibitor therapy, others demonstrated increased maximum urine flow rate during the 
treatment period23,73,84,93–95. Moreover, no differences were noted between placebo and treatment 
groups when assessing storage symptoms and voiding parameters, namely sensory perception, 
poor bladder compliance, voided volume and postvoid residual volume23. Thus, although PDE5 
inhibitors improve LUTS, we currently don’t know how exactly they work. On the basis of current 
evidence, however, PDE5 inhibitors seem to be a promising alternative (or at least, an adjunct) to 
treatment with α-blockers to relieve the symptoms of storage and voiding dysfunction, particularly 
in men with BPH (with or without erectile dysfunction). A meta-analysis of 107 articles also 
concluded that PDE5 inhibition significantly improves both LUTS and erectile dysfunction in men 
with BPH96.
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Table 2. Clinical trials evaluating the efficacy of selective PDE inhibitors in the treatment of storage and voiding dysfunction.
Study Study design Inhibitor* Comparator group n‡ T-duration Clinical effects
Truss et al. (2001)65 Double-blind RCT Vinpocetine Placebo 68 4 weeks Reduced micturition
frequency
Mulhall et al. (2006)72 Comparative Sildenafil Pretreatment versus 48 3 months Improved IPSS
questionnaire  post-treatment   and QoL
McVary et al. (2007)71,74 Double-blind RCT Sildenafil Placebo 189§ 12 weeks Improved IPSS
Kaplan et al. (2007)78 Randomized Alfuzosin + Alfuzosin 41 12 weeks Improved IPSS
parallel group sildenafil
McVary et al. (2007)73 Placebo-controlled, Tadalafil Placebo 281 12 weeks Improved IPSS
double-blind
Dmochowski et al. Muticentre double- Tadalafil Placebo 200 12 weeks Improved IPSS
(2010)84 blind RCT No effect on MVP
Taie et al. (2010)81 Cohort study Tadalafil Urodynamics pre- 20 Single dose Improved bladder
and post treatment   compliance, MBC, 
MVP and MFP
Maselli, et al. (2011)77 Parallel-group Tadalafil Solifenacin 25 12 weeks Similar IPSS 
improvements in 
both groups
Donatucci et al. (2011)85 Open-label, extension Tadalafil None 427 1 year Safety and sustained
of dose-finding study  improvements in 
IPSS, QoL
Bechara et al. (2008)79 Double-blind, Tadalafil Tamsolusin 27 45 days Improved IPSS Qmax, 
randomized + tamsolusin  QoL, and reduced
crossover post residual volume
Gacci et al. (2007)76 Single-centre, Vardenafil Placebo 25 Single dose Improved MFP, MBC
double-blind RCT
Stief et al. (2008)75 Placebo-controlled Vardenafil Placebo 222 8 weeks Improved IPSS, 
RCT erectile dysfunction 
and QoL
Gacci et al. (2012)80 Placebo controlled Vardenafil Tamsolusin 60 12 weeks Improved IPSS
RCT + tamsolusin  and Qmax
Giuliano et al. (2010)83 Multicentre, UK 369,003 10 , 25, 50 mg 310 12 weeks No significant effects
double-blind, or 100 mg 
placebo-controlled, versus placebo
parallel-group
Tamimi et al. (2010)82 Multicentre, UK 369,003 10 , 25 , 50 or 418 12 weeks Improved IPSS, which 
double-blind, 100 mg, versus   increased with
placebo controlled  40 mg immediate-   increasing dose
release tamsulosin 
0.4 mg or placebo
*All agents listed are PDE5 inhibitors, except for vinpocetine, which is a PDE1 inhibitor. ‡Total number of patients in the study, 
except where noted. §Number who received PDE inhibitors. Abbreviations: IPSS, international prostate symptom score; MBC, 
maximum bladder capacity; MFP, maximum filling pressure; MVP, maximum voiding pressure; n, number of patients; Qmax, 
maximum urinary flow rate; QoL, quality of life; RCT, randomized controlled trial; T-duration, Treatment Duration.
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Future perspectives
Additional, large-scale, well-designed trials are needed to assess whether PDE1 inhibitors might 
be useful in the future as a standard therapy for LUTS or OAB in both male and female patients. 
On the basis of results from preclinical studies, PDE4 inhibitors might also be an interesting 
tool to treat storage and voiding symptoms in humans38,43–47,97,98. Some PDE4 inhibitors, such as 
rolipram and roflumilast, are already being investigated in clinical trials, as treatments for mental 
health disorders and pulmonary diseases. In the case of PDE5 inhibitors, although some evidence 
suggests that these agents are safe and effective in male patients with LUTS14,70–83,85,99,100, their use in 
women with storage and voiding symptoms (specifically urgency, urgency incontinence and OAB) 
remains to be explored. In the meantime, the promising results for combinations of PDE5 inhibitors 
with either α-blockers or anticholinergic agents in patients with OAB might in the future add to the 
current armamentarium of drug treatments for such individuals.
Conclusions
The importance of the cGMP and cAMP pathways in the control of bladder function has been 
demonstrated in many in vitro and in vivo studies. PDEs hydrolyse cAMP and cGMP, and PDEs 
7–9 and 15 are expressed in the human urinary bladder. Consequently, a number of selective PDE 
inhibitors have been investigated for use in the management of patients with LUTS and OAB. To 
date, however, only inhibitors of PDE1 and PDE5 have been studied in a clinical setting for the 
treatment of storage and voiding disorders. Such studies provided only limited evidence that PDE1 
inhibition could improve the symptoms of OAB, whereas PDE5 inhibition has been clearly shown 
to alleviate LUTS in male patients with and without BPH. Moreover, the combination of a PDE5 
inhibitor and an α-blocking agent had superior efficacy compared to monotherapy with either agent 
in this setting.
The role of PDE5 inhibitors in the management of OAB, however, remains to be investigated in 
adequate detail. Despite favourable findings in preclinical and clinical studies, a pivotal role for 
nitric oxide and cGMP-mediated and cAMP-mediated signalling in the control of urinary bladder 
function has yet to be convincingly demonstrated, and specifically which PDE (PDE1, PDE5 or a 
further, as yet uncharacterized, isoenzyme) is the most relevant to the regulation of bladder smooth 
muscle tone remains to be elucidated. In the current quest for improved treatment options for 
OAB, the available data point towards an important role for PDE inhibition in the pharmacological 
management of functional bladder disorders.
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Box 1. Definitions of storage and voiding disorders
Lower urinary tract symptoms 
Defined as the subjective indicator of a disease or change in condition perceived by  the patient, 
caregiver or partner that might lead them to seek help from health care professionals. Symptoms 
can either be volunteered or described during the patient interview, are usually qualitative, and 
cannot be used to make a definitive diagnosis. Symptoms can be divided into three groups: 
• Storage symptoms—frequency, nocturia, urgency, urinary incontinence, stress incontinence, 
urge incontinence 
• Voiding symptoms—slow stream, splitting or spraying, intermittent stream, hesitancy, straining 
• Post micturition symptoms—feeling of incomplete emptying, postmicturition dribble
Detrusor overactivity
Defined as uncontrolled contractions of the detrusor muscle during bladder filling, seen on 
urodynamic measurements
Overactive bladder syndrome
Defined by symptoms of urge, with or without urge urinary incontinence, usually with fre-
quency and nocturia.105 In about half of patients with OAB, detrusor overactivity can also 
be demonstrated; however, up to 50% of patients with detrusor overactivity do not report 
relevant clinical symptoms.106
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Abstract 
Purpose
To study PDE5 localisation by visualising the product of phosphodiesterase type 5 (PDE5) inhibition, 
namely cGMP, to determine the site of action of inhibitors in the urinary bladder.
Materials and Methods
Bladders of nine male guinea pigs were dissected and treated in wells containing 2 mL Krebs’ solution 
and 1 mM of the specific PDE5 inhibitor vardenafil at 36 °C for 30 min. After stimulating tissues with 
100 mM of the nitric oxide (NO) donor diethylamine-NONOate for 10 min, the tissues were snap-
frozen and 9–10 mm sections were cut. Sections were examined for cGMP immunoreactivity and 
also stained for vimentin, a marker for interstitial cells and the neuromarkers protein gene product 
9.5 (PGP9.5), synaptic vesicle protein 2 (SV2), neurofilament (NF) and calcitonin gene-related 
peptide (CGRP), using the two-step indirect immunohistochemistry technique. 
Results
After PDE5 inhibition, cGMP was found to be present in the urothelium, suburothelial interstitial 
cells and endothelium of blood vessels. cGMP was not expressed in nerves positive for CGRP, NF 
and SV2, and was expressed only in very few efferent nerves positive for PGP9.5.
Conclusion
Our data show that the possible sites of action of PDE5 inhibition in the bladder are the urothelium,
suburothelial interstitial cells and blood vessels, rather than the bladder nerve fibres.
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Introduction
Phosphodiesterases (PDEs) are a class of enzymes, consisting of 14 subtypes and more than 
50 distinct isoforms1, that break down phosphodiester bonds. Usually, when speaking of PDE, 
one is referring to cyclic nucleotide PDEs, which have great clinical significance. In the present 
paper, we concentrate on a specific PDE subtype, the PDE type 5 (PDE5), which is selective for 
the degradation of the intracellular second messenger cGMP. The cGMP molecule is produced 
by soluble guanylate cyclase after stimulation by nitric oxide (NO) and is involved in important 
signalling cascades2. The inhibition of PDE5 slows the breakdown of the cyclic nucleotide cGMP, 
leading to an accumulation of cGMP3. Inhibitors targeting the different subtypes of PDE are widely 
used as therapeutic agents. Perhaps the most well known application of PDE inhibitors is in 
urology where PDE5 inhibitors are well known, extensively studied and prescribed in the treatment 
of erectile dysfunction4. Interestingly, recent clinical studies on PDE5 inhibitors in patients with 
erectile dysfunction, also showed a reduction in LUTS in these patients5–8. This clinical observation 
on LUTS was subsequently confirmed in placebo controlled studies in patients with LUTS and BPH 
with PDE5-inhibitors such as sildenafil9 and vardenafil10. Furthermore, functional proteins of the 
NO/cGMP signalling pathway have been identified in the human lower urinary tract, which might 
suggest a role for PDEs in the control of bladder function11. The exact mechanism and site of action 
of PDE5 inhibition in the bladder of patients with LUTS is currently unknown. In the present study, 
immunohistochemistry techniques are applied to investigate the site of action of a commonly used 
PDE5 inhibitor, vardenafil, within the lateral wall of male guinea pig bladder. There are no reliable 
and specific PDE5 antibodies available, therefore, the localisation of the PDE5 enzyme was indirectly 
visualised using antibodies against intracellular cGMP on bladder tissue pre-incubated with the 
PDE5 inhibitor, vardenafil.
Materials and Methods
Nine male guinea pigs (weighing 220–300 g) were killed by cervical dislocation. The bladders were 
immediately removed from each animal and placed in ice-cold Krebs solution (121.1 mM NaCl, 1.87 
mM KCl, 1.2 mM CaCl
2
, 1.15 mM MgSO
4
, 25 mM NaHCO
3
, 1.17 mM KH
2
PO
4
 and 11.0 mM glucose) 
that was bubbled with 5% CO
2
 and 95% O
2
 (pH 7.4). Strips were cut from the lateral wall, and divided 
into two groups. One group was maintained in Krebs’ solution. The second group was maintained 
in a Krebs’ solution containing 1 mM of the PDE5 inhibitor vardenafil at 36 °C for 30 min. To stimulate 
the production of cGMP, all tissues of both groups were incubated with a 100 mM solution of the 
NO donor diethylamine-NONOate for 10 min. Incubation was terminated by immersing bladder 
pieces in ice-cold fixative solution of 4% freshly prepared depolymerized paraformaldehyde for 120 
min at 4 °C. Tissues were then fixed in three steps of two overnight and one daytime incubation at 
4 °C in 0.1M phosphate buffer with 10, 20 and 30% sucrose, respectively. On day 3, the tissues were 
placed in Tissue-Tek® OCT™ compound (Sakura Finetek, Torrance, CA, USA) to form a single 
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block, snap-frozen in isopentane and cooled in liquid nitrogen. Cryostat sections (9–10 mm) were 
cut such that each section was perpendicular to the urothelial surface. Sections were thawed on 
chrome alum-gelatin coated slides and processed for immunohistochemistry using the two-step 
indirect method. All procedures were performed in agreement with Maastricht University ethical 
committee guidelines.
Antibodies
Six different primary antibodies were used to study the PDE5 location in the bladder wall. Sheep 
anti-formaldehyde fixed cGMP (1:4000) was used to detect PDE5, as described by de Jongh et al. 12
In order to stain the nerves in the tissue, the sections were co-stained with the antibodies polyclonal 
rabbit against protein gene product 9.5 ( PGP9.5 1:4000; Bioconnect, Huissen, The Netherlands),
mouse antibody against synaptic vesicle protein 2 ( SV2 1:500; DS Hybridoma Bank, University 
of Iowa, Iowa City, USA), monoclonal anti-vimentin (1:1000, Biogenex, Fremont, CA, USA), 
monoclonal rabbit antibody against neurofilament ( NF 1:1000; Epitomics, Burlingame, CA, USA) 
and polyclonal rabbit antibody against calcitonin gene-related peptide ( CGRP 1:1000; Caliochem, 
EMD Chemicals, San Diego, CA, USA). 
Immunohistochemistry
The sections were prepared for two-step indirect immunohistochemistry as described in our 
previous paper13. In short, the sections were prepared for two-step indirect immunohistochemistry 
by drying for 20 min at room temperature followed by three washes with TBS (pH 7.4). The slides 
were then incubated overnight with primary antibodies at 4 °C. The primary antibodies were diluted 
in TBS containing 0.3% (v/v) TBS-T. After the overnight incubation with the primaries, sections 
were washed in TBS-T, and TBS and TBS-T; each wash step lasted 15 min. Rabbit primary antibodies 
were visualised using Alexa Fluor 488 donkey anti-rabbit IgG (H + L) conjugate (Molecular Probes, 
Invitrogen Ltd, Paisley, UK), diluted 1:100 in TBS-T. Mouse primary antibodies were visualised with 
Alexa Fluor 488 donkey anti-mouse IgG conjugate (Invitrogen), diluted 1:100 in TBS-T. Sheep
primary antibodies were visualised with two different antibodies, Alexa Fluor 594 donkey anti-sheep 
IgG conjugate (Invitrogen) and Alexa Fluor 546 donkey anti-sheep, and both diluted 1:100 in TBS-T. 
Thereafter, sections were incubated with the secondary antibodies for 60 min at room temperature 
in the dark. After washing with TBS-T, cell nuclei were visualised by Hoechst staining with a dilution 
of 1:1000 in TBS-T and incubated for 10 min at room temperature. After washing with TBS-T and 
then TBS, sections were mounted with TBS-glycerol. Then, cover slits were placed on top of tissues. 
Sections were analysed and photographed using an Olympus AX70 microscope using X10, X20, 
X40 and X100 objectives. For the detection of Alexa 488 fluorescence and the detection of Alexa594 
and 546, a narrow band-pass MNIBA-filter and a filter with a narrow excitation band, the U-M41007A 
filter (both filters from Chroma Technologies, Rockingham, VT, USA) were used, respectively. The 
microscope was equipped with a cooled CCD Olympus Digital video camera F-view. Images were 
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stored digitally as 8-bit images and analysed using Image-J software. All sections were checked 
under the microscope and estimations of the prevalence of a certain staining pattern were made 
visually using a 1 X 1 mm matrix field and by visually counting the observation in each field. This was 
then repeated in sections of all animals and with different stainings.
Figure 1. Negative control of the distribution of cGMP and vimentin in the urothelium of the lateral wall of the guinea pig bladder. 
The coloured panel shows a high power image of the urothelium of the lateral wall of a guinea pig bladder, stained with the 
antibody to cGMP (red) and vimentin (green). The bladder lumen (LU), the urothelium (UR) and the suburothelial layer (SU) 
are marked. The black and white panels show the individual images of cGMP and vimentin. Calibration bar: 50 μm.
Results
The data were obtained by taking pictures of all nine guinea pig bladders from several stainings 
conducted on several days. Images were analysed for the presence of cGMP as well as other markers. 
Typical images are shown in figures 1-8. A negative control of the urothelium and suburothelium, 
i.e. without pre-inhibition of PDE5, is shown in figure 1. There is a weak expression of cGMP in 
the urothelium, showing a low basal level of cGMP after NO stimulation and without any PDE 
inhibition. A section of the lateral bladder wall after PDE5 inhibition is shown in figure 2A. The tissue 
was stained for cGMP (red) and the interstitial cell marker vimentin14 (green). The umbrella cells of 
the urothelium were stained strongly positive (red) for cGMP, whereas the intermediate and basal 
layer urothelial cells exhibited a cGMP expression which was clearly less than the umbrella cells. 
This is shown in figure 2A in more detail. This finding is in agreement with previous studies on 
the location of cGMP15. A large population of vimentin-positive interstitial cells (green) were also 
cGMP-positive (red). A more detailed image of the urothelium of the lateral wall of a guinea pig 
bladder, stained with the antibody to cGMP (red), vimentin (green) and the nuclei staining Hoechst 
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(blue) is shown in figure 2B. Details of this staining are shown in panel A. It can be noted that the 
suburothelial interstitial cells were stained positive for cGMP (red) indicating PDE5 activity. The red 
signal for cGMP can be seen in both the processes of these suburothelial interstitial cells as well as 
their cytoplasm.
Figure 2. The distribution of cGMP and vimentin after PDE5 inhibition in the 
urothelium of the lateral wall of the guinea pig bladder. (A) shows a low power 
image of the urothelium of the lateral wall of a guinea pig bladder, stained with 
antibodies to cGMP (red) and vimentin (green). The bladder lumen (LU), the 
urothelium (UR) and the suburothelial layer (SU) are marked. (B) shows a high 
power image of the urothelium of the lateral wall of a guinea pig bladder, stained 
with the antibody to cGMP (red), vimentin (green) and Hoechst (blue). The black 
and white panels show the individual images of cGMP, vimentin and Hoechst. 
Calibration bars: 50 μm.
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In figure 3, double stainings of cGMP with the general neuronal marker PGP9.5 are shown. A few 
nerve fibres that are cGMP-negative and PGP9.5-positive, running from the suburothelium through 
the urothelial layer, are shown (marked #). After visual inspection of two different PGP9.5-stained 
slides for each of the nine guinea pigs, it was concluded that a small minority of PGP9.5-positive 
fibres showed a weak cGMP signal after PDE5 inhibition. In panel B, an enlarged image of such 
cGMP-positive suburothelial nerves staining positive for PGP9.5 (marked +) are shown. 
Figure 3. The distribution of cGMP and PGP9.5 after PDE5 inhibition in the nerves of the lateral wall of the guinea pig bladder. 
The urothelium and suburothelial layer of the lateral wall of a guinea pig bladder, stained with the antibody to cGMP (red) 
and PGP9.5 (green), are shown. In panel A, the bladder lumen (LU), the urothelium (UR) and the suburothelial layer (SU) 
are marked. Panel B shows an enlarged image of cGMP positive suburothelial nerves staining positive for PGP9.5. A blood 
vessel staining positive for cGMP only can be noted in the suburothelium of panel B marked by astriks(*). The black and 
white panels show the individual images of cGMP and PGP9.5. Calibration bars: 50 μm.
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Figure 4. The distribution of cGMP and CGRP after PDE5 inhibition, in the urothelium and 
suburothelium of the lateral wall of the guinea pig bladder. Panel A shows a low power 
image and panel B a high power image of the urothelium of the lateral wall of a different 
guinea pig bladder, stained with the antibody to cGMP (red) and CGRP (green). The 
bladder lumen (LU), the urothelium (UR) and the suburothelial layer (SU) are marked 
in panel A. The black and white panels show the individual images of cGMP and CGRP. 
Calibration bars: 50 μm in panel A and 20 μm in panel B.
cGMP co-stained with the afferent nerve marker CGRP is shown in figure 4. Panel A shows the 
CGRP-positive nerve fibres that were all cGMP- negative. An enlarged image of a nerve in the 
suburothelial layer is shown in panel B. We did not find any CGRP-positive nerve fibres in the 
urothelium or suburothelium that were co-stained for cGMP. The distribution of cGMP stained 
with the efferent nerve marker SV2 is shown in figure 5. In all SV2- stained slide studies, none 
of the SV2-positive nerve fibres were found to stain positive for cGMP after PDE5 inhibition. An 
enlarged image showing a SV2-positive, cGMP-negative nerve fibre is shown in panel B. Stainings 
with the afferent nerve marker NF are shown in figure 6. Again, all the NF-positive fibres were 
cGMP-negative. An NF-positive fibre is shown in more detail in panel B. Another observation was 
the strong expression of cGMP in the blood vessels after PDE5 inhibition as indicated in figures 
3, 4 and 6 by asterisks. More specifically, cGMP expression was seen in the endothelium of the 
arterioles running through the urothelium and the suburothelial layers. Figures 7 and 8 show 
cGMP expression in the blood vessels of the suburothelium counterstained with vimentin, CGRP, 
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PGP9.5, SV2 and NF, respectively. Vimentin co-stains with cGMP in the endothelium of the blood 
vessels. From all the nerve markers stained, only PGP9.5 co-stains with cGMP around the blood 
vessels.
In panel A of figure 8 it can be noted that, the endothelium and the muscle layer below the 
endothelium of the artery stain strongly positive for cGMP after PDE5 inhibition by vardenafil but 
are PGP9.5-negative; however, around the artery, PGP9.5 and cGMP co-stain. The endothelium of 
the artery shown in panel B, stains strongly positive for cGMP after PDE5 inhibition by vardenafil but 
is SV2-negative. Moreover, panel C also shows an artery where the subendothelial layer shows PDE5 
activity. Again the endothelium and the subendothelial layer of this artery stain strongly positive for 
cGMP after PDE5 inhibition by vardenafil but are NF-negative. 
Figure 5. The distribution of cGMP and SV2 after PDE5 inhibition in the urothelium and suburothelium of the lateral wall 
of the guinea pig bladder. Panel A shows a low power image of the urothelium and suburothelium. A SV2-positive fibre is 
marked (#). The bladder lumen (LU), the urothelium (UR) and the suburothelial layer (SU) are marked in panel A. Panel B 
shows an enlarged image of a suburothelial nerve staining positive for SV2 but not for cGMP. The black and white panels 
show the individual images of cGMP and SV2. Calibration bars: 50 μm in panel A and 20 μm in panel B.
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Figure 6. The distribution of cGMP and NF after PDE5 inhibition in the lateral wall of the guinea pig bladder.  The urothelium and 
suburothelium of the lateral wall of a guinea pig bladder, stained with the antibody to cGMP (red) and NF (green), are shown. In 
panel A the bladder lumen (LU), the urothelium (UR) and the suburothelial layer (SU) are marked. Panel B shows an enlarged image 
of a different guinea pig bladder. A suburothelial nerve, positive for neurofilament but negative for cGMP is shown. The black and 
white panels show the individual images of cGMP and neurofilament. Calibration bars: 50 μm in panel A and 20 μm in panel B.
Discussion
The most recent support for NO-cGMP involvement in the bladder physiology comes from a study 
in rats showing that long-term administration of a soluble guanlylate cyclase activator (BAY 41-2272) 
prevents bladder dysfunction in NO-deficient rats, resulting in the normalisation of the increased 
threshold pressure, peak pressure and micturition frequency. These data indicate that restoration of 
the NO/cGMP pathway by this compound may be of benefit in the treatment of bladder symptoms16. 
Moreover, it has been shown that compounds activating the NO/cGMP pathway inhibited bladder 
hyperactivity, whereas compounds inhibiting the NO/cGMP pathway increased it17. These results 
suggest that the NO/cGMP signalling pathway is involved in the regulation of the micturition 
reflex17. In addition, carbachol-pre-contracted human detrusor strips are shown to be relaxed by 
the PDE5 inhibitor sildenafil18. In earlier studies, it has been suggested that the relaxant effect of 
the same PDE5 inhibitor used in the present study, vardenafil, in bladder smooth muscle, could at 
least in part be ascribed to a cGMP/protein kinase-dependent inhibition of RhoA-RhoA/Rho-kinase 
Thesis M.S. Rahnama’i.indd   160 10-10-13   13:36
161
signalling6. In fact, vardenafil does not affect responsiveness to a physiological stimulus such as 
carbachol, suggesting that PDE5 inhibitors may not interfere with bladder function in physiological 
conditions. In pathological conditions, however, as in the case of overactive bladder19, it is suggested 
that increasing cGMP levels through PDE5 inhibition restore normal bladder calcium sensitivity by 
reducing RhoARhoA/ Rho-kinase signalling overactivity. Together with data from recent clinical 
studies10,20,21, these results indicate that vardenafil may reduce RhoA-RhoA/ Rho-kinase signalling 
in the dysfunctional bladder, thus decreasing bladder overactivity6. Currently, no antibodies are 
available to directly visualise the presence of PDE5 enzymes; therefore, an indirect measurement 
was chosen in the present study. NO stimulation is known to induce an increase of intracellular 
cGMP, which is in turn degraded by PDE enzymes. At the chosen concentration of 1 mM, vardenafil 
has been shown to inhibit the PDE5 enzyme22, so pre-incubating the bladder with vardenafil, leads 
to an increased cellular level of cGMP, which can be visualized by specific antibodies against cGMP. 
The presence of high levels of cGMP then demonstrates sites that contain the PDE5 enzyme. The 
present data visualize increased cGMP levels indicating the presence of PDE5 in the urothelium 
and in a large population of suburothelial interstitial cells, as well as in the endothelium of the 
blood vessels running through the suburothelial layer. Furthermore, from all slides studied, PDE5 
activity was only found in a very small number of PGP9.5 nerves, whereas the SV2-, NF- and CGRP-
positive nerve fibres did not show any PDE5 activity. As shown in figures 2–6, a small population of 
suburothelial interstitial cells do not stain positive for cGMP after PDE5 inhibition. This observation 
is explained by the idea that interstitial cells form a very diverse population and a subpopulation that 
apparently does not respond to NO stimulation with an increase in cGMP after PDE5 inhibition. 
This idea has been suggested previously15. 
The presence of PDE5 activity in the interstitial cells of the bladder raises the suggestion that 
after PDE5 inhibition a rise in cGMP occurs in the umbrella cells and in the interstitial cells and 
that this effect might be spread through the network of interstitial cells. In fact, the idea of the 
existence on an interstitial network as a modulatory network through which signal propagation is 
achieved is not new. This idea has been put forward previously, in relation to the coordination of 
localized contractions in the bladder wall23. Coordinated non-voiding contractions, also referred 
to as autonomous activity, are thought to be part of a motor/sensory system which might regulate 
bladder afferent activity23. The idea of the involvement of an interstitial cell network in bladder non-
voiding activity is further supported by experimental evidence showing that bladder interstitial 
cells are indeed excitable24. Moreover, it has been shown that activation of these cells can initiate 
smooth muscle contraction, possibly via direct electrical coupling between these cells through gap 
junctions25. With regard to the present data, the hypothesis can be put forward that PDE5 inhibition 
alters the cGMP/NO system in the interstitial cells, which might play a role in the transduction 
of signals from the urothelium. This idea is consistent with the fact that, in the present study, 
PDE5 activity was virtually absent in the bladder nerve fibres (figures 3–5). Thus, we conclude that 
the relatively low PDE5 activity in efferent nerve fibres is not the main site of action of PDE5 in 
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the guinea pig bladder, given the small numbers of the cGMP-positive fibres (i.e. only a small 
number of PGP9.5 fibres as shown in figure 3B) compared with the strong cGMP staining on 
the interstitial cells. We therefore suggest that the PDE5 effect in the bladder is situated in the 
umbrella cells of the urothelium and interstitial cells. In the present study, we also observed PDE5 
activity in the endothelium of blood vessels in the bladder. It is known that PDE5 inhibitors have 
a relaxant effect  7 and 8 show that the blood vessels are surrounded by nerve fibres. A more close 
observation shows these blood vessels to be surrounded by a layer of PGP9.5-positive cells co-staining
A
B
Figure 7. The distribution of cGMP and vimentin and cGMP and CGRP after PDE5 
inhibition in the veins of the lateral wall of the guinea pig bladder. The coloured 
panels show a high power images of blood vessels (veins) in the suburothelium 
of the lateral wall of a guinea pig bladder. In panel A, the tissue is stained with the 
antibody to cGMP (red), vimentin (green) and Hoechst (blue). The black and white 
panels show the individual images of cGMP and vimentin. In panel B, the tissue is 
stained with the antibody to cGMP (red), CGRP (green) and Hoechst (blue). The 
black and white panels show the individual images of cGMP and CGRP. 
Calibration bars: 25 μm.
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Figure 8. The distribution of cGMP counterstained with SV2, 
PGP9.5 and NF after PDE5 inhibition in the arteries of the 
lateral wall of the guinea pig bladder. In the coloured panels, 
high power images of different blood vessels (arteries) in 
the lateral wall of a guinea pig bladder are shown. In (A) the 
tissue is stained with the antibody to cGMP (red), PGP9.5 
(green) and Hoechst (blue). The black and white panels 
show the individual images of cGMP and PGP9.5. In (B), 
the tissue is stained with the antibody to cGMP (red), SV2 
(green) and Hoechst (blue). The black and white panels 
show the individual images of cGMP and SV2. In panel C, 
the tissue is stained with the antibody to cGMP (red), NF 
(green) and Hoechst (blue). The black and white panels 
show the individual images of cGMP and NF. 
Calibration bars: 25 μm.
A
B
C
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for cGMP after PDE5 inhibition (figure 8B). Moreover, in figure 7A, it can be seen that the same layer 
of cells ensheathing the blood vessels is vimentin-positive. It is known that vimentin can be used to 
characterize blood vessels by staining endothelial cells, fibroblasts and smooth muscle cells, which 
are all found in the blood vessels27. In addition, it has been shown previously that a subpopulation of 
vimentin-positive interstitial cells also stain positive for PGP9.528. The exact physiological meaning 
of PDE5 activity in the bladder endothelium is not yet understood; however, it may be suggested that 
the known vasodilatative effect of PDE5 inhibitors, such as vardenafil, might be coordinated in the 
bladder through these interstitial cells surrounding the blood vessels. In conclusion, a few possible 
sites of action for PDE5 inhibitors in the guinea pig urinary bladder lateral wall can now be suggested, 
i.e. the urothelium, the endothelium of bladder blood vessels and the network of interstitial cells. The 
involvement of nerve fibres is less probable as in the present study we found only a very limited number 
of nerve fibres were stained positive for cGMP after PDE5 inhibition. This suggests that PDE5 inhibition 
has its effect mainly through the NO-mediated cGMP system in the interstitial cells. As the present 
data are the first available on the site and distribution of PDE5 activity in the bladder and are limited 
to a study of the distribution of PDE5 activity in the bladder, future in vitro and in vivo experiments are 
needed to determine the exact physiological meaning of the PDE5 activity arrangement found in the 
guinea pig urinary bladder.
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Chapter 9
General Discussion
Aim of study
The lack of satisfactory therapeutic options for the symptoms of the Overactive Bladder syndrome 
(OAB) is mainly due to an incomplete understanding of the complex bladder physiology and the 
multi-factorial cause of the OAB symptoms. In our studies summarized in this thesis, we have 
aimed at studying two local control systems of the bladder; namely: the prostaglandin E2 (PGE
2
) 
and the (PGE
2
) and the Nitric Oxide (NO) – Guanosine 3’,5’-cyclic monophosphate (cGMP) – 
phosphodiesterase (PDE) system. We have applied immunohistochemistry techniques by which we 
can identify different receptors and enzymes by fluorescence labelling. Signal transduction is one of 
the most fundamental processes underlying the basics of living organisms. This process includes 
the recognition of signals by cells and their appropriate transformation into biological responses1. 
It has become evident that neurons can also communicate with their targets without synaptic 
connections and that this form of non-synaptic interactions is of physiological significance2. 
Therefore, a disruption of this mechanism, can be of pathological significance2. In the bladder, a 
part of such non synaptical cellular signal is mediated through prostaglandin and the NO/cGMP 
pathway which is explored in our studies presented in this thesis.
Study model 
Both clinical and basic researchers try to gain a better understanding of the principles involved 
in the integrated control of the lower urinary tract. To this end, the scientifically preferable study 
subjects are human subjects. However, legal, ethical and moral issues make experiments in human 
subjects difficult and in some cases even impossible. Moreover, it is often not possible to acquire 
enough human bladder tissue to conduct all the in vitro experiments needed. Therefore, the use of 
animal models in this field of research is necessary. In our studies we have chosen the guinea pig 
bladder since it shows significant structural similarities with the human bladder3-6. Previous studies 
have shown that, obstructed guinea pig bladders show similar cystometric changes as in patients 
suffering from OAB3-6. 
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Definition of interstitial cells 
Smet et al., reported the presence of stellate shaped cells located throughout human and guinea 
pig bladders, called interstitial cells (IC’s)7. These cells were identified by an immunohistochemical 
marker called vimentin. In a later study, McCloskey et al. used a different marker, called C-kit to 
identify IC’s that were called interstitial cells of Cajal in analogy with IC’s in the gut8. It was found 
that vimentin stains a larger population of IC’s than C-Kit8. Hence, it is better to use the general term 
‘interstitial cells’ when referring to vimentin-positive IC’s. The term interstitial cells of Cajal has to 
be used to indicate C-kit-positive cells and the term ‘interstitial cells of Cajal like’ can be used to 
point to the population of IC’s which are vimentin positive but C-kit-negative. All previous research 
in Maastricht, has been consistent in using vimentin staining to identify IC’s. These cells are 
defined as cells lying in the interstitium, that are vimentin positive. In order to retain consistency in 
terminology and to make a comparison with previous papers possible, vimentin was used instead 
of C-kit to stain IC’s. 
EP1 and EP2 distribution in the bladder wall
From all prostanoids, PGE
2
 has been put forward as the most likely candidate to contribute to 
overactivity of the urinary bladder9. This is due to the presence of clear evidence that PGE
2
 infused 
into the bladder reduces bladder capacity10-13. Furthermore, it has been shown that in detrusor 
overactivity models14,15, as well as in patients with symptoms of overactive bladder syndrome16-18
local PGE
2
 production in the bladder is increased. PGE
2
 is a subtype of prostaglandin (PG) targeting 
the EP receptors that mediate its physiological effect19. There are four subtypes (EP1-EP4), each 
responding to the natural agonist PGE
2
 in a different manner20. 
Each of the EP receptors uses a different G-protein coupled transduction system21,22. EP1 
and EP3 are thought to cause contraction of the smooth muscle, whereas EP2 and EP4 are 
thought to cause relaxation21,22. This difference in response of the muscle to each of the EP 
receptors has been shown in the uterine smooth muscle23. EP1 receptors are found in many 
tissues in which intracellular signals are generated in response to PG, involving diacylglycerol 
and 1,4,5-triphosphate24. In such systems, EP1 is involved in regulating intracellular Ca2+ and 
cell excitability. EP2 receptors have been shown to couple to a G-protein, resulting in increased 
formation of cAMP. In the smooth muscle of different organs, this rise in cAMP through EP2 
leads then to muscle relaxation25. 
In our studies on the distribution of EP1 and EP2 receptor in the urothelium and suburothelial layer 
of the guinea pig bladder, we found that the EP1 staining was located in urothelial cells and in the 
suburothelium. Both EP1 and EP2 receptor are expressed by the urothelium and the suburothelial 
interstitial cells (SU-IC’s)26. The EP2 expression in the urothelium is clearly stronger than the 
EP1 expression. Furthermore, unlike in umbrella cells, cyclooxygenase 1 (COX1) was present 
in basal urothelial cells, making them a possible site of PG synthesis26. These results suggest 
that, PG produced by the urothelium could target EP1 and EP2 receptors in the urothelium and 
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suburothelium. Furthermore, these findings indicate that the urothelium of the lateral wall and the 
lamina propria have a high degree of structural complexity and potential for signalling, despite their 
relatively low nerve density. Hence, it can be suggested that complex signalling systems operate 
in the urothelium and between the urothelium and lamina propria suburothelial interstitial cells 
(SU-IC’s). 
The basal urothelial cell layer and, to a lesser extent the intermediate layer, express COX1. Hence, 
this layer is capable of generating PG. The local cellular targets for PG are most probably the 
intermediate layers and the umbrella cells of the urothelium, and SU-IC’s. Therefore, we can 
hypothesize that this close spatial arrangement of signalling and responding cells could reflect 
some functional specialization involving interaction between the basal and outer urothelial cell 
layers. 
It is known that guinea pig SU-IC’s express type 3 muscarinic receptors27. Since the urothelium 
may synthesize and release acetylcholine28, this raises the possibility that SU-IC’s receive multiple 
inputs like acetylcholine and/or PG. Our observations show further that SU-IC’s also express EP1 
and EP2, indicating that they respond to PG. In the intact animal, a major source of PGs acting on 
these cells may be derived from the basal and intermediate urothelial layers. As a consequence, 
SU-IC’s may be a site of integration of different signals. If some signals such as PG are also under 
modulation by other urothelial signals (ATP and NO), the physiology of this bladder wall region is 
particularly complex. 
In the muscle layer, we showed that the EP1 receptor was expressed on smooth muscle cells, on 
surface muscle interstitial cells (SM-IC’s) and on intramuscular interstitial cells (IM-IC’s)29. Muscle 
staining however, was less intense than stainings on the SM-IC’s and IM-IC’s. Both SM-IC’s and 
IM-IC’s have been suggested as the potential source of PG in the muscle layers before30 which was 
confirmed in our study29. This localized expression of the EP1 and EP2 receptors and the sites of PG 
production (COX1 expression) indicate an unusual and interesting micro-anatomical arrangement 
in IC’s. 
In addition, the PG production site (COX1) in the IC’s was shown to be different from the site 
that expresses the receptors, which could imply a classic autocrine arrangement. Moreover, the 
specialization of discrete signal producing regions and signal responsive regions suggests a further 
degree of complexity. As EP1 and EP2 receptors act through different mediators in the cell and have 
been shown to have different and in some cases, opposing effects32,33, we make a distinction in our 
hypothesis between these two receptors. In case of EP1, we propose the hypothesis that the PG 
system operates to facilitate signal propagation in the IC network. Cell activation would stimulate 
the COX1 enzyme and induce local PGE
2
 production and release, which would then activate an 
adjacent cell via its EP1 receptor region. The physiological consequence of this structural finding 
needs further exploration. Based on micro-anatomical evidence however, we can suggest that the 
network of suburothelial, lamina propria and muscle interstitial cells may form a communicating 
network30. Support for this hypothesis can be found in the studies on an isolated lamina propria 
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preparation which have revealed that signals released from urothelium are targeted at the 
suburothelial cell layer31. 
Similar results as found for EP1 were found in our studies on EP2 receptor distribution in the muscle 
layer. The EP2 receptor was shown to be located on SM-IC’s, IM-IC’s and to a lesser extend on the 
smooth muscle cells32. The EP2 receptor and the COX1 enzyme were also found to be co-expressed 
in the same cell. However, a spread and augmentation of a signal mediated by PGE
2
 via EP2 is 
unlikely as in most smooth muscle preparations, EP2 has been shown to cause muscle relaxation21. 
In several tissues, EP2 receptors have been shown to couple to a G-protein (G_s), resulting in 
increased formation of cAMP. In the smooth muscle of different organs, this rise in cAMP through 
EP2 leads then to muscle relaxation25. It is not yet known whether this is the predominant effect of 
EP2 in the detrusor muscle. 
The EP1/EP2 balance hypothesis
The question to be answered is the possible physiological meaning of the shown EP2 arrangement 
in relation to the previously shown EP1 distribution in the bladder muscle layers. It is known that, 
PGE
2
 may have multiple and at times apparently opposing functional effects on a given target 
tissue such as vascular smooth muscle33,34. Although no functional experiment was included in our 
studies on EP1 and EP2, some possible hypothesis could be put forward. It is explicitly mentioned 
that these hypotheses are not based on data and need to be confirmed in future functional studies. 
A possible explanation could be found in the differences in affinity of PGE
2
. It has been shown that 
the rat EP2 receptor signal transduction pathway is approximately 20-fold more sensitive for PGE
2
than for EP1, as the concentration of PGE
2
 required to produce a half-maximal response was 37 
nM for EP2 against 2.1 nM for EP135. Furthermore, in order to determine the affinity of PGE
2
 for EP1 
and EP2, saturation analysis has been performed showing KD values of PGE
2
 for EP1 and EP2 be 
around 24 and 5 nM, respectively35. Therefore, we hypothesize that under normal conditions, PGE
2
levels in the detrusor might be such that the inhibiting EP2 effect predominates the activating EP1 
effect, which might result in a stabilization of the muscle layer. Under certain circumstances, the 
PGE
2
 levels may increase above a certain threshold level in which case the contractile EP1 effect 
becomes more predominant. Small sub-threshold increases of PGE
2
 might be, in such a case, 
due to subtle bladder wall irritation, inflammation or stretch. The exact role of the EP2 receptor in 
the bladder wall remains to be determined by future analysis of the activation, signal propagation 
and bladder sensory pathways by functional studies. The PGE
2
 signal is suggested to spread out 
through suburothelial and intramuscular interstitial cells expressing EP1. The narrow balance 
between the contractile EP1 and the possible relaxant EP2 effect might be a system that modulates 
the autonomous, non-voiding contractions and relaxation which can become disrupted when PGE
2
levels reach certain higher levels. As there is a cAMP coupling of the EP2 receptor in many other 
tissues and a lower dissociation constant of EP2 compared to EP1, it is suggested that a rise in PG 
levels may gradually push the balance from a relaxant EP2 effect towards a contractile EP1 effect. 
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Hence, PG could have a modulatory role on non-voiding bladder contractions by changing the 
threshold level for excitability of the IC network. This idea is supported by earlier studies showing 
that frequency and amplitude of the non-voiding activity is reduced by stimulation of an adrenergic/
cAMP-linked mechanism36.
Autonomous bladder activity
Activating IC’s can initiate smooth muscle contraction, possibly via direct electrical coupling 
through gap junctions37. This idea was put forward in relation to the coordination of localized 
contractions in the bladder wall (autonomous activity) as part of a motor/sensory system regulating 
bladder afferent activity38,39. Many studies described and characterised IC’s, which are known 
to form a network throughout the bladder wall8,38,40,41. Our results show that this network of IC’s 
extends from the suburothelial layer and runs through the muscle layer and expresses EP1 and EP2 
among other receptors. PGE
2
 mediated signals can then be relayed through this network via the 
PGE
2
 produced by the COX1 enzyme that was recognized in the basal urothelial cell layer. In both 
our studies in the bladder muscle, we found that the COX1 enzyme was also expressed on SM-IC’s 
and IM-IC’s. COX1-positive IC’s were more prevalent in the muscle bundles of the inner muscle 
than in the outer muscle layers. Signal transduction through coupled IC’s would be more rapid 
than via the spread of electrical or muscle Ca2+ signals. Hence, such coordinated contractions are 
more likely to be mediated via EP1 and EP2 receptors on IC’s than on muscle cells, since by local PG 
release, random activation of the latter would result in random uncoordinated activity. Thus, the 
EP1 and/or EP2 stimulation of muscle IC’s are suggested to be involved in the modulation of the 
rapid generation of coordinated contractile responses.
The PGE
2
 signal and OAB 
The PGE
2
 signal is suggested to be spread out through suburothelial and intramuscular IC’s 
expressing EP1. The narrow balance between the contractile EP1 and the possible relaxant EP2 effect 
might be a system that modulates the aforementioned autonomous, non-voiding contractions and 
relaxation which can become disrupted when PGE
2
 levels reach certain higher levels. Increased 
bladder sensation is suggested to be associated with localized contractile activity in the bladder wall 
of human subjects (micro-motions) which are significantly more prevalent in patients with urgency 
than in asymptomatic volunteers42. Hence, urgency is suggested to be associated with autonomous 
activity of the detrusor and altered micro-motions. If the hypothesis is right and a PGE
2
 system 
is involved in the modulation of autonomous bladder activity, this system could be a potential 
therapeutic target. Cyclooxygenase inhibiting drugs, have been shown to alter normal voiding 
function in rats as well as bladder hyperactivity induced by chemical irritation43. Furthermore, it is 
known that intra-arterial administration of PGE
2
 to the urinary bladder enhances the micturition 
reflex13. It would be interesting to study the possible role of selective drugs which modulate the EP1 
and/or EP2 receptor in the bladder. The EP1 receptor is shown to be involved in the initiation of the 
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micturition reflex in normal rats and more specifically, in animals with bladder outlet obstruction44. 
Therefore, it is suggested that EP1 contributes to the generation of detrusor overactivity after 
bladder outlet obstruction44. 
There is hardly any literature about the exact role of the EP2 receptor in the bladder. However, it 
is known that the normal guinea pig bladder does express EP2 receptors26 and that the combined 
EP1/EP2 receptor antagonist AH 6809 decreases detrusor contraction in isolated human bladder 
experiments45. 
The effect of COX inhibition 
A link between the PG system and the muscarinic system had been suggested before46,52,53. In the 
guinea pig bladder, ATP can activate PGE
2
 production by a complex mechanism, involving the 
purinergic receptors P2X and P2Y46. This ATP response was shown to be inhibited by the COX 
inhibitor indomethacin46. Another clue for a link between PG and the muscarinic system comes 
from clinical data. It is known that inhibition of cholinergic activity in the bladder by antimuscarinic 
drugs, although effective in reducing the symptoms of urgency and frequency, does not have a high 
enough dosage to target the muscle cells47,48. Therefore, the suggestion is made that anticholinergic 
drugs could target the mechanisms, operating during the filling phase49-51 through locally 
produced substances such as ATP, NO and PG30,52. Our data show that blocking PG synthesis with 
indomethacin, decreased the cholinergically stimulated autonomous contractions in the isolated 
bladder. These data suggest that PG could modify normal cholinergically evoked responses. 
In order to evaluate the effect of PG on the autonomous activity in the presence of local reflex 
loops and control by the central nervous system, more experiments should be performed in vivo. A 
combination of drugs inhibiting both muscarinic receptors and PG function or production could be 
proposed as an interesting focus of research in the quest for a better treatment for OAB. 
The role of PDE’s in the bladder
The cyclic nucleotide mono-phosphates, cAMP and cGMP, are now generally accepted to be 
important intracellular regulators of several physiological processes, including smooth muscle 
function53. A possible new target for drug therapy in patients with OAB, is the PDE5 enzyme. These 
drugs prescribed to men with erectile disorders, have appeared to exert an inhibitory effect on the 
symptoms of OAB54. The role of cGMP in the modulation of detrusor contractile activity, has clearly 
been shown55,56. The intensity and the duration of the existence of intracellular cyclic nucleotides, are 
regulated by PDE’s. Different PDE subtypes have been shown to be present in animal and human 
bladders, including PDE5 in the rat57, PDE1 to PDE5 in the rabbit58-60 and PDE1 to PDE5 and PDE7 to 
PDE9 in the human urinary bladder59-62. 
We have studied the distribution of the PDE5 enzyme in the urothelium and suburothelium of 
the guinea pig bladder. In our study, we stimulated cGMP production in fresh guinea pig bladder 
tissue by an NO-donor, with or without pre-incubation with the PDE5 inhibitor, vardenafil. After 
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that, tissue stainings were conducted with a cGMP antibody. A positive cGMP staining in the tissue 
indicated the site of action of vardenafil. A few possible sites of action for PDE5 inhibitors in the 
guinea pig urinary bladder lateral wall can be suggested based on our results, i.e. the urothelium, 
the endothelium of bladder blood vessels and the network of IC’s. The urothelium can release 
NO which is needed for cGMP production. We have shown PDE5 activity in the urothelium which 
suggests that the urothelium can be the site where cGMP is generated. 
As both blood vessels and IC’s express the PDE5 enzyme, this signal could be relayed in both ways. 
Moreover, PDE5 inhibitors are known to have a relaxant effect on the smooth muscle cells of the 
blood vessel wall, particularly arteries63 and can therefore, increase the blood flow in these arteries63. 
This might also be an effect of the cGMP signal generated in the urothelium. 
The involvement of nerve fibers is less probable since in our study we found only a very limited 
number of nerve fibers to stain positive for cGMP after PDE5 inhibition. 
As we have not conducted any functional studies, only a hypothesis can be forwarded which needs 
to be further investigated and proven. Based on our morphological data it is suggested that PDE5 
inhibition has its effect mainly through the nitric oxide mediated cGMP system in the IC’s, rather 
than having a direct effect on neuronal activity. Our data belong to the first set of data available on 
the site and distribution of PDE5 activity in the bladder and is limited to a study of distribution of the 
PDE5 activity in the bladder. Therefore, future in vitro and in vivo experiments are needed to reveal 
the exact physiological meaning of the found PDE5-activity arrangement in the guinea pig urinary 
bladder. 
Although we have reasons to think that PDE reduces the symptoms of OAB, it is still not known 
how this effect might be explained. The safety and high tolerability of PDE inhibitors make them 
an attractive tool to investigate. Their additional physiological and pharmacological functions, for 
example, the modulation of intracellular cGMP pools and interactions with other local modulatory 
mechanisms are interesting for future investigation. Some recent papers show that PDE inhibition 
suppressed rhythmic bladder contractions in humans, guinea pig and rat64. This implies that PDE’s 
alter micro contractions and exert their effect on OAB via the non-voiding bladder contractions 
as explained by the autonomous bladder theory. The clinical application of other PDE inhibitors, 
including those of the PDE4 and recently developed PDE5 inhibitors in storage and voiding 
disorders, certainly needs more scientific attention and seems likely to become a challenging new 
treatment alternative in the future. 
Future perspectives
A logical next step after the morphological studies presented in this thesis, would be to study the 
functional meaning of the structural data found. In this thesis, the distribution of EP1 and EP2 in the 
guinea pig bladder has been studied and presented. In vitro studies using selective EP1 and/or EP2 
blockers and agonists are necessary to explore the exact role of these receptors in bladder physiology 
by assessing excitation–contraction coupling, excitatory synchronization and contractility. One way 
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to do so, is by organ bath studies, such as the one used in our study. A further step, and a more 
challenging one, would be to study the effects of selective EP1 and EP2 blockers and agonist in vivo. 
Urodynamic measurements of the effects of PG given intravesically in anaesthetized rats have 
been conducted in our lab as a pilot study. A challenging problem is the effect of anesthesia in 
these animals which could be prevented by using decerebrate animals. The ultimate in vivo study 
would be to study both voiding parameters as well as urodynamic effects of PGE
2
 or EP1 and EP2 
selective inhibition in an awake animal. These studies require accurate measuring devices. Since 
the urodynamic measurement devices are wired, the moving awake animal will present significant 
technical challenge. Depending on the results, these studies could lead to phase I and II studies in 
human subjects. A selective modulation of the EP1 and EP2 receptor could be a therapeutic target 
in functional bladder disorders such as OAB.
In case of phosphodiesterase inhibitors, future clinical use is closer. As these drugs have been 
studied and registered for other indications such as erectile dysfunction in men, in vivo studies 
in human subjects can be conducted on short term. However, from a scientific point of view it is 
equally important to unravel the exact site of action and role of PDE inhibition with in vitro and in 
vivo studies as is the case with prostaglandin receptors. This information, in combination with 
clear and reproducible biomarkers, is needed when we target to modulate different excitatory and 
or inhibitory control systems at the same time. 
In order to achieve this, we need to be able to improve our categorization of patients with symptoms 
of OAB, and offer more tailored pharmacological treatment. More specifically, patients with OAB 
but without proven DO on urodynamic studies, might need a different therapy than patients who 
exhibit DO at the same time. A combination of drugs targeting different mechanisms involved in 
bladder physiology such as PG, cGMP, cAMP, TRPV-channels and muscarinic receptors, could 
then, due to lower necessary concentrations, provide us with a more favorable effect/side effect 
balance. 
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Summary
This thesis is composed of two parts. The first part focuses on the distribution and the role of 
prostaglandins (PG) in the guinea pig urinary bladder and the second part on the distribution of the 
phosphodiesterase (PDE) enzymes, in particular the type 5 enzyme (PDE5). 
A general introduction presenting the overactive bladder syndrome (OAB) and its impact on the 
quality of life and economical burden in patients affected, is given in chapter 1. Moreover, the 
anatomy, physiology and histology of the lower urinary tract are discussed, followed by a brief 
overview on the possible role of PG and PDE5 in the urinary bladder. 
The current literature on the role and distribution of PGE
2
 and its receptors in the urinary bladder is 
discussed in chapter 2. Five primary prostanoids are synthesized by the cyclo oxygenase enzymes, 
COX-1 and COX-2: the prostaglandins PGE
2
, PGF
2α
, PGI
2
, PGD
2
 and thromboxane A
2
. In both animal 
models and in human studies, high levels of these signaling molecules have been implicated, 
in decreased functional bladder capacity and micturition volume, as well as in increased voiding 
contraction amplitude. As a consequence, inhibition of prostanoid production or the use of 
prostanoid receptor antagonists, might be a rational way to treat patients with detrusor overactivity. 
Similarly, prostanoid receptor agonists, or agents that stimulate their production, might have a 
function in treating bladder underactivity. 
The distribution of the PGE
2
 receptors EP1 and EP2 in the urothelium and suburothelium of the 
guinea pig urinary bladder is presented in chapter 3. In this morphological study of the guinea pig 
bladder, immunohistochemical stainings with antibodies against EP1, EP2, vimentin and COX1 
were applied. EP1 staining was seen in urothelial cells and in the suburothelium. Urothelial EP1 
staining was punctuate, weak and detected in all urothelial cell layers, including suburothelial cells. 
In contrast, strong EP2 staining was seen in the urothelium and in suburothelial cells. COX1 was 
absent in interstitial cells and umbrella cells and had the highest concentration in the basal cell 
layer. Vimentin was used to identify interstitial cells. These interstitial cells express both EP1 and 
EP2, indicating that they can respond to PGE
2
. The COX1 enzyme was present in basal urothelial 
cells, making them a possible site of PGE
2
 synthesis. PGE
2
 produced by urothelium may target EP1 
and EP2 in the urothelium and suburothelium. Therefore, PGE
2
 is hypothesized to have a role in 
signal regulation in the bladder wall.
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The distribution of EP1 in the detrusor muscle layer of the guinea pig is portrayed in chapter 4. 
Immunohistochemical stainings with antibodies against EP1, vimentin and COX1 were used to 
visualize the EP1 distribution. EP1 was identified on smooth muscle cells, vimentin positive surface 
muscle cells and intramuscular interstitial cells. Muscle staining was less intense than on interstitial 
cells and had a punctuate appearance. EP1 expression on interstitial cells was highly localized. 
Discrete regions of intense staining were noted on interstitial cell long stretched cell bodies, also 
known as processes. COX1 was also expressed in muscle interstitial cells. COX1 positive interstitial 
cells were more prevalent in the muscle bundles of the inner muscle than in the outer muscle layers. 
COX1 staining was noted on discrete regions of the cell or cell processes. Double staining with EP1 
and COX1 suggested that cell regions expressing the former are different from those expressing 
the latter. The discovered arrangement of EP1 and COX1 may have the potential to facilitate the 
propagation of signals in the interstitial cell network. Such a signalling system may have a role in 
coordinating events, as in bladder pathology, facilitating the global coordinated changes associated 
with bladder wall remodelling.
In chapter 5, the distribution of the EP2 receptor in the detrusor muscle layer is described. EP2 
distribution was studied through immunohistochemical stainings with antibodies against EP2, 
vimentin and COX1. EP2 receptor immunoreactivity was located on the smooth muscle cells as well 
as on vimentin positive surface muscle cells and intramuscular interstitial cells. EP2 expression 
on interstitial cells was highly localized. Discrete regions of intense staining were observed on the 
interstitial cell processes. COX1 expression was shown in the muscle interstitial cells and was found 
to be located on discrete regions of the cell and cell processes. Double staining with EP2 and COX1 
suggests that the regions of a cell expressing EP2 are different from those expressing COX1. The 
presence of COX1, and EP2 on the network of interstitial cells suggests a role of this network in the 
propagation of signals. Due to a cAMP coupling of the EP2 receptor in many other tissues and a 
lower dissociation constant of EP2, it is suggested that a rise in PG levels may gradually push the 
balance from a relaxant EP2 effect towards a contractile effect. Hence, PG could have a modulatory 
role on the non-voiding bladder contractions by changing the threshold level for excitability of the 
interstitial cell network.
The effect of PG depletion by means of COX-inhibition on cholinergic enhanced spontaneous 
contractions is displayed in chapter 6. In this study, the urethra and bladder of male guinea pigs 
were placed in an organ bath with Krebs’ solution and a transurethral catheter was introduced to 
measure intravesical pressure. The muscarinic agonist arecaidine, the non-selective COX inhibitor 
indomethacin, and PGE
2
 were subsequently added to the organ bath. The average frequency (F
ini 
)
and amplitude (P
ini
) of spontaneous contractions in the first 2 minutes after arecaidine as well as the 
average frequency (F
steady
) and amplitude (P
steady
) during the 5 minutes before the next wash out, were 
studied. Application of 1µM PGE
2
 increased the amplitude of spontaneous contractions without 
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affecting frequency. Indomethacin (10 µM) reduced amplitude but not frequency. The addition 
of indomethacin did not alter F
ini
 after the first application (p=0.7665). However, after the second 
wash, F
ini
 was decreased (p=0.0005). F
steady
, P
steady
 and P
ini
 were not significantly different in any of the 
conditions. These effects of indomethacin were reversible by PGE
2
 addition. Blocking PG synthesis 
decreased the cholinergically stimulated autonomous contractions in the isolated bladder. These 
data suggest that PG could modify normal cholinergically evoked responses. 
A review of the current knowledge on the role of PDE in the bladder pathophysiology is given 
in chapter 7. PDE enzymes hydrolyse the cyclic nucleotide monophosphates cAMP and cGMP, 
which have been suggested to play a role in bladder physiology. The inhibition of PDE, resulting in 
an increase in cAMP- and cGMP levels, has been shown to relax isolated urinary bladder smooth 
musculature of different species. Different PDE subtypes are known to be present in animal and 
human bladders, including PDE5 in the rat, PDE1 to PDE5 in the rabbit and PDE1 to PDE5 and PDE7 
to PDE9 in the human urinary bladder. The majority of preclinical functional studies have been 
conducted in the rat bladder, focussing on selective inhibitors of the PDE4 and PDE5 and inducing 
a relaxation effect. To date, only the significance of PDE1 and PDE5 has been studied clinically 
for the management of storage and voiding disorders. PDE1 inhibition has been suggested to 
improve micturition frequency. However, there are, to date, only limited clinical studies to prove 
this theory. PDE5 inhibition has been studied widely and shown to improve IPSS in men with 
lower urinary tract symptoms with or without benign prostate hyperplasia. Furthermore, PDE5 
inhibitors in combination with an alpha-adrenoceptor antagonist have been shown to be superior 
to monotherapy with either of the agents to improve IPSS. The role of PDE5 inhibitors in the 
treatment of women with detrusor overactivity remains unclear and is an interesting field for 
future research. The clinical application of other PDE inhibitors, including those of the PDE4 and 
the recently developed PDE5 inhibitors, in storage and voiding disorders, certainly needs more 
scientific attention and seems likely to become a challenging new treatment alternative in the 
future.
The distribution and the site of action of PDE5 in the guinea bladder are discussed in chapter 8. 
The data of this chapter were obtained through an indirect visualization technique. This was 
accomplished by visualizing the result of PDE5 inhibition (i.e. cGMP) in the guinea pig bladder tissue 
that was stimulated with nitric oxide (NO) and pre-incubated with the PDE5 inhibitor Vardenafil. 
After PDE5 inhibition, cGMP is shown to be present in the urothelium, suburothelial interstitial cells 
and the endothelium of blood vessels. cGMP is not expressed in nerves positive for CGRP, NF, and 
SV2 and only in very few efferent nerves positive for PGP9.5 staining. The possible site of action of 
PDE5 inhibition in the bladder is on urothelium, suburothelial interstitial cells and blood vessels, 
rather than on bladder nerve fibers. 
Summary
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A general discussion of all the studies presented in the thesis is written in chapter 9. Functional 
studies would be a next step to understand the functional meaning of the data described in this 
thesis. The data presented are a basis for further research on selective modulation of the EP1 and 
EP2 receptor which could be a therapeutic target in functional bladder disorders such as OAB. 
PDE inhibitors are closer to clinical use, as these drugs have been studied and registered for other 
indications such as erectile dysfunction in men. Therefore, in vivo studies in human subjects can be 
conducted on short term. However, from a scientific point of view, it is very important to unravel the 
exact site of action and role of PDE inhibition with in vitro and in vivo studies as is the case with PG. 
In this way, a combination of drugs targeting different mechanisms involved in bladder physiology 
such as PG, cGMP, cAMP, and muscarinic receptors, could reduce side effects and improve efficacy. 
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Samenvatting
(Summary in Dutch)
In dit proefschrift wordt de verspreiding en de rol van prostaglandinereceptoren en de verdeling 
van de fosfodiësterase (PDE)-enzymen, in het bijzonder het type 5 (PDE5) in de urineblaas van de 
cavia besproken. 
Het eerste hoofdstuk is een algemene inleiding over het overactieve blaas syndroom (OAB) en de 
invloed ervan op de kwaliteit van leven met de daarbij behorende economische gevolgen. In het kort 
wordt de anatomie, fysiologie en histologie van de lage urinewegen besproken, gevolgd door een 
kort overzicht van de mogelijke rol van prostaglandine (PG) en PDE5 in de urineblaas. 
De huidige kennis over de rol en de verspreiding van PGE
2
 en de receptoren in de urineblaas wordt 
besproken in hoofdstuk 2. Er zijn vijf primaire prostanoïden: de prostaglandines PGE
2
, PGF
2α
, PGI
2
, 
PGD
2
 en Thromboxaan A
2
. Deze prostanoïden worden gesynthetiseerd door de cyclo oxygenase 
enzymen, COX1 en COX2. Zowel in diermodellen als in studies bij proefpersonen, zijn deze 
signaalmoleculen aangetoond in geval van verminderde functionele blaas capaciteit. Op basis 
hiervan is de gedachte ontstaan dat remming van de prostanoïd productie of het gebruik van de 
prostanoïd receptorantagonisten, een potentiële behandeling van patiënten met overactive blaas 
syndroom kan zijn. Op dezelfde manier kunnen wellicht prostanoïd receptor agonisten of stoffen 
die de productie van prostanoïden stimuleren een plaats hebben bij de behandeling van blaas 
onderactiviteit. 
In hoofdstuk 3 wordt een studie gepresenteerd naar de verdeling van de PGE
2
 receptoren EP1 en 
EP2 in het urotheel en het suburotheel van de urineblaas van de cavia. In deze morfologische studie 
worden immunohistochemische technieken met antilichamen tegen EP1, EP2, vimentin en COX1 
toegepast. De resultaten tonen een zwak en puntsgewijze EP1 kleuring verdeeld over alle cellagen 
van het urotheel met inbegrip van de suburotheliale cellen. Daarnaast wordt in het urotheel en het 
suburotheel een sterke EP2 kleuring waargenomen. Het COX1 enzym was afwezig in interstitiële 
cellen en paraplu cellen maar had de hoogste concentratie in de basale cellaag van het urotheel. 
Het antilichaam vimentin werd gebruikt voor de identificatie van interstitiële cellen. Deze cellen 
kleurden aan voor EP1 en EP2, hetgeen erop wijst dat zij op PGE
2
 kunnen reageren. Het COX1 enzym 
was aanwezig in basale urotheliale cellen. Dit toont aan dat deze laag mogelijk een plaats is van 
PGE
2
 productie. PGE
2
 geproduceerd door het urotheel kan zo zijn werking hebben via de EP1 en EP2 
receptoren in het urotheel en het suburotheel. 
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De verdeling van de EP1 receptoren in de spierlaag van de caviablaas (de detrusor) wordt 
weergegeven in hoofdstuk 4. Immunohistochemische technieken met antilichamen tegen 
EP1, vimentin en COX1 werden gebruikt om EP1 te visualiseren. EP1 werd gezien op de gladde 
spiercellen, vimentin positieve oppervlakte interstitiële cellen en de intramusculaire interstitiële 
cellen. De kleuring van de gladde spiercellen was minder intens dan die op interstitiële cellen. EP1 
expressie op interstitiële cellen was steeds op een klein stuk van de cel gelokaliseerd. Daarnaast 
werd het COX1 enzym op de interstitiële cellen in de spierlaag aangetoond. COX1 positieve 
interstitiële cellen werden vaker in de spierbundels van de binnenste spierlaag gevonden dan in de 
buitenste spier lagen. Uit de ontdekte rangschikking van EP1 en COX1 kan worden geconcludeerd 
dat de PG signalen via het netwerk van interstitiële cellen door de spierlagen van de blaas verspreid 
zou kunnen worden. Dit systeem kan dan een rol vervullen in de coördinatie van verschillende 
processen in de blaas.
In hoofdstuk 5, wordt de verspreiding van de EP2 receptor in de spierlaag beschreven. De 
verspreiding van de EP2 receptoren werd bestudeerd door middel van immunohistochemische 
technieken met antilichamen tegen EP2, vimentin en COX1. EP2 receptoren werden gezien op 
gladde spiercellen, op vimentin positieve oppervlakte interstitiële cellen en intramusculaire 
interstitiële cellen. EP2 expressie op interstitiële cellen was steeds op een klein gedeelte van de cel 
gelokaliseerd. Op de uitlopers van de interstitiële cellen werd afzonderlijke regio’s van intense EP2 
kleuring waargenomen. Het COX1 enzym werd in de interstitiële cellen gelokaliseerd. Dit enzym 
was op afzonderlijke regio’s van de cel en de cel uitlopers gelokaliseerd. Dubbel kleuringen met 
EP2 en COX1 wijzen erop dat de expressie plaats van EP2 een andere is dan die van COX1. De 
aanwezigheid van COX1 en EP2 op het netwerk van interstitiële cellen kan erop wijzen dat het 
netwerk van interstitiële cellen een rol heeft in de verspreiding van PG signalen. 
Op basis van een lagere dissociatieconstante van EP2, wordt voorgesteld dat een stijging van PG 
niveaus geleidelijk het evenwicht van een relaxerend EP2 effect naar een contractiele EP1 effect kan 
doen doorslaan. PG kan derhalve een rol hebben in het regelmechanisme van de blaas middels 
verandering van de drempelwaarde voor de prikkelbaarheid van het netwerk. 
Het effect van PG concentratieverlaging middels COX-remming op cholinerg geïnduceerde spontane 
contracties wordt uiteengezet in hoofdstuk 6. In deze studie, werd een katheter door de urinebuis 
geplaatst om de intravesicale druk van geïsoleerde cavia blazen te meten. De blazen werden geplaatst 
in een orgaanbad met Krebs oplossing. Een cholinerge, muscarinerge agonist (Arecaidine), een 
niet-selectieve COX-remmer (indomethacin) en PGE
2
 werden opeenvolgend toegevoegd aan het 
orgaanbad. De gemiddelde frequentie (F
ini
) en de amplitude (P
ini
) van spontane contracties in de 
eerste 2 minuten na arecaidine werden bestudeerd, evenals de gemiddelde frequentie (F
steady
) en de 
amplitude (P
steady
) tijdens de 5 minuten voordat de volgende wasstap gebeurde. Toevoeging van 1µM 
PGE
2
 verhoogt de amplitude van spontane contracties zonder een effect te hebben op de frequentie. 
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COX-remming middels indomethacin (10 µM) verminderde de amplitude maar niet de frequentie. 
De toevoeging van indomethacin had geen effect op F
ini
 na de eerste stimulatie(p = 0.7665). Echter, na 
de tweede wasstap, was F
ini 
verlaagd (p = 0.0005). F
steady
, P
steady
 en P
ini
 veranderen niet significant. Door 
PGE
2
 toevoeging werd de omkeerbaarheid van deze effecten van indomethacin gecontroleerd en 
aangetoond. De frequentie van muscarinerg gestimuleerde autonome contracties in de geïsoleerde 
blaas daalt door het blokkeren van de PG synthese. Deze gegevens duiden erop dat PG nodig is voor 
de normale muscarinerg geïnduceerde contractie. 
Een overzicht van de huidige kennis over de rol van PDE in de blaas pathofysiologie wordt in 
hoofdstuk 7 geven. PDE enzymen hydrolyseren de cyclische nucleotide monophosphates cAMP en 
cGMP die een rol spelen in de blaas fysiologie. De remming van PDE, resulterend in een verhoging 
in cAMP- en cGMP niveaus, heeft een ontspannende werking in geïsoleerde urineblaas gladde 
spieren cellen van verschillende diersoorten. Er zijn verschillende PDE subtypen aangetoond in 
de dierlijke en menselijke blaas waaronder PDE5 in rat, PDE1 en PDE5 in konijn en PDE1 - PDE5 en 
PDE7 -PDE9 in de menselijke urineblaas. De meerderheid van de preklinische functionele studies 
zijn uitgevoerd in de rattenblaas en zijn toegespitst op selectieve inhibitoren van de PDE4 en PDE5. 
Tot op heden is alleen de betekenis van PDE1 en PDE5 klinisch bestudeerd. Van PDE1 inhibitie is 
gesuggereerd dat het de plasfrequentie verlaagt. Er zijn echter, tot nu toe, alleen beperkte klinische 
studies beschikbaar om deze suggestie te onderbouwen. PDE5 inhibitie is uitgebreid bestudeerd 
en daarvan is aangetoond dat het een verbetering geeft op de scorelijst van plasklachten (IPSS) bij 
mannen met lage urineweg symptomen met of zonder goedaardige prostaatvergroting. Bovendien, 
is bekend dat PDE5-remmers in combinatie met een alpha-adrenoceptor antagonist superieur zijn 
aan monotherapie met een van de twee genoemde medicijnen als het gaat om de verbetering 
van IPSS. De rol van PDE5-remmers bij de behandeling van vrouwen met detrusor overactiviteit 
blijft onduidelijk en is een interessant gebied voor toekomstig onderzoek. De klinische toepassing 
van andere PDE-remmers, waaronder PDE4 en de onlangs ontwikkelde PDE5-remmers, verdienen 
zeker meer wetenschappelijke aandacht en kunnen in de toekomst een uitdagend therapeutisch 
alternatief worden. 
De verdeling en de lokatie van effect van het PDE5 enzym in de caviablaas wordt besproken in hoofdstuk 8. 
De gegevens van dit hoofdstuk zijn verkregen door middel van een indirecte visualisatie techniek. 
Hierbij werd het product van PDE5 inhibitie (d.w.z. cGMP) bestudeerd in blaas weefsels welke na 
voorbewerking met de PDE5-remmer vardenafil met stikstofmonoxide (NO) waren gestimuleerd. 
Na PDE5 remming, wordt cGMP aangetoond in het urotheel, de suburotheliale interstitiële cellen 
en het endotheel van bloedvaten. cGMP is niet aanwezig in zenuwen die aankleurden met een 
CGRP, NF of SV2 kleuring. In slechts enkele efferente zenuwen was er een cGMP kleuring te zien 
na PDE5 inhibitie. De mogelijke werkingsplaats van PDE5 inhibitoren is daarom het urotheel, de 
suburotheliale interstitiële cellen en de bloedvaten, en niet de eerder gesuggereerde zenuwvezels. 
Samenvatting
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Een algemene discussie van alle studies gepresenteerd in dit proefschrift volgt in hoofdstuk 9. 
Functionele studies zijn de volgende stap om de betekenis van de gegevens die in dit proefschrift 
worden beschreven beter te begrijpen. De gepresenteerde gegevens vormen een basis voor verder 
onderzoek naar selectieve modulatie van de EP1 en EP2 receptoren. Deze kunnen een potentieel 
therapeutisch middel zijn in de behandeling van functionele blaas aandoeningen zoals OAB. PDE-
remmers, zijn dichterbij klinisch gebruik, daar deze middelen reeds zijn bestudeerd en geregistreerd 
voor andere indicaties zoals erectie stoornissen bij mannen. Klinisch onderzoek bij proefpersonen 
kan daarom op korte termijn worden uitgevoerd. Echter, vanuit een wetenschappelijke visie is het 
belangrijk de exacte werkingsplaats van PDE remming met in vitro en in vivo studies te ontrafelen. Op 
deze manier kan wellicht een combinatie van middelen worden gevonden waarvan elk gericht is op 
een bepaald mechanisme van de blaas fysiologie bijvoorbeeld PG, cGMP, cAMP en muscarinerge 
receptoren. Hierdoor kunnen hopelijk de bijwerkingen van de behandeling verminderd, en de 
werkzaamheid, verhoogd worden.
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AC, Adenylyl Cyclase
ATP, Adenosine Triphosphate 
BPH, Benign Prostate Hyperplasia 
BOO, Bladder Outlet Obstruction 
cAMP, Adenosine 3’, 5’-cyclic Monophosphate 
cGMP, Guanosine 3’,5’-cyclic Monophosphate  
CGRP, Calcitonin Gene-Related Peptide
CNP, C like Natriuretic Peptide
COX, Cyclooxygenase
COX1, Cyclooxygenase type 1
COX2, Cyclooxygenase type 2
DO, Detrusor Overactivity
DP
1
, Prostaglandin D Receptor Type 1
ED, Erectile Dysfunction 
EP1, Prostaglandin E Receptor Type 1 
EP2, Prostaglandin E Receptor Type 2 
EP3, Prostaglandin E Receptor Type 3
EP4, Prostaglandin E Receptor Type 4
DP2, Prostaglandin D Receptor Type 2
FP2, Prostaglandin F Receptor Type 2
GC, Guanylyl Cyclase 
GTP, Guanosine Triphosphate
Gsα,  Stimulatory G protein Subunit α
IBMX, 3 Isobutyl 1-Methylxanthine
ICs, Interstitial Cells
IHC, Immunohistochemistry 
IM, Inner Muscle Layer
IM-ICs, Intramuscle Interstitial Cells 
IP, Prostaglandin I Receptor
IPSS, International Prostate Symptom Score
Ki, Inhibitor Binding Activity 
LP, Lamina Propria
LPICs, Lamina Propria Interstitial Cells
LUTS Lower Urinary Tract Symptoms 
MBC, Maximum Bladder Capacity
MFP, Maximum Filling Pressure
MVP, Maximum Voiding Pressure 
n, Number of Patients
NB, Northern Blot 
NF, Neurofilament
NO, Nitric Oxide
NOS, Nitric Oxide Synthase
OAB, Overactive Bladder Syndrome 
OM, Outer Muscle Layer
pAC, Particulate (Plasma Membrane) Adenyl Cyclase
PDE, Phosphodiesterase
PDE5, Phosphodiesterase Type 5
PG, Prostaglandin 
pGC, Particulate (Plasma Membrane) Guanylyl Cyclase
PGD
2
,  Prostaglandin D
2
PGE
2
, Prostaglandin E
2
PGF
2α
,  Prostaglandin F
2α
PGI
2
,  Prostaglandin I
2
PGP9.5, Protein Gene Product 9.5
PLA
2
, Phospholipase A
2
QoL, Quality of life 
Qmax, Maximum Urinary Flow Rate
RCT, Randomized Controlled Trial
RhoA,  Ras Homolog Gene Family, Member A 
ROCK, Rho-Associated Protein Kinase 
ROI, Region Of Interest 
RT PCR, Reverse Transcription Polymerase Chain 
Reaction
sAC, Soluable Adenylyl Cyclase (Located in the 
Cytoplasm)  
sGC, Soluable Guanylyl cyclise (Located in the 
Cytoplasm) 
SM-IC, Surface Muscle Interstitial Cell 
SU-IC, Suburothelial Interstitial Cell 
SV2, Synaptic Vesicle Protein 2
TBS, Tris Buffered Saline 
TBS-T, Tris Buffered Saline with 0.3% (volume per 
volume) Triton X-100
TP, Tromboxaan A
2
  Receptor Type 1
UR, Urothelium
WB, Western Blot
Abbreviations
Thesis M.S. Rahnama’i.indd   197 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   198 10-10-13   13:36
199
List of publications
Rahnama’i, M.S., Ückert, S., Hohnen, R. & van Koeveringe, G.A. The Role of Phosphodiesterases in 
Bladder Pathophysiology. Nature Reviews Urology (2013) PMID: 23670184
Rahnama’i,M.S., van Koeveringe, G.A., Hohnen, R., Ona, S., Van Kerrebroeck, Ph.E.V. & de Wachter 
S.G. Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary 
bladder. British Journal of Urology International (2013)  PMID: 23452226
Rahnama’i, M.S., van Koeveringe, G.A., Van Kerrebroeck, Ph.E.V. & de Wachter, S.G. The effect of 
indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary 
bladder. Biomed Central Urology (2013) PMID:23388044
Rahnama’i, M.S., Biallosterski, B.T., de Wachter, S.G., Van Kerrebroeck Ph.E.V. & van Koeveringe 
G.A. The distribution of the prostaglandin E receptor type 2 (EP2) in the detrusor of the guinea pig.
Prostaglandins and Other Lipid Mediators (2012) PMID: 22960431
Rahnama’i, M.S., Van Kerrebroeck, Ph.E.V., de Wachter, S.G. & van Koeveringe, G.A. The role of 
prostanoids in urinary bladder physiology. Nature Reviews Urology (2012) PMID: 22410675
Callewaert, P.R., Biallosterski, B.T., Rahnama’i,M.S. & Van Kerrebroeck Ph.E.V. Robotic extravesical 
anti-reflux operations in complex cases: technical considerations and preliminary results. Urologica 
Internationales (2012) PMID:22076472
Gakis, G., Ninkovic, M., van Koeveringe, G.A., Raina, S., Sturtz, G., Rahnama’i, M.S., Sievert, K.D. 
& Stenzl, A. Functional detrusor myoplasty for bladder acontractility: long-term results. The Journal 
of Urology (2011) PMID:21168866 
Rahnama’i, M.S., de Wachter, S.G., van Koeveringe, G.A., Van Kerrebroeck, Ph.E.V., de Vente, J. & 
Gillespie, J.I.  The relationship between prostaglandin E receptor 1 and cyclooxygenase I expression 
in guinea pig bladder interstitial cells: proposition of a signal propagation system. The Journal of 
Urology (2011) PMID:21075388
Callewaert P.R., Rahnama’i, M.S., Biallosterski, B.T. & Van Kerrebroeck, Ph.E.V. Scrotal Approach to 
Both Palpable and Impalpable Undescended Testes: Should It Become Our First Choice? Urology 
(2010) PMID: 20156655
Thesis M.S. Rahnama’i.indd   199 10-10-13   13:36
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall
200
Rahnama’i, M.S., van Koeveringe, G.A., Essers, P.B., de Wachter, S.G., de Vente, J., Van Kerrebroeck, 
Ph.E.V. & Gillespie, J.I. Prostaglandin receptor EP1 and EP2 site in guinea pig bladder urothelium 
and lamina propria. The Journal of Urology (2010)  PMID: 20096878
Van Koeveringe, G.A., Rahnama’i, M.S. & Berghmans, B.C.. The additional value of ambulatory 
urodynamic measurements compared with conventional urodynamic measurements. British 
Journal of Urology International (2010) PMID:19673868
Rahnama’i, M.S., Leue, C. & van Koeveringe, G.A. Wired Bladder in a cordless era. British Medical 
Journal case reports (2009) PMID:21686350 
Rahnama’i, M.S., Wagenvoort, J.H. & van der Linden, C.J. Amoxicillin/clavulanate (Augmentin) 
resistant Escherichia coli in bacterial peritonitis after abdominal surgery--clinical outcome in ICU 
patients. The Netherlands Journal of Medicine (2009) PMID: 19581666
Rahnama’i, M.S., Geilen, R.P, Singhi, S., van den Akker, M. & Chavannes, N.H. Which clinical signs 
and symptoms predict hypoxemia in acute childhood asthma? Indian Journal of Pediatrics (2006) 
PMID:17006033
Vestjens, J.H., Rahnama’i, M.S., Brans, B.T. & Buijs, J. A case of abdominal mesothelioma diagnosed 
by indium-III leucocyte scintigraphy. The Netherlands Journal of Medicine (2006) PMID:16702616
Thesis M.S. Rahnama’i.indd   200 10-10-13   13:36
201
Abstracts and Presentations
International Continence Society (ICS) Beijing 2012, Poster presentation
Effectivity and complications of repeated botulinum toxin-A injections in patients with therapy 
resistent detrusor overactivity
M.S. Rahnama’i , F.T. Jansen, K.P.J. Delaere
Nederlandse Vereniging voor de Urologie (NVU) 2010, Oral presentation
De lokalisatie van de activiteit van phosphodiesterase type-5 in de cavia blaas 
M.S. Rahnama’i,  G.A. van Koeveringe, S.G.G. de Wachter, J. de Vente,  Ph.E.V. Van Kerrebroeck, 
J.I. Gillespie 
European Association of Urology (EAU) Barcelona 2010, Poster presentation
Phosphodiesterase type 5 Site of Action in the Guinea Pig Bladder, a novel visualization technique
M.S. Rahnama’i, G.A. van Koeveringe, S.G.G. de Wachter, J. de Vente, Ph.E.V. van 
Kerrebroeck, J.I. Gillespie
International Continence Society (ICS) San Francisco 2009, Oral presentation
Evidence for Prostaglandin involvement in neuron-modulation in the guinea pig bladder   
M S. Rahnama’i, G.A. van Koeveringe , S. G.G. de Wachter, J. de Vente, J.I Gillespie, Ph.E.V. Van 
Kerrebroeck
American Urology Association (AUA) Chicago 2009, Poster presentation
Evidence for prostaglandin involvement in afferent signaling of the guinea pig bladder 
M.S. Rahnama’i, J. de Vente, G.A. van Koeveringe, Ph.E.V. Van Kerrebroeck , J.I. Gillespie 
European Association of Urology (EAU) Stockholm 2009, Poster presentation
Latissimus Dorsi Detrusor Myoplasty (LDDM) in patients with acontractile bladder, long-term 
results of a multicenter study 
G. Gakis G , G.A. van Koeveringe, S. Raina, S, Lorenz , M.S. Rahnama’i, K.D. Sievert   M. Ninkovic, 
A. Stenzl 
Nederlandse Vereniging voor de Urologie (NVU) 2008, Oral presentation
De Lokalisatie en de rol van Prostaglandine receptoren (Type 1 : Ep1) in de Cavia blaas en urethra 
M.S. Rahnama’i, J. de Vente, G.A. van Koeveringe, Ph.E.V. Van Kerrebroeck, J.I. Gillespie
Thesis M.S. Rahnama’i.indd   201 10-10-13   13:36
Prostaglandins and Phosphodiesterases in the Urinary Bladder Wall
202
Nederlandse Vereniging voor de Urologie (NVU) 2007, Oral presentation
De Lokalisatie van EP1- en EP2-prostaglandine receptoren in de blaas en hun mogelijke rol in de 
behandeling van de overactieve blaas
M.S. Rahnama’i , S. Grol, J. de Vente, G.A. van Koeveringe, Ph.E.V. Van Kerrebroeck 
Controversies in Urology congress (CURY) Barcelona 2007, Poster presentation
Localization of COX Iimmunoreactivity (COX-I-IR) and prostaglandin receptors (EP1 and EP2) in 
the Human bladder
M.S. Rahnama’i, G.A. van Koeveringe, J. De Vente, J.I. Gillespie,  Ph.E.V. Van Kerrebroeck 
European Association of Urology (EAU) Milaan 2008, Poster presentation
Complex signalling within the urothelium and suburothelial interstitial cell layer involving 
prostaglandins and nitric oxide
M.S. Rahnama’i, J. De Vente,  G.A. van Koeveringe,  Ph.E.V. Van Kerrebroeck, 
International Continence Society (ICS) Cairo 2008, Poster presentation
The location and role of prostaglandin receptors (type 1: EP1) in the bladder and urethra
M S. Rahnama’i, P. Essers, J. de Vente, G.A. van Koeveringe, Ph.E.V. Van Kerrebroeck, J.I. Gillespie
International Continence Society (ICS) Cairo 2008, Poster presentation
The additional value of ambulatory urodynamic studies in patients with an overactive bladder 
syndrome and patients with an acontractile detrusor
M.S. Rahnama’i, G.A. van Koeveringe, Ph.E.V. Van Kerrebroeck
Nederlandse intensivisten dagen (NVIC) 2005, Poster presentation
Sepsis behandeling op de Intensive Care.
M S. Rahnama’i, M. van de Woude, C. van der Linde
Thesis M.S. Rahnama’i.indd   202 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   203 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   204 10-10-13   13:36
205
Curriculum Vitae
Mohammad Sajjad Rahnama’i was born on May 18th 1979 in Tehran 
(Iran). After finishing elementary school at the age of twelve in Iran, 
his family emigrated to the Netherlands, where he was sent to a 
school for basic technical skills (LTS, Delta college in Brunssum), 
like all newly arrived, foreign children. After figuring out the Dutch 
schooling system, he tried to change his high school to a higher level, 
in order to gain access to University and study medicine. After one 
year of LTS and one year at a middle level high school (MAVO), he was 
able to convince the school board to make an exception and let him 
attend the Dutch grammar school (Atheneum, Rombouts College in 
Brunssum), from which he graduated in 1998. During that year, he was not selected at the Dutch 
national lottery for entrance into medical school. He therefore took the entrance exam for the 
medical school in Belgium and entered the medical school in this country (LimburgsUniversitair 
Centrum LUC in Diepenbeek). He passed the first year with honours and returned to the medical 
faculty of the Maastricht University in 1999, from where he graduated his bachelors in 2003 and 
masters in 2005, both with honours degree. He started his clinical work as a medical doctor at 
the intensive care unit in Heerlen followed by one year at the surgery department in Sittard. In 
2007, he started his PhD research at the urology department in Maastricht, under the supervision 
of Prof. Philip Van Kerrebroeck, Dr. Gommert van Koeveringe and Prof. James Gillespie from 
Newcastle university (United Kingdom). In 2008, he received a personal Mozaïek grant from the 
Netherlands Organization for Scientific Research (NWO). He was accepted to the Dutch urology 
resident program in 2009 and started his training in January 2011. Besides his research, Sajjad 
has always kept working as a medical doctor at emergency departments and intensive care units 
of different hospitals during the weekends. Moreover, he has been a member of the city counsel of 
his hometown Heerlen from 2006 and has taken part in Persian music ensembles like Mezrab and 
Pardis. He is married to Elham Siasati and is a proud father of two sons and a daughter, Behzad 
(2008), Niekdad (2010) and Dorzad (2013), respectively.
Thesis M.S. Rahnama’i.indd   205 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   206 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   207 10-10-13   13:36
Thesis M.S. Rahnama’i.indd   208 10-10-13   13:36
